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ABSTRACT
Electrospray mass spectrometry (ESI-MS) has been used to examine a range o f intact monoclonal 
antibodies (MAbs), antibody fragments ie. F(ab')2, Fob and Fc, chemically-modified fragments and a range
o f other chemically-modified peptides and proteins as part of a broader study aimed at establishing ESI- 
MS as a method for the characterisation o f radioimmunoconjugates (ie. radiolabelled monoclonal 
antibodies). For example, the addition of up to 10 biotin molecules to the ‘papain-sensitive' 50 kDa Fab
fragment can be easily detected in ESI mass spectra. For intact MAbs, however, it is only possible to 
detect average shifts in the mass of intact antibodies following modification. Successful ESI-MS analysis 
o f complexes formed between chelators and other small molecules conjugated to synthetic peptides, hen 
egg-white lysozyme (HEL) (Mr 14 306) and horse heart myoglobin (Mr 16 951) has been demonstrated.
ESI-MS offers considerable advantages compared with existing methods for the characterisation o f  
chemically-conjugated proteins including speed and sensitivity of analysis and the capability for obtaining 
specific structural information. The conditions for ESI-MS of intact MAbs and MAb fragments have 
been examined in detail and it was found that 150 kDa MAbs generally required lower sample 
concentration and higher skimmer potentials compared with the 50 kDa Fob fragment and other lower
molecular weight proteins. In addition, the mh range over which ions from MAbs were observed was 
higher (mh ~2000-4500) than for smaller proteins. ESI-MS was also found to be extremely useful for 
probing the action of the protease papain, that is used to generate MAb fragments (F(abY2, Fab ond Fc).
Further, different sensitivities to papain for different MAb preparations was demonstrated. Finally, the 
tandem mass spectra of a range of peptides modified by iodine and biotin were examined. In the case o f  
biotinylated peptides, a characteristic fragment ion was identified that could potentially be used to screen 
peptides produced from enzymatic preparations of modified proteins. For the iodinated peptides, however, 
a fragment ion specific to iodinated tyrosine residues was not evident. Overall the results in this thesis 
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1.1 PROTEIN CHEMISTRY AND MASS SPECTROMETRY -----------------------------------------------------------------
Proteins play a key role in virtually all biological processes and the functional diversity 
they exhibit can be attributed to their broad range of structural variability (1). Proteins 
mediate a wide range of functions including: enzyme catalysis, transport and storage, 
coordinated motion, mechanical support, immune protection, integration of metabolism 
and control of growth and differentiation. This remarkable range of functions arise from 
the folding of proteins into distinctive and unique three-dimensional structures as well as 
their interactions with for example, cofactors, metal ions and other peptides or 
proteins (2).
Comprehending the complete primary structure of a protein, including the amino acid 
sequence as well as the type and sites of post-translational modifications, greatly 
facilitates the understanding of the protein at a molecular level (3). With current methods 
in molecular biology, the amino acid sequences of proteins can be readily determined by 
sequencing the DNA of the corresponding gene, however, this yields no information 
regarding modifications that occur subsequent to translation of the gene product; so-called 
post-translational modifications. Furthermore, DNA sequencing is subject to errors such 
as shifts in the 'reading frame' due to the insertion or deletion of a nucleotide base or the 
misidentification of a base leading to translation of the genetic code into an incorrect 
amino acid residue (4). Hence there is a need for an analytical technique that can confirm 
predicted protein sequences and to identify and locate post-translational modifications.
The classical method for determining the amino acid sequence of a protein is based on the 
degradation scheme developed by Edman in 1950 (5). The process sequentially removes 
one amino acid residue from the N-terminal end of a peptide, which is then detected
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chromatographically. Edman degradation fails when the N-terminus is blocked 
(££• pyroglutamylation or A-acetylation), the peptide is cyclic, there are amino acid 
structures present in the peptide that differ from the twenty naturally occurring residues or 
when post-translational modifications are present (6). Information regarding the structure 
and sequence location of post-translationally modified amino acids is often lost during the 
Edman degradation procedure as the modified residue may not survive the harsh 
conditions to which it is exposed; particularly if the stability of the modification is less 
than that of the amide bond linking the residues together (7). Thus, modified amino acids 
may be lost or converted to the ’parent' amino acid. In some instances, modified 
residues can be converted to derivatives that are stable to the Edman degradation process, 
but this is the exception rather than the rule. If  the m odification survives 
(eg. hydroxylysine), it is often misidentified as an unmodified residue due to similar 
chromatographic retention times (7). In addition to these limitations to Edman chemistry, 
sequence data generated by step-wise chemical degradation can only be interpreted if the 
peptide is purified to near homogeneity (6).
There are a wide variety of structural problems in protein chemistry that can be solved 
simply by knowing the molecular mass of the peptide or protein in question, particularly 
when accurate molecular mass determinations are combined with partial sequencing 
information. Mass spectrometry (MS) can be used to solve problems that are not 
accessible by classical methods and offers the advantages of speed and sensitivity in 
protein structure determination. The technique of mass spectrometry involves ’weighing' 
individual molecules by transforming them into ions in vacuo and then measuring the 
response of their trajectories in either electric or magnetic fields or a combination of 
both (8). Mass spectrometry was first developed in the early 1900's by physicists and 
was initially applied to the analysis of volatile petrochemicals in the 1940's and to 
synthetic organic molecules in the 1950's. From the early to mid 1950's research efforts 
began to focus on the development of mass spectrometry as a tool for applications in 
biological sciences (9). Attempts to extend the sensitivity and accuracy of MS to the
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analysis of biomolecules of interest in biology and medicine had long been frustrated by 
the difficulties of transforming such fragile molecules into gas-phase ions. These 
molecules can not be vaporised direcdy without extensive decomposition. The classical 
methods of ionisation, ie. electron ionisation (El) (10) and chemical ionisation (Cl) (11) 
required samples to be introduced in the gas-phase. Thus early work on peptides was 
limited by their low volatility and thermal instability, and necessitated the development of 
derivatisation methods to enhance volatility (eg. reduction to polyaminoalcohols, 
permethylation, trimethylsilylation) an area of research pioneered by Biemann and 
co-workers (12).
The development of mass spectrometric methods directly applicable to involatile and 
thermally labile compounds began in the late 1960's, early 1970's with field desorption 
mass spectrometry (FD-MS) (13). FD-MS was soon shown to produce mass spectra of 
small peptides (14). This period also saw the development of plasma desorption MS 
(PD-MS) using a 252Cf source (15-17), which was also applied to small peptides and 
was the method of choice for large proteins until the late 1980's. In 1981, fast atom 
bombardment (FAB) was introduced by Barber and colleagues (18,19). This technique 
produced protonated molecular ions [M+H]+ of large peptides by bombarding a solution 
of the peptide, in a matrix such as glycerol, with a beam of atoms (Ar or Xe). FAB-MS 
was technically much simpler than FD-MS and could be coupled with conventional 
quadrupole and magnetic sector analysers. FAB-MS and PD-MS were widely employed 
during the 1980's and marked the beginning of the rapid progress in peptide and protein 
analysis by mass spectrometry.
The introduction of two ’soft’ ionisation methods, matrix assisted laser desorption 
ionisation (MALDI) (20, 21) and electrospray ionisation (ESI) (22) began a revolution 
that profoundly expanded the role of mass spectrometry in biological research. Although 
these methods have origins extending back more than two decades, the potential for 
analysis of very large biomolecules exceeding molecular masses of 100 kDa was only
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demonstrated as recently as 1988. These methods show extremely high ionisation 
efficiencies and, for ESI-MS in particular, the capability for very precise 
Mr measurements.
1.2 ELECTROSPRAY IONISATION MASS SPECTROMETRY (ESI-MS)-
1.2.1 Historical Perspective ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The study of the electrospray phenomenon extends back two and a half centuries to the 
initial work of Bose (23) and to that of Zeleny early this century (24). The use of 
electrospray as an ionisation method for the production of free gas-phase macromolecules 
from analyte species in solution was first proposed and investigated for mass 
spectrometry by Dole and colleagues (25, 26) who, more than twenty years ago, 
performed extensive studies of the electrospray process. The experimental evidence 
presented by Dole and subsequent interpretation of the data remains somewhat equivocal 
because of problems in the ion mobility method of mass analysis that was used. The 
importance of Dole's contributions to mass spectrometry, however, cannot be overstated; 
his research clearly suggested the facile ionisation of macromolecules and defined many 
of the experimental parameters currently utilised for ESI-MS today.
In 1984 combined electrospray ionisation mass spectrometry (ESI-MS) was reported, 
essentially simultaneously, by Yamashita and Fenn (27) and by Aleksandrov and 
co-workers (28,29). Fenn and colleagues (27) employed atmospheric pressure sampling 
of ions and analysis with a quadrupole mass spectrometer and also demonstrated ESI-MS 
in the negative ion mode (30). Using a magnetic sector instrument, Aleksandrov and 
colleagues independently demonstrated the on-line combination with liquid 
chrom atography (29), and over the next few years applied ESI-M S to 
oligosaccharides (31), intact polypeptides Mx to 1500 (32) and developed chemical 
digestion-based methods for sequence determination (33). Interest in ESI-MS for 
proteins was heightened following a presentation by Fenn at the 1988 ASMS Meeting in 
San Francisco in which the ESI spectrum of a large protein was presented (34).
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Since that tim e, the practice and application of ESI-M S have grown 
impressively (35,36). The strengths of this technique include the capability of ESI to be 
coupled with mass analysers that have high mass accuracy and resolving power; and the 
ease with which it can be coupled directly to microscale (LC-MS) or 'nanoscale' capillary 
separation devices (CZE) for the analysis of liquid samples and solutions. In addition, 
electrospray combined with tandem mass spectrometry (MS-MS) has shown to be useful 
for enhancing the fragmentation of biomolecules produced by ESI.
1.2.2 ESI-MS Instrumentation -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
1 2 2 .a The Electrospray Interface----------------------------------------------------------------------
The electrospray ionisation source is typically a small diameter metal capillary 
(eg. stainless steel hypodermic needle) (37) maintained at an elevated voltage 
(+4-6 kV for positive ion ESI) relative to a counter electrode. The electrode has an orifice 
where ions and/or charged droplets (at atmospheric pressure) entrained in a flow of 
nitrogen bath gas enter the high vacuum region of the spectrometer for mass analysis and 
detection. Alternative source designs employ a capillary/skimmer (37), dual skimmer or 
heated capillary arrangement (38) (the latter does not require a bath gas).
The potential difference between the tip of the capillary and the counter electrode causes 
charge to accumulate on the surface of the liquid emerging from the capillary terminus, 
dispersing the liquid into a fine spray of highly charged droplets. Upon leaving the tip of 
the capillary and driven by the electric field, the analyte solution forms a supersonic free 
j e t  After a short distance the jet destabilises and breaks into a fine aerosol that disperses 
rapidly, since each droplet carries a charge of the same polarity (39). The resulting 
dispersed ions pass through a small orifice or channel and are accelerated into the higher 
vacuum region of the mass spectrometer for mass analysis.
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The most crucial feature of an ionisation source operated at atmospheric pressure is the 
efficient sampling and transport of ions into the mass spectrometer vacuum 
{eg. <3x1 O'6 mbar for a quadrupole mass filter). The highly charged droplets/ions 
produced at near atmospheric pressure drift against a countercurrent flow of dry nitrogen 
bath gas at moderate temperatures (~60-80°C). This curtain of nitrogen serves as a 
drying agent to remove the solvent vapour and to exclude large droplets and other 
uncharged particles.
A 1-20 fiL/min flow of analyte solution (typically water containing an organic modifier 
such as acetonitrile or methanol and a few percent of acetic, formic or another volatile 
acid to enhance ionisation of sample constituents in positive ion mode) is infused into the 
capillary by a direct infusion syringe pump. Alternatively, the eluent from 
high-performance liquid chromatography (HPLC), capillary chromatography or capillary 
zone electrophoresis (CZE) can be infused directly into the ESI source. The electrospray 
ion source of the quadrupole instrument used in this study is shown schematically in 
Figure 1.1.
F igure 1.1 Schematic representation of the electrospray ionisation quadrupole mass spectrometer 
source used in this study. See text for details of operation.
Chapter 1 Introduction 7
1 2 2 .b Electrospray Ionisation Mass Analysers-----------------------------------------------------
ESI has been coupled most frequently with quadrupole mass analysers (or filters) of 
modest mlz range (2000-4000) and resolution (9). Quadrupoles have the advantage of 
relatively low cost, ease of operation and tolerance of high pressures. Examples of ESI 
interfaces on other instruments are also commercially available. The combination of ESI 
with magnetic instruments was accomplished in 1984 by Aleksandrov and 
co-workers (28, 29, 31-33) and more recently by Meng and colleagues (40). The 
capability for higher mlz resolution and high-energy collisionally-induced dissociation 
(CID) for tandem mass spectrometry experiments (see Section 1.4 on CID) are 
advantages of the ESI-magnetic sector combination. The initial results with time-of-flight 
(TOF) instrumentation suggested that improved sensitivity (by ion storage and 
accumulation) was necessary to yield results comparable to quadrupole instruments (41). 
Such improved sensitivity appears practical in designs utilising orthogonal extraction 
(or acceleration) (42) and recently, impressive results with time-of-flight instrumentation 
have been reported (42-44). The unlimited mlz range of the ESI-TOF combination is a 
significant advantage for macromolecules and molecular complexes of relatively low 
charge. The capability for high resolution ESI allows direct determination of the charge 
on the ions giving rise to a single peak simply from the spacing of the peaks containing 
different numbers of 13C isotopes. Data from quadrupole ion trap mass spectrometers 
(IT-MS) are particularly encouraging, although the mass measurement accuracy is 
currently lower than with conventional quadrupole instruments (45, 46). Sensitivity is 
comparable to, or better than, quadrupole mass spectrometers, suggesting efficient 
injection and trapping of ions. The sensitivity of MS-MS experiments on ion traps is 
high in comparison with conventional tandem instruments. McLafferty and co-workers 
have pioneered the combination of ESI with Fourier-transform-ion cyclotron resonance 
mass spectrometry (FTICR-MS) (47,48). Significant advantages in MS-MS sensitivity, 
the capability for multistage MS-MS, MSn (n>3) and especially resolution are obtainable 
for both the IT-MS and FTICR-MS methods.
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1.2.3 The Mechanism of Ion Desorption in ESI-MS ---------------------------------------------------------------------------------------------------------
At present there are two major theories used to describe the electrospray process, 
however, experimental evidence concerning the detailed mechanism of ESI, particularly 
related to the identity of the charged species desorbed, evaporated, or ’ejected' from the 
surface of highly charged and rapidly evaporating droplets (22) is inconclusive. The two 
mechanisms that are commonly cited to account for the formation of gas-phase ions from 
small charged droplets are: Ion Evaporation Theory (IET) (49, 50) and; Single Ion in 
Droplet Theory (SIDT) (51).
The mechanism proposed by Iribarne and Thomson (49, 50), known as the 
'ion evaporation' model is based on experiments obtained by electrospraying aqueous 
solutions of an ionic analyte (NaCl). This model holds that a sequence of rapid solvent 
evaporation and 'Coulombic explosions' would ultimately lead to droplets with radii so 
small and charge densities so high that the resulting electrostatic field at a droplet surface 
would be sufficiently intense to lift solute ions into the ambient gas or vapour. The 
sequence is schematically represented in Figure 1.2.
The ion evaporation mechanism has been criticised by Roellgen and associates (51), who 
argue that the actual field strength required for ion evaporation from even the smallest 
aqueous droplets almost always exceeds that for Rayleigh fission. Thus, an ion 
evaporation process yielding a single ion is improbable since it is thought that such an 
event would almost certainly induce a Rayleigh explosion (causing a je t of very small 
charged droplets to be emitted). Additionally, droplet disintegration for ESI may be 
augmented by a non-uniform charge distribution (as likely for large multiply-charged ions 
in a low conductivity medium).
Roellgen and colleagues proposed that as the solvent evaporated from the charged 
droplets, the charge density on the surface would increase until the Rayleigh limit was 
reached at which point the forces due to Coulombic repulsion were comparable to the
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forces of cohesive surface tension. The resulting instability is supposed to disrupt the 
parent droplet into smaller droplets that continue to evaporate. Successive 'Coulombic 
explosions' or fissions are thought to ultimately give rise to droplets so small, ~1 p.m in
diameter, that each one would contain a single solute molecule that retained the droplet 
charge as the remaining solvent vaporised. This mechanism, called the Single Ion in 
Droplet Theory (SIDT), is similar to the 'charged residue' mechanism originally 
proposed by Dole and co-workers (25).
Figure 1.2 Sketch of the ion desolvation process according to the ’Ion Evaporation’ Model Small,
charged droplets produced by the electrospray evaporate, generating a high electric field 
at the droplets surface. Analyte molecules that were dissolved in the droplet can attach 
to charges and be lifted into the gas phase by this field.
The actual distinction between the Ion Evaporation and the Single Ion in Droplet 
mechanisms may become blurred and a process involving the field evaporation of highly 
solvated ions may be mechanistically indistinguishable for smaller molecules from a 
process yielding jets of very small droplets by Rayleigh fission. Clarification of the ion 
formation mechanism awaits further experimental study. Regardless of the mechanism
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by which ions are formed during the electrospray process, it is clear that the very small 
droplets produced appear to allow almost any species carrying a net charge in solution to 
be transferred to the gas-phase after evaporation of residual solvent.
1,2.4 Molecular Mass Determination  - --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Electrospray mass spectra of large biomolecules typically exhibit a distinctive 
gaussian-shaped distribution of multiply-charged molecular ions arising (in positive ion 
mode) by either proton or alkali ion attachment, with little or no evidence of 
fragmentation. The mass of any multiply-charged molecular ion is determined by 
multiplying the m/z ratio at which the ion is observed by the derived charge (35,36,52). 
Simple mathematical calculation allows the mass of the intact molecule to be determined 
from any two consecutive charge states of known mh  ratio (see below) (8,53).
The simplest algorithm for molecular mass determination of a macromolecule may be 
determined from the distribution of charge states in an ESI spectrum given the following 
assumptions:
(i) adjacent peaks of a series differ by only one charge;
(ii) the charge arises from proton attachment to the molecular ion (for positive ions) or 
successive proton losses (for negative ions); and
(iii) the peaks arise only from the intact molecule.
The multiply-charged ions observed in positive ion ESI spectra can be denoted by:
(M+nH)n+
where: M = the average molecular mass of the molecule .
n = the number of charges (integer value) ,
H = the mass of a proton
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The mass-to-charge {mh) ratios of adjacent peaks in positive ion ESI spectra differ by 
one charge and are given by:
/ , s M+nH *(mh) i = — -—  ...1
M+(n+l)H
(m/z)2 -  “ i n — ...2
The value of n is determined to the nearest integer value by solving Equations 1 and 2 
simultaneously. Since every peak associated with the mass spectra of a protein is 
separated by one charge from adjacent peaks, then it is easy to determine the charge states 
on all the peaks when the charge on one is known. The molecular mass of the protein 
can then be determined by Equation 3.
M = n(m/z-H) ...3
Several mathematical methods have been described for the generation of ’zero-charge’ 
(molecular mass) spectra from ESI data in which each component in a mixture is 
transformed from the multiply-charged ion series on a mh scale to a single peak on a 
molecular mass scale (54). Fenn and co-workers developed an algorithm that 
deconvolutes or converts the ESI m h  spectrum to a plot from which the mass of the 
protein can be calculated (55). This method, however, tends to produce artefacts and a 
baseline that increases with mass.
A method for generating artefact-free ’zero-charge' spectrum with an improved 
signal-to-noise ratio has been developed, but identification of the multiply-charged ion 
series prior to transformation to a molecular mass scale is necessary (56). Most of the 
current software allows semi-automatic identification of the charge states, but 
nevertheless a degree of operator intervention is usually required. Identification of the 
ion series is a simple procedure with mixtures containing few components, but it 
becomes extremely tedious with complex mixtures, especially those containing proteins
3  0 0 0 9  0 3 1 3 2 5 0 4  1
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of widely differing molecular masses. When several components are present in the 
electrospray data, each giving rise to a series of multiply-charged ions, accurate values 
for m h  ratios of the components in an unresolved multiplet may not be obtainable and 
hence some form of deconvolution is desirable (57). In addition, since the data in the 
original multiply-charged spectrum are directly transformed onto a true mass scale, 
components which are unresolved in the original data remain unresolved in the 
'zero-charge' spectrum.
1.2.5 Maximum Entropy (MaxEnt™) Deconvolution --------------------------------------------------------------------------------------------------------
An alternative means of converting ESI data to a molecular mass scale, without first 
assigning the charge states, is to employ a maximum entropy (MaxEnt™) 
calculation (54,57). Maximum entropy is a mathematical technique based on probability 
theory. The MaxEnt™ program (MaxEnt™ Solutions, Cambridge, UK) creates a 
'damage model' and reconstructs it mathematically by repeatedly processing different 
trial spectra of mass and charge (mock data). The results are compared with the observed 
data to eventually produce the 'ideal' spectrum (54). The program repeatedly takes 
revised trial spectra that fit the observed data more closely with each iteration in order to 
converge on the most probable single spectrum. Each trial spectrum in the progression is 
damaged, just as it would have been in the actual mass spectrometer and it is the 
differences between the mock data set and the actual, observed data that guide the 
algorithm toward each improved spectrum (54). The reliability of the definitive 
MaxEnt™ spectrum can be assessed by probabilistic methods. Thus a probable error 
range can be calculated for each mass. This is achieved by sampling the distribution of 
possible spectra at about a dozen points near the most probable spectrum. Hence the 
error analysis requires a further dozen iterations of the MaxEnt™ kernel, and for this 
reason, it is a separate process. By using MaxEnt™, 'zero-charge' spectra on a true 
molecular mass scale are automatically produced from entire electrospray data sets and 
otherwise unresolvable components in mixtures are effectively separated (54).
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The peaks in ESI spectra are known to be broadened, by both the natural isotopic 
distribution of the elements in the molecule (isotopic broadening) and the performance of 
the mass spectrometer (58). Hence the true underlying spectrum of m h  ratios will be 
sharper than the peaks in the original data. By allowing for isotopic broadening the 
MaxEnt™ program is able to deconvolute this effect from the ESI data, thus enhancing 
the resolution observed in the final MaxEnt™ mass spectrum (54). In summary, 
MaxEnt™ is a superior algorithm for deconvoluting mixtures, however, the greater time 
taken compared with simple deconvolution methods means this is usually only employed 
when necessary, otherwise the simpler algorithm is more efficient.
1.3 ESI-M S OF PRO TEIN S -------------------------------------------------------- =-------------
A feature of ESI mass spectra of most proteins is that the average charge state increases in 
an approximately linear fashion with molecular mass, extending the mass range of the 
MS experiment by the addition of compensating charge. The net number of possible 
protonation sites in solution appears to be one of the principal factors affecting the 
maximum extent of multiple charging observed in positive ion ESI mass spectra. For 
most proteins examined to date (prepared in aqueous solution, pH<4), an approximate 
linear correlation is observed between the maximum charge state detected and the number 
of basic amino acid residues (eg. arginine, lysine, histidine) plus the NH2 terminus 
(35,52, 53). Although there are a number of examples where this 'rule' does not hold, 
a rough correlation of 0.5-1.0 charge/kDa is observed for most proteins. Presumably the 
native folded state of some proteins may make certain possible protonation sites 
inaccessible to solvent (35). Nonetheless this relationship can be used to provide a 
simple and quick estimate of the maximum number of expected charges in a 
given protein.
ESI-MS offers the opportunity to measure molecular masses with unprecedented 
accuracy and provide mass information against which postulated amino acid sequences, 
purity and chemical or post-translational modifications can be assessed (59). Relative
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molecular mass measurements for proteins of up to 150 kDa, and greater, have been 
successfully analysed by this method using commercially-available quadrupole 
instruments. The largest protein examined successfully to date is the human complement 
C4 protein with a molecular mass of more than 190 kDa (60).
Mass assignment accuracies of 0.01% are routine, and accuracies of 0.001% to 0.005% 
are achievable with appropriate curve-fitting and centroiding of the multiply-charged 
peaks. In favourable cases, precision of measurement may be better than 0.005%, far 
superior to those obtainable by more traditional techniques. Sodium dodecyl sulphate 
po lyacry lam ide gel e lectrophoresis (SD S-PA G E), chrom atography and 
ultracentrifugation, produce measurements of molecular mass that are typically accurate to 
only 5% to 10%, two to three orders of magnitude lower than that obtainable with 
ESI-MS. With higher resolution instrumentation, such as FTICR mass spectrometers, 
charge state assignments in even complex mass spectra is possible by measuring the 
1 Dalton isotopic peak separation (61). This combination of high resolution and high 
accuracy are crucial for further advancement in identifying unknowns and complex 
mixture analysis. *
1.3.1 Covalent Interactions --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Proteins can be covalently modified by a range of synthetic and/or biological 
processes (62). Synthetically-modified, or derivatised, proteins are produced, for 
example, as antigens and enzyme tracers in immunoassay development (63), and 
post-translational modifications largely dictate protein function (64). In addition to these 
modifications, unregulated events such as oxidative damage and exposure to extremes of 
pH or high temperature (65) can also modify proteins resulting in their functionality being 
adversely affected (66). 'Pure' proteins are thus often chemically heterogeneous and as a 
consequence, the characterisation of modifications responsible for protein heterogeneity 
represents a challenge to structure-function studies.
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1.3. La Post-translational Modification o f Proteins--------------------------------------------------
Post-translational modification of proteins is a common cellular process. By definition, 
these structural modifications are introduced after polymerisation of the amino acids on 
the ribosome-messenger RNA (mRNA) complex (67). Covalent modifications of the 
side chains of amino acids are common and over 150 different modified amino acids 
derived from proteins have been identified to date (7). Some of the more common 
post-translational modifications include removal of N- or C-termini amino acids by 
in vivo peptidases, acylation of the amino terminus (68), disulphide bond formation, 
glycosylation of Asn, Ser and Thr (69-71), sulphation of Tyr (72), phosphorylation of 
Ser, Thr, Tyr, Pro, Lys and Asp (73), A-methylation of Lys, Arg, His and Gin, 
O-methylation of Glu and Asp (74) and carboxylation of Glu and Asp (75).
The location and structure of covalent post-translational modifications in proteins have, 
until recently, been determined by utilising common analytical and physical techniques. 
Heterogeneity on polyacrylamide gel electrophoresis (SDS-PAGE), size exclusion 
chromatography, or reverse-phase HPLC often signals the presence of a 
post-translational modification. Once the presence of a modification has been determined, 
several sophisticated methods are available for the separation of modified proteins from 
their unmodified forms. These include separation of the 'native' from the modified 
protein based on the properties of the modified group eg. lectin affinity chromatography 
is useful for separating various glycosylated proteins (76). Alternatively, an introduced 
modification may change the charge, hydrophobicity or solubility of the protein thereby 
allowing its separation from the unmodified protein by techniques such as 
anion-exchange chromatography. Isoelectric focussing (IEF) is particularly applicable to 
the separation of post-translational modification products in which the charges are 
different (76). Isoforms of proteins in which even a single amide side-chain in the 
'normal' (wild-type) protein has been converted to the corresponding acid may be 
resolved on the basis of this single charge difference. This technique will also separate 
proteins differing in the number of negatively-charged sialic acid residues (a common
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source of heterogeneity in preparations of glycoproteins) in the complex carbohydrate 
chains in glycoproteins. The combination of IEF with SDS-PAGE ie. two-dimensional 
electrophoresis, is a particularly useful technique as the separation of 'native' and 
modified proteins is achieved by differences in molecular mass and isoelectric point 
(77, 78). Nuclear magnetic resonance (NMR) spectroscopy and X-ray analysis can be 
used in certain instances to identify added groups, and often their mode of attachment 
(76). All of the techniques described usually indicate that a modification exists, although 
the precise chemical structure and the location of the modified residue in the peptide chain 
are not always unambiguously identified (7,79).
Structural problems of proteins that are not accessible by classical techniques can often be 
solved by mass spectrometry. MS is particularly useful if the protein is modified, either 
in the course of natural post-translational events or by chemical derivatisation involving 
new covalent bonds (discussed below). The difference between the molecular mass 
expected from sequence data and the actual mass determined by ESI-MS of a native 
protein are often due to errors in the DNA sequence. Nonetheless, post-translational 
modifications or chemical derivatisation of the amino acid side chains often also explain 
discrepancies in observed masses from ESI and masses determined from the translated 
DNA sequence. Since these mass differences can be accurately determined by ESI-MS, 
the type and number of modifications that have been introduced can be ascertained. The 
feasibility of ESI-MS for the analysis of protein mixtures has been demonstrated as a 
powerful method for the identification of covalent post-translational modifications 
(80, 81). An increasing number of definitive publications detailing the determination by 
MS of the sites and nature of native or induced protein modification clearly illustrates that 
this technology, either used alone or in conjunction with HPLC and MS-MS, is rapidly 
becoming the method of choice for a wide variety of modified amino acid residues (6).
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Identifying the sites of post-translational modifications is an important application of MS 
and tandem mass spectrometry (82). Methods to selectively detect phosphopeptides (83) 
or glycosylated peptides (84) using LC-ESI tandem mass spectrometry have been 
developed. Phosphopeptides containing phosphoserine, phosphothreonine, or 
phosphotyrosine yield fragment ions at m/z 63 (PO2') and mlz 79 (PO3') (83). Once 
marker ions are observed, phosphopeptide containing fractions can be further analysed 
by other techniques to corroborate the presence of phosphate and to identify the precise 
phosphorylation site(s). Glycosylated peptides are identified by a diagnostic 
m/z 204 (HexNAc+) fragment ion (84). Selective-ion monitoring of these diagnostic ions 
during an LC-MS-MS experiment of a digested protein mixture can be a sensitive and 
time-saving procedure for identification of sites of modifications (85). The combination 
of selective proteolysis, chromatography and MS-MS has been used to locate the sites of 
phosphorylation of rhodopsin (86, 87). There are a wide variety of examples of 
post-translationally modified proteins analysed by ESI-MS in the literature and this 
continues to be a field of great interest for protein structure-function analysis.
13.Lb Chemical Modification of Proteins------------------------------------------------------ —
Chemical modification of proteins is an area of protein chemistry that has made major 
advances in the last two decades (88). The chemistry of proteins has its origin in the 
chemistry of the amino acids and only later concerned the amino acid side chains of intact 
proteins. A variety of procedures for protein modification had been developed and used 
many years prior to any significant interest in, or understanding of, protein chemistry. 
Interest in quantitative determinations of proteins and their various constituent amino 
acids was a major impetus for many early studies of chemical modification (89). Some 
of the earliest attempts to use chemical modification procedures to identify particular 
amino acid residues were seriously hampered by the absence of sensitive and accurate 
procedures to determine the number and type(s) of amino acid residues undergoing 
modification and by the absence of effective procedures to separate, purify and 
characterise the products (89). Nevertheless, these early studies into the chemical
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modification of proteins provided a starting point for other investigators and served as 
important steps to the later development of improved procedures.
Ammo acid side chains are generally found on the surface of a molecule and are usually 
accessible for derivatisation with limited disturbance to molecular integrity (90). The use 
of side-chain-selective reagents (ie. those which react, under certain specified conditions, 
with a single or limited number of side-chain groups in a fairly predictable manner) is a 
simple approach to understanding the function of these groups in the protein. The 
retention of biological activity after treatment with one of these reagents is usually 
evidence that the modified amino acid side chain(s) are not required for that particular 
activity. Under appropriate conditions, each reagent normally reacts only with the 
indicated target side chain(s). Depending on the protein, the reagent, and the particular 
conditions, however, complete modification of all such side chains is not always 
obtained. In most cases, the extent of reaction can be increased by the use of more 
vigorous reaction conditions, eg. longer reaction times, larger excesses of reagent and the 
presence of denaturing agents. Using more severe conditions, however, is usually 
accompanied by some decrease in side-chain selectivity and greater risk of conformational 
change. Consequently, protein chemical modification reactions have long been employed 
in structure-function studies (91, 92). The incorporation of new chemical groups into 
proteins can have important effects on the biological properties of proteins (76), thus it is 
necessary to have reliable methods for determining the incorporation of derivatising 
molecules into proteins. Previously, the techniques employed for determining the degree 
of incorporation of a derivatising agent into a protein have included laborious analytical 
procedures (eg. radio actively-labelled reagents) (79), direct spectrophotometric 
measurements or amino acid analyses.
Chemical modifications of proteins lead to a generally predictable change in molecular 
mass and can therefore be subjected to identification or confirmation by mass 
spectrometry. MS has thus proven to be well suited for the unequivocal characterisation
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of multiple chemical modification sites in proteins (93). The combination of tertiary 
structure-selective chemical modification and mass spectrometric analysis has enabled the 
selectivity of the derivatising agent to be characterised and the relative reactivities at 
specific modification sites to be determined (94). There are few examples in the literature 
of ESI-MS of chemically-derivatised proteins and/or peptides in comparison with data 
presented for 'native' modifications. Some key examples are given below.
ESI-MS and MS-MS were used to study the interaction of human a rth ro m b in
(M r 36 029) with a potent and selective inhibitor, methyl 3-(2-m ethyl-1-
oxopropoxy)[l]benzothienol[3,2-b]furan-2-carboxylate (LY806303). Using ESI-MS it
was shown that LY806303 covalently modifies human a-thrombin as evidenced by a
shift in mass of the native protein by 72 Da, which is consistent with isobutyrylation of
the enzyme at a single site. Tryptic digestion of the modified protein and MS-MS
205
analysis of isolated peptide fragments indicated that LY806303 acylates S of the heavy
205 43 99chain of a-thrombin. S , along with H and D make up the catalytic triad within the 
active site of thrombin (95).
The chemistry of the reaction of the cytotoxic aldehyde ira/w-4-hydroxy-2-nonenal 
(HNE) with the model protein P-lactoglobulin B (Mr 18 277) was explored by ESI (62). 
HNE is the product of peroxidation of polyunsaturated fatty acids (96) and the formation 
of protein-HNE adducts are believed responsible for the formation of foam cells and 
atherosclerotic plaques. HNE is an a , ¡3-unsaturated aldehyde and can undergo a Michael 
reaction or form Schiff bases (imines) with cysteine, histidine and lysine residues. Direct 
characterisation of derivatised P-lactoglobulin B by ESI yielded a spectrum containing 
from three to nine aldehyde groups per molecule of protein. The mass difference of 
156 Da between the major peaks in the transformed spectrum, indicated that the addition 
of HNE to the protein occurred by Michael addition. Mass shifts of 138 Da were also 
evident suggesting the addition of HNE to the protein by Schiff base adducts and/or 
dehydration products, differing from the Michael addition adducts by 18 Da (62).
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The interaction of HNE with apomyoglobin has been investigated by Bolgar and 
Gaskell (97). These investigators initially used ESI-MS to establish the stoichiometry of 
HNE incorporation. The adducted protein was then subjected to proteolytic digestion 
followed by MS-MS analysis of HNE-adducted histidine residues identified by scanning 
for precursors of m/z 266, which corresponds to an immonium ion derived from 
HNE-adducted histidine. The application of this approach to the characterisation of 
HNE-modified apomyoglobin indicated that there were between three and ten HNE 
adducts per protein molecule and that the adduction occurred solely on histidine residues.
Mirza and co-workers used ESI-MS to identify, quantify and characterise modifications 
of synthetic peptides and an enzymatic protein as a result of exposure to nitrous oxide 
(NO) (98). Known targets of NO on proteins are the amino acid residues Cys and Tyr. 
The molecular mass of a decapeptide containing a single Cys residue increased by 29 Da 
upon treatment with NO, consistent with the addition of a single NO moiety via the 
formation of a nitrosothiol bond. The mass of reduced somatostatin (a peptide with two 
Cys residues) increased by 58 Da, consistent with the substitution of two NO moieties. 
These studies were extended to the enzyme p 2 lras, whose activity has been postulated to 
be modulated by nitrosothiol formation, and it was revealed by ESI-MS that a single 
nitrosothiol was formed on p21ras upon NO treatment.
ESI-MS alone cannot define the precise structural change in a protein; only that the 
molecular mass is not the expected one and is thus a complementary technique to classical 
methods of protein analysis in obtaining formal proof of the identity of a modification. 
When used with caution, and in the context of all other available structural data, molecular 
mass information can be used to solve a variety of structural problems (67). ESI-MS has 
thus proven to be an indispensable analytical tool in protein biochemistry and molecular 
biology (7) and is clearly the most convenient and effective method for the 
characterisation of post-translationally modified or chemically-derivatised proteins and 
peptides (99).
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1.3.2 Non-covalent In teractions----------------------------------------------------------------
Non-covalent associations between proteins and other polypeptides and small molecules 
are important in a wide variety of biochemical systems (2). Intermolecular non-covalent 
interactions are also responsible for aggregation of proteins into m ultim ers 
(quaternary structure) (100). Consequently, the detection of non-covalent 
protein-protein and protein-ligand complexes is a challenging problem in Structural 
biology. Ganem and co-workers reported the first application of ESI-MS for 
non-covalent binding between FKBP (an immunosuppressive binding protein) and 
immunosuppressive agents (FK506 and rampamycin) (101). These workers also 
examined enzyme-substrate interactions in the enzymatic reaction of hen egg-white 
lysozyme with various substrates (102). Since these initial reports, specific non-covalent 
in terac tions including protein-protein  (103, 104), pro tein-peptide (105), 
protein-substrate/inhibitor (103), protein-ligand (106), protein-cofactor (107), 
p ro tein -ligand-m eta l ion (108-110), protein-m etal ion (111), DNA-DNA 
(ie. duplex formation) (112, 113) and protein-nucleic acid (114, 115) interactions have 
been observed by direct determination of the mass of the intact complex by ESI-MS.
All of the studies described required sampling of ions from solutions that were suitable 
for the formation of non-covalent complexes, namely buffered aqueous solutions 
(pH 5-7) with little or no organic modifier. Under these solution conditions, the compact 
structure of the non-covalent association in the gas-phase and the imposed Coulombic 
constraints typically results in the formation of molecular ions at high m/z, with relatively 
few charge states (116). Thus a mass analyser with a m/z range greater than 2000 is 
often required to detect these intact species. The coupling of ESI to mass analysers with 
extended m/z ranges, such as magnetic sector instruments, single quadrupole instruments 
modified to operate at m/z greater than 4000 or time-of-flight instruments have enabled 
large non-covalent complexes to be observed. These include: the tetrameric complex of 
avidin (Mr 64 870) (117), streptavidin (Mr -60  000) (118), yeast alcohol dehydrogenase 
(Mr -147 000) and rabbit muscle pyruvate kinase (Mr -232 000) (119).
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Most of the reports of non-covalent interactions in the literature suggest that through the 
careful control of mass spectrometric interface conditions, the data from gas-phase 
ESI-MS can be used for probing molecular interactions that occur in the solution-phase. 
In cases where mass spectral data indicate apparent associations, however, care must be 
taken to differentiate molecular interactions that occur in the bulk solution from processes 
that occur in the ESI droplet desolvation process (120). It is not yet clear how 
representative ESI mass spectra are of the solution chemistry of macromolecules but it 
would appear that for selected biological systems data from ESI-MS do broadly correlate 
with known solution chemistry.
Unresolved issues remain regarding the applicability of ESI-MS to the analysis of 
non-covalent interactions, with respect to possible artefacts produced in the gas-phase 
and the quantitative accuracy of inferences about the stabilities of resultant 
complexes (121). Controlled experiments are necessary to exclude ubiquitous 
non-specific interactions (ie. non-specific aggregation) (122). In the future, it may be 
possible that dissociation constants for solution reactions may be extracted from mass 
spectral data, but further work is certainly necessary to determine the validity of the 
measurements (100).
1.3.3 Higher-Order Protein S tructure --------------------------------------------------------
The higher-order or three-dimensional structure of a protein is important for 
understanding and predicting its function in biological systems. The conformation of a 
protein in solution is dependent on the intramolecular forces dictated by its amino acid 
sequence, and the conversion from the native state to a denatured one often renders the 
protein biologically inactive (123). Various instrumental techniques have been used to 
probe conformational changes of proteins in solution. These methods provide 
information that a conformational change has occurred, but do not always indicate which 
regions within the protein have changed. ESI-MS potentially offers greater speed and
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sensitiv ity  in qualita tively  probing conform ational changes in pro tein  
higher-order structure.
The conformation of a protein in solution can be altered by a variety of methods, 
including the presence of organic solvents or dénaturants (eg. guanidine hydrochloride 
or urea), changes in pH, ionic strength or temperature or by reductive cleavage of 
disulphide bonds with 1,4-dithiothreitol (DTT). The resulting ESI mass spectra of 
denatured proteins typically show an increase in average charge state (at lower 
mlz) (124). The hydrogen exchange kinetics of a protein can be probed by substituting 
D2O for H2O and monitoring the degree and rate of hydrogen/deuterium (H/D) isotopic 
exchange. The extent of H/D exchange depends on the variable accessibility of labile 
hydrogens. ESI-MS can provide important information regarding protein conformation 
by monitoring the degree of deuterium exchange as a function of time. Consistent with 
expectations, data from ESI-MS H/D exchange experiments show the rate of H/D 
exchange to be enhanced in the unfolded forms of the protein versus the folded 
forms (125, 126).
It is difficult to completely decouple the many contributions which determine the ESI 
charge state distribution. Changes in physical parameters may have important effects on 
the desorption/ionisation processes which ultimately may affect the observed charge state 
distribution. Although the distribution observed for proteins in the gas-phase is at least 
partially governed by solution-phase structure and chemistry, it is uncertain how 
liquid-phase structure is related to the relevant gas-phase structure(s). Thus, to what 
extent higher-order protein structure is preserved through the electrospray process to be 
reflected in the ESI charge state distribution is yet to be determined.
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1.4 TANDEM MASS SPECTROMETRY (MS-MS) OF PEPTID ES-------------
Electrospray ionisation mass spectra are usually dominated by ions due to molecular 
species with little fragmentation (9). Accurate molecular mass measurement provides 
some confirmation to the identity of the biomolecule, however, yields little information 
regarding the molecular structure. A more complete indicator is to determine whole or 
part of the sequence of the macromolecule (85). Additional structural information on 
peptides and proteins is obtained through the combination of electrospray ionisation 
techniques with tandem mass spectrometry (MS-MS) (127,128).
Tandem MS involves the coupled use of two stages of mass analysis. The first stage is 
employed to select a peptide precursor ion of interest from the other precursor ions 
produced in the ionisation source (85). Following the 'mass selection' stage is a collision 
cell where the precursor ion is fragmented by transfer of energy to the ion by inducing 
ion/molecule collisions with an inert gas (usually argon or helium). This process is 
known as collision-induced dissociation or decomposition (CID) or collision-activated
F igure 1.3 Tandem mass spectrometry (MS-MS) experiment depicting the selection of a precursor 
ion in the first mass analyser, induced fragmentation of the ion with an inert gas in the 
collision cell and the transmission and detection of ’product' ions in the second mass 
analyser (128).
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dissociation (CAD) (CID is used throughout). The charged fragment ions produced in 
the collision cell are mass analysed by a second mass analyser. The result is a 'product' 
or 'daughter' ion spectrum in which all fragment ions are derived from the selected 
precursor (Figure 1.3). The 'product' ion spectrum is essentially free of interferences 
from other components that may be present in the sample (67).
Fragmentation of peptides by CID mainly occurs in the amide bonds of the peptide 
backbone (129-133) often with transfer of one or two hydrogens to yield stable ion 
structures (134). These fragmentations result in a series of peaks differing by amino acid 
residue masses (135). The presence of a basic amino acid residue at either termini of the 
peptide results in the generation of fragment ions that contain the particular terminus 
(131, 136). A basic amino acid (Arg, His, Lys) at or near the N-terminus results in a 
tandem mass spectrum containing primarily An fragment ions, whereas a basic amino 
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Schem e 1.1 Characteristic fragment ions observed in tandem MS spectra of peptides. Nomenclature 
is that proposed by Roepstorff and Fohlman (137).
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ions (134). This characteristic appears to be due to the localisation of the positive charge 
at a particular site within the peptide (131). The nomenclature for denoting peptide 
fragments proposed by Roepstorff and Fohlman (137) is outlined in Scheme 1.1. The 
variation of the Roepstorff nomenclature proposed by Biemann (136) is also frequently 
used, however, for the purpose of clarity, only the nomenclature proffered by Roepstorff 
and Fohlman (137) is used throughout this thesis.
Tandem MS offers several advantages for peptide sequencing over traditional Edman 
chemistry (138) including the speed of analysis, high sensitivity and the ability to obtain 
information from unseparated peptide mixtures. Tandem MS, particularly when used in 
conjunction with Edman degradation and amino acid analysis, has the capability to 
sequence peptides present in mixtures (130), corroborate DNA or cDNA sequence 
predictions (139-143), locate and correct errors in these sequences (144), sequence 
peptides with blocked N-termini (130, 145) and identify enzymatic or non-enzymatic 
post-translationally modified amino acids (130,144-152).
In a landmark study by Johnson and Biemann in 1987 (153), the primary structure of 
thioredoxin, a redox protein isolated from Chromatium vinosum, was determined entirely 
by tandem mass spectrometry. The reduced and carboxymethylated protein 
(Mr 11 751.2) was digested with several specific proteolytic enzymes and then subjected 
to HPLC separation. The separated peptides were subsequently analysed by MS-MS to 
derive the complete primary sequence of the protein. One of the most well-known 
applications of ESI tandem mass analysis (with a triple quadrupole mass analyser) is the 
work performed by Hunt and colleagues (154-157). In these studies tandem MS was 
used in conjunction with microcapillary HPLC separation techniques and automated 
Edman degradation to identify and sequence peptide antigens associated with class I and 
class II major histocompatibility complex. The quantity of peptide used to obtain 
structural information was in the order of tens of femtomoles, ultimately resulting in the 
identification of a peptide with a high affinity for cytotoxic T lymphocytes
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(killer T cells) (157). In combination with chemical and proteolytic digestion and in 
conjunction with Edman chemistry, protein sequencing by MS-MS has thus proven to be 
a sensitive and powerful methodology (130,136).
Chapter 1 Introduction 28
1.5 MONOCLONAL ANTIBODIES--------- -----------------------------------------------------
1.5.1 Definition  —-------------------------------- - , _____________________________
Antibodies, or immunoglobulins, are host proteins produced in response to the presence 
of foreign molecules (antigens) in the body (158). Antibodies are synthesised primarily 
by plasma cells (ie. terminally-differentiated cells of the B-lymphocyte lineage) and 
circulate throughout the blood and lymphatic systems where they bind to the specific 
antigen against which they are produced. The antigen-antibody complexes are removed 
from circulation primarily through phagocytosis by macrophages (ie. antigen-antibody 
complexes are engulfed by macrophages or other cells of the reticuloendothelial system). 
The antigen-antibody response is highly specific, thus antibodies are important reagents 
for use in immunological research, clinical diagnosis and therapy.
1.5.2 Structure o f Antibodies--------------------------------------------------------------------
Antibodies are large glycoproteins comprised of 82-96% polypeptide and 4-18% 
carbohydrate and are composed of one or more symmetrical Y  shaped molecules. Each 
’Y' molecule contains four polypeptides - two identical glycosylated heavy chains (H) of 
Mx 50 to 75 kDa, and two identical non-glycosylated light chains (L) of Mx ~25 kDa. The 
heavy chains are joined together by disulphide bonds, and each light chain is joined by a 
disulphide bond to one heavy chain (Figure 1.4).
Antibodies are grouped into five main classes based on the number of 'Y'-like units and 
the type of heavy-chain polypeptide they contain. Thus the classes IgM, IgD, IgG, IgE 
and IgA possess 11, 8, y, e and a  heavy chains, respectively. The differences in the 
heavy-chain polypeptides allow these proteins to function in different types of immune 
responses and at particular stages of the maturation of the immune response (158). In 
addition, the IgG class may be further divided into four subclasses (G1-4 in humans; Gi, 
G2a, G2b and G3 in the mouse; G i, G2a, G2b and G2c in the rat). There are two types of 
light chains, K and X, which take part in all biological functions of antibodies and play an
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Figure 1.4  Structure of an IgG molecule. Each chain is made up of a series of homologous units 
of approximately 110 amino acids. Adapted from Goding (159).
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important part in determining the specificity of antibodies. All known 'effector functions' 
of antibodies (eg. complement-mediated lysis of cells) are determined by the 
heavy chains (159).
Light and heavy chains are comprised of a series of homologous units with each unit 
characteristically containing one intra-chain disulphide bond between cysteine residues 
situated about 20 amino acids from each end. The homologous units are folded into a 
domain, which is a compact, globular structure containing large amounts of P-pleated 
sheet (160). Light chains are approximately 220 amino acid residues in length and are 
divided into two regions, of approximately equal length. The N-terminal unit is known 
as the variable (Vl) region and the C-terminal portion is known as the constant (Cl) 
region. Heavy chains are approximately 440 amino acids in length and are divided into 
one variable (Vh) and three constant regions (Ch1, Ch2 and Ch3). Like the light chain, 
each of these four regions are approximately equal in length. The N-terminal units of 
heavy and light chains are designated Vh and Vl, respectively (158,159).
The Vh and Vl domains combine to form one antigen binding site. The heterogeneity of 
the variable regions provides the structural basis for the large repertoire of binding sites 
used by an animal to mount an effective immune response (158). The sequence 
heterogeneity does not occur randomly throughout the variable regions, but is 
concentrated in the areas that form the sites of contact with the antigen. Most of the 
variability occurs in three short regions of each chain, giving three hypervariable regions 
for the light chain and three hypervariable regions for the heavy chain. These regions 
form the majority of contact residues for the binding of the antibody to the antigen and are 
located on short loops extending into the region that interacts with the antigen. Because 
they are the actual binding sites for the antigen, they are referred to as the 
complementarity-determining regions or CDR's (158).
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1.5.3 Hybridoma Technology-------- —------------------------------------------------------------
With the birth and development of genetic engineering in the last two decades it is now 
possible to study, control and manipulate genes in ways which have resulted in a 
quantum leap in our understanding of biological problems. The development of a 
technique for the production of monoclonal antibodies (MAbs) was an integral part of this 
revolution (159). In 1975, Kohler and Milstein (161) developed a method that enabled 
antibody-producing cell lines to be established routinely and maintained in vitro. Normal 
antibody-producing lymphocyte cells isolated from immunised animals were fused with 
myeloma cells to produce a hybrid containing genetic material from both the normal cell 
and its malignant counterpart. The myeloma cells provided the correct genes for 
continuous cell division in tissue culture, and the antibody-producing cells provided the 
functional immunoglobulin genes to produce MAbs of a predefined specificity. In 1984, 
Kohler and Milstein were awarded the Nobel Prize in Physiology and Medicine for then- 
monumental achievements in hybridoma technology. .
The production of normal antibody-producing lymphocyte cells involves the 
administration of an antigen-containing preparation to an appropriate immune recipient 
(often of rodent origin). The treated animal then becomes the source of sensitised 
antibody-producing cells (162). The preferred lymphocyte donor is the spleen, in which 
approximately 20% of cells are B-lymphocytes. These cells carry the rearranged 
immunoglobulin genes that specify the desired antibody (158).
Myeloma cells or plasmacytomas are neoplasms (ie. tumours) caused by the malignant 
transformation of lymphocyte cells and are generally induced by injecting mineral oil into 
the peritoneum of rodents (or other animals). Each tumour represents the proliferation of 
a single clone of antibody-forming cells (162). The myeloma system alone has been 
disappointing as a source of antibodies with known antigen binding specificity, because 
to date it has not been possible to generate antigen-specific myelomas (158). *
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The fusion between a myeloma cell and an antibody-producing lymphocyte cell can be 
effected by any fusogen (eg. Sendai virus) (161), but in practice hybridoma fusions 
became routine after the introduction of the use of high concentrations of polyethylene 
glycol (PEG) (163). PEG fuses the plasma membranes of adjacent myeloma and/or 
antibody-producing cells, to form a single cell with two or more nuclei (164). The 
resultant multinucleate heterokaryon retains the nuclei until the nuclear membranes 
dissolve prior to mitosis. During mitosis and further rounds of division, the individual 
chromosomes are segregated into daughter cells such that they possess a more or less 
equal share of the genetic material (158). The mechanisms involved in the fusion of the 
two cell-types is still poorly understood (165).
When a cell mixture is subjected to reagents which promote fusion, the fusion events are 
uncontrolled (159). Even in the most efficient hybridoma fusions, only about 1% of the 
starting cells are fused, and only about 1 in 105 form viable hybrids (158). 
Antibody-producing cells from an immunised animal have a finite life and do not continue 
to grow in tissue culture, however, the myeloma cells are well adapted to tissue culture 
and must be destroyed. Thus, to produce an immortal antibody-producing hybrid cell 
line, a procedure for the selection of hybrid cells is mandatory. The procedure that is 
commonly used was devised in 1964 by Littlefield (166) and is based on the fact that 
when the main biosynthetic de novo pathway for guanosine production is blocked by the 
folic acid antagonist aminopterin, there is an alternative 'salvage' pathway in which the 
purine.nucleotide metabolites hypoxanthine or guanine are converted to guanosine 
monophosphate via the enzyme hypoxanthine guanine phosphoribosyl transferase 
(HGPRT) (Scheme 1.2). Myeloma cells containing a non-functional HGPRT protein 
will die in a medium containing hypoxanthine, aminopterin and thymidine 
(HAT medium), because both the de novo and 'salvage' pathways are blocked. 
However, a cell which is HGPRT will grow in HAT medium if it is provided with the 
missing enzyme by fusion with a H G PR T cell (ie. a hybrid cell).
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Schem e 1.2  Metabolic pathways relevant to hybrid selection in medium containing hypoxanthine, 
aminopterin and thymidine (HAT medium). When the main synthetic pathways are 
blocked with the folic acid analogue aminopterin (*), the cell must depend on the 
'salvage' enzymes HGPRT and thymidine kinase. HGPRT cells cannot survive in HAT 
medium unless they are fused with HGPRT+ cells. Adapted from Goding (159).
The next stage in the production of MAbs is the separation of the hybridoma cells capable 
of synthesising and secreting the antibody of choice from all the other irrelevant ones that 
are present. This is achieved by the process of cloning (162), which involves the 
repeated growth of cell colonies from very low original numbers until it can be adduced 
with certainty that the colony has been derived from a single cell. By definition, such a 
cell culture will be monoclonal in origin and, if it retains the capacity to synthesise 
antibody, then those antibodies will be MAbs in that all the cells present will be 
synthesising an identical antibody gene product. Such MAb preparations will exhibit 
reactivity with a single antigenic determinant. The overall strategy for the production of 
MAbs is shown in Figure 1.5.
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F igure 1.5  Production of hybridomas. Spleen cells from immune mice are fused with HGPRT 
myeloma (plasmacytoma) cells using polyethylene glycol. The binucleate fusion 
products are known as heterokaryons. At the next division, the nuclei fuse, generating 
hybrid cells, which grow in HAT medium. Unfused myeloma cells die in HAT medium 
and unfused spleen cells can only survive a few days in culture. Hybrids are tested for 
production of antibody of the desired specificity and cloned in vitro. Adapted from 
Goding (159).
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1.5.4 Production of Monoclonal Antibodies-----------------------------------------------
Once viable hybridoma clones have been identified and isolated, the next stage in the 
production of MAbs is the propagation of the clones in such quantities that large amounts 
of antibody may be produced from the hybrids. Hybridoma cells can be propagated 
either in vitro or in vivo. On the laboratory scale, cells can be grown in stationary tissue 
culture to produce typical MAb levels in the supernatant of 5-50 |ig/mL.
Fermenters or bioreactors, originally developed for microbial growth, have been adapted 
for the in vitro growth of hybridoma cells. Mammalian cells have more complex 
nutritional needs and tolerate much lower densities than microbial cultures, therefore they 
require a more carefully controlled culture environment. Antibody yields typically range 
between 40 and 500 mg/L (167) with higher yields achieved with adapted 
fermenters (168).
It is possible to obtain greater amounts (up to 1000-fold) of MAb by adopting an in vivo 
approach to the propagation of hybrids. In most instances, 106-107 hybridoma cells are 
injected intraperitoneally into histocompatible animals that have had their normal 
immunological function depressed (158). Within two to six weeks of hybridoma cell 
injection, ascitic fluid (or ascites) containing 1-10 mg/mL of the MAb accumulates in the 
peritoneum of the animal and can be extracted by means of a syringe and needle (158). 
The response of the hybridoma cells will vary considerably according to the individual 
cell line, both in terms of volume and concentration of MAb produced and in the period 
of development (162).
1.5.5 Purification of Monoclonal Antibodies---------------------------------------------------
Ascitic fluid contains non-immune mouse antibodies and other extraneous proteins, while 
most of the culture supernatant contains proteins from foetal calf serum that may interfere 
with immunological applications of MAbs. Therefore, it is usually necessary to purify 
MAbs from other contaminating proteins (162). The choice of purification method will
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depend on a number of variables, including the final use of the antibody, the species in 
which the antibody was raised, its class and subclass, and the source that will serve as 
the starting material for the purification. Thus it is often necessary to combine several 
methods to achieve the purified end product (158). There are a wide variety of methods 
used to purify antibodies. In practice, simple salt fractionation may be sufficient, 
however, greater levels of purity can be obtained using techniques such as affinity 
chromatography (eg. S. aureus protein A or Streptococcus sp. Protein G), ion exchange, 
size exclusion (SEC) or gel permeation (GPC) chromatography (162).
Ammonium sulphate precipitation is one of the most commonly used method for the bulk 
purification of antibodies. Proteins in solution form hydrogen bonds with water through 
their exposed polar and ionic groups. When high concentrations of small, 
highly-charged ions such as ammonium or sulphate are added, these ions compete with 
the proteins for binding to water, ultimately leading to the removal of water molecules 
from the protein thereby decreasing its solubility and resulting in precipitation (158). The 
concentration of ammonium sulphate at which antibodies precipitate varies from species 
to species, but 50% saturation is a convenient level to use for most applications as most 
of the other components of ascitic fluid or culture supernatant do not precipitate below 
this range. Antibodies purified by this method will be contaminated with high-molecular 
mass proteins, as well as other proteins that are trapped in the large flocculant 
precipitates. The ammonium sulphate precipitation method, although providing 
substantial enrichment of the antibody, is not suitable for purification of antibodies to 
homogeneity and is usually used in conjunction with other purification techniques (158).
Affinity chromatography is based on the irreversible immobilisation of one component of 
a system on a solid-phase matrix (usually agarose), and the subsequent binding and 
elution of a complementary ligand in free solution. Fractionation of MAbs by affinity 
chromatography offers excellent purification in a single step, even if the sample is dilute. 
The volume of recovered protein is independent of the sample volume. The main
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disadvantages of affinity chromatography are the relatively low capacity and high cost of 
immobilised ligands, and the need to subject antibody to denaturing conditions for 
elution (159). Ion-exchange chromatography is one of the simplest and most useful 
ways of purifying MAbs, because simple gradient elution enables a compromise to be 
reached between yield and purity. Ion-exchange chromatography is a gentle method and 
is capable of very high capacity (159). The techniques of size exclusion chromatography 
(SEC) or gel permeation chromatography (GPC) separates proteins according to their 
size. The procedure is simple to perform, and good recovery is achieved, however, it 
usually results in greater dilution and a smaller degree of purification than either ion 
exchange or affinity chromatography (159).
1.5.6 Proteolytic Fragmentation of Monoclonal Antibodies-----------------------
MAbs are composed of three major protein domains, two identical antigen-binding sites 
termed Fab fragments and an effector domain involved in immune response regulation 
termed the Fc fragment, so-called because in some cases it can be crystallised. The 
region .between the Fab and Fc subunits is called the hinge, and it is this segment that 
enables lateral and rotational movement of the two antigen-binding domains 
(Figure 1.6) (158, 159). The use of intact MAbs in many immunochemical techniques 
can introduce problems such as high levels of 'non-specific binding' due to the presence 
of the glycosylated Fc subunit. This can be overcome by antibody preparations in which 
the Fc portion has been removed. Fragmentation of MAbs can be achieved by controlled 
proteolysis, however, the rate and nature of fragmentation will vary considerably with 
species and antibody class or subclass (162).
MAbs can be fragmented by partial digestion with either the enzyme papain or pepsin 
(Figure 1.6). Proteolytic attack of MAbs by papain at neutral pH cleaves at the hinge, 
generating two identical 50 kDa Fab fragments, each containing one intact light chain 
disulphide-bonded to a fragment of the heavy chain (Fj) containing the Vh and Ch 1
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Figure 1.6  The sites of enzymatic cleavage of a monoclonal antibody (MAb) by the sulphydryl 
protease papain and pepsin. Papain cleavage produces Fab and Fc subunits (in the 
presence of cysteine) and the F(ab')2 subunit (in the absence of cysteine). Pepsin 
cleavage also produces a F(ab’)2 subunit Adapted from Liddell and Cryer (162).
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domains (Figure 1.4). The remaining 50 kDa Fc portion of the MAb consists of a dimer 
of Ch2 and Ch3 domains (158, 159).
Papain is a thiol protease (ie. it has a sulphydryl group in the active site, which must be in 
the reduced form for activity). The presence of reducing agents necessary for the 
activation of papain (cysteine, P-mercaptoethanol or dithiothreitol, in order of increasing 
potency) may also facilitate digestion on the substrate. All of these reducing agents have 
the potential of cleaving the labile inter-chain disulphide bonds of MAbs, but the extent to 
which this occurs depends on the nature and the concentration of the individual reducing 
agent (158, 162).
Proteolytic cleavage of MAbs by the non-specific protease pepsin at pH ~4 can be used to 
release the two antigen-binding domains still bound together through the inter-chain 
disulphide bonds. The conditions first described by Stanworth and Turner (169) show 
that MAbs are cleaved at the C-terminal side of the inter-heavy chain disulphide bond. 
The 100 kDa bivalent subunit so produced is known as F(ab')2 fragment 
(Figure 1.6) (158). The application of these procedures to murine and rat MAbs does not 
always produce satisfactory results. Murine F(ab')2 fragments can, however, be prepared 
by papain digestion in the absence of a reducing agent (170).
1.5.7 The B72.3 Monoclonal Antibody—----------------------------------------------------
The advent of hybridoma technology and the subsequent availability of standardised and 
virtually unlimited quantities of monoclonal antibodies have led to the development and 
characterisation of literally dozens of MAbs that are reactive with human adenocarcinoma 
cells. One of the most studied monoclonal antibodies is the B72.3 murine IgGi MAb 
which was first generated in 1981, from mice immunised with an antigen derived from 
membrane-enriched cell extracts of a human metastatic mammary gland carcinoma (171). 
This antibody binds to a tumour-associated glycoprotein termed TAG-72 (172).
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The TAG-72 reactive antigen has been purified and characterised as a high-molecular 
mass glycoprotein (Mr ~106) with mucin-like biochemical properties (172,173).
The B72.3 monoclonal antibody has been reacted with a wide spectrum of adult and 
foetal human tissues using immunohistochemical techniques to evaluate the expression of 
the reactive TAG-72 antigen (174). B72.3 MAb has been shown to have selective
reactivity with a wide range of human adenocarcinomas from the lungs (175), mammary 
glands (176), gastrointestinal tract (177-179), ovaries (180), pancreas (181), and 
prostate (182). Nonepithelial-derived human neoplasms, including melanoma, sarcoma, 
leukaemia, and lymphosarcoma, are generally non-reactive with MAb B72.3 (183). Most 
cell types of normal adult human tissues are non-reactive or only weakly reactive with 
MAb B72.3 (183, 184), with limited reactivity in a few benign tissues such as those of 
the breast and colon tissue and transitional epithelium (183, 185). TAG-72 has also been 
shown to be expressed at high levels in secretory endometrium (186) and transitional 
colonic epithelium (179, 185). The B72.3-reactive antigen is also expressed in some 
human foetal tissues, including foetal colon, stomach and oesophagus (183). The B72.3 
MAb has been used for radioimmunodiagnosis in model systems (187, 188) and the 
m In-labelled B72.3 (Oncoscint™) was the first radiolabelled MAb product to be 
approved for diagnostic use in clinical oncology (189). The B72.3 MAb was the major 
MAb used in this study. For information on other MAbs used, refer to Chapter 3.
1.5.8 Monoclonal Antibody-based Pharmaceuticals-----------------------------------
1.5.8.a Introduction-----------------------------------------— ---------------------------------------
Monoclonal antibodies have long been considered as potential tools for the diagnosis and 
treatment of human carcinomas (190) as well as for diagnosis of non-malignant 
diseases (191). MAbs can serve as selective carriers of radionuclides, drugs or cytotoxic 
agents to specific in vivo tumour-associated antigens. MAbs are ideal carrier molecules 
as they have a variety of surface side-chain functional groups (carboxyl, amino, 
sulphydryl) that are suitable for selective derivatisation using group-specific
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reagents (90). The following discussion is based on the two labelling procedures 
commonly used for the addition of a radionuclide to a MAb, so-called 
radioimmunoconjugates, specifically for the in vivo targeting of tumour-associated 
antigens.
1.5.8.b Direct Labelling Methods----------------------------------------------------------------------
Direct labelling of MAbs exploits the functional groups naturally present in the protein to 
coordinate or incorporate a radionuclide (192). Radionuclides of iodine have been used 
as labels for proteins for several decades and they were the natural choice for early MAb 
labelling research (193). Methods for radioiodination of MAbs (194) include the 
common electrophilic substitution methods which involve oxidation of radioiodine to a 
reactive cationic species (I+). The hydrogen on the carbon atom ortho- to the hydroxy 
position of the phenyl ring of tyrosine residues is replaced by the reactive I+ (as shown in 
Chapter 4, Section 4.4.1, Scheme 4.3).
MAb iodination procedures have several disadvantages (90) including dénaturation of the 
protein under the oxidative conditions employed (189) and, in many instances, there is a 
loss of biological activity which results from damage to the structural integrity of the 
protein (90). In addition, the tyrosyl residues of MAbs are often 'buried' within the 
globular structure of the protein and are not readily accessible for iodination unless some 
unfolding of the protein occurs (90). There are other limitations for the use of iodinated 
MAbs in vivo as dehalogenation of iodinated MAb occurs, resulting in the rapid loss of a 
substantial amount of radioactive isotope, with a concomitant generation of high levels of 
circulating free radioiodine in the blood and subsequent accumulation in the thyroid, 
stomach and bladder (189). Deiodination is presumed to result from the action of in vivo 
deiodinases (191).
Many radionuclides of interest are metals which can not be covalently bound to proteins 
directly (195). Labelling of MAbs with metal radionuclides can be gentler than the
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oxidative methods for iodination and can circumvent the problem of in vivo 
deiodination (191). Many MAbs intrinsically contain a large number of potential sites 
that can bind metal ions, however, metal ions bound to non-specific sites on a protein 
generally have very weak interactions with the protein and hence can be transferred to 
other body proteins (90). Thus, the long-term label stability of direct attachment of 
radiometals to MAbs is low as the stability and inertness of such links are usually 
questionable (196). Hence, direct labelling of MAbs with metal radionuclides has so far 
been limited to technetium and rhenium isotopes (191).
1.5.8.C Indirect Labelling Methods--------------------------------------------------------------------
To alleviate the many apparent problems observed with direct labelling of MAbs with 
radionuclides, as well as the potential denaturation of the MAb due to harsh conditions, 
several indirect labelling methods which utilise ligands that can chelate a metal ion and 
covalently bind to MAbs have been developed (189).
Indirect labelling of MAbs with metal radionuclides is achieved through the use of 
'bifunctional' chelating agents. A bifunctional ligand contains a reactive functional group 
that is involved in the covalent attachment of the ligand to the amino acid residues 
(or carbohydrate moiety) of a MAb and also has the ability to selectively bind a given 
metal (197). The chelating agents provide a known number of high affinity binding sites 
on the protein to which radiometals may be strongly bound (192).
Indirect labelling involves either one of two approaches. In the first approach, the 
radiometal chelate is formed first and then conjugated to the MAb. The advantages of this 
approach are that the metal chelate structure and stability are carefully controlled and the 
MAb is not exposed to the sometimes harsh chelation conditions (191). The major 
disadvantages are the need to perform multiple steps as well as post-labelling purification. 
The second and more widely applicable indirect labelling approach involves the covalent 
attachment of the bifunctional chelating agent to the MAb to form a MAb-ligand conjugate
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(immunoconjugate) which can then be used to bind the radiometal under mild chemical 
conditions (191). .
The bifunctional chelating ligands that have most commonly been used for the indirect 
labelling of MAbs are polyaminocarboxylic acids eg. diethylenetriaminepentaacetic acid 
(DTPA) (198). A covalent amide bond is formed between a MAb amine (generally a 
lysine residue) and one of the carboxylate groups of the ligand (191) (as shown in 
Chapter 4, Section 4.6.6, Scheme 4.5); however, the promiscuity of these acyclic 
chelating agents that can bind a range of metal ions in solution is compromised by 
instability of the complex in vivo. The dissociation of the metal ion in vivo is essentially 
irreversible as the metal ion will be rapidly sequestered by serum proteins eg. transferrin, 
and the complexing agent will be simultaneously occupied by one of the abundant 
serum cations (199). ,
In an effort to resolve the problem of metal retention, numerous other ligands and 
labelling strategies have been developed (191). For example, the incorporation of a 
/7-isothiocyanato-substituted benzyl group into the ethylene backbone of DTPA has been 
shown to increase the serum stability of the labelled immunoconjugate and provide 
improved biodistribution (198, 200, 201). With these ligands the MAb is bound to the 
radiochelate via a covalent linkage with the phenyl ring and thus, unlike with conventional 
dianhydrides, all five carboxylate groups are available for complexation of the metal 
(191).
In spite of these improvements, benzyl derivatives of polyaminocarboxylic acids are not 
optimal ligands for all metals eg. copper. With the introduction of macrocyclic 
bifunctional agents, however, immunoconjugates with higher in vivo stability have been 
prepared (191). The increased stability of the macrocyclic complex is attributed to the 
structural rigidity of the ligand which prevents coordination sites on the ligand from 
rotating away from the metal. Various macrocyclic ligands eg. ^-substituted analogues of
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benzyl TETA (1,4,8,11 -tetraazacyclotetradecane-A^A^V",//'" tetraacetic acid) (202) 
and benzyl DOTA (l,4,7,10-tetraazacyclododecane-V,iV',V",Af" tetraacetic acid) (203) 
have been developed and evaluated for use with a range of metal ions (202-204). These 
more rigid chelating agents yield radiometal immunoconjugates with substantially higher 
in vivo stability and as a consequence there is a marked reduction in non-specific 
radioactivity uptake and improved blood clearance of non-tumour radioactivity.
The methods for characterising MAb-based pharmaceuticals have largely relied on 
techniques such as radioactivity trace assay (200, 205, 206), UV spectrophotometry 
(207, 208), gel filtration and HPLC. These methods are principally used at present to 
quantitate the loading of chelating agents or anticancer drugs on MAbs. Each of these 
methods have potential problems as a number of assumptions and experimental 
difficulties often results in the inaccurate determination of loading values of chelators on 
the proteins (ie. average numbers of moles of chelator bound to the protein). 
An assumption made in the radioactivity trace assay is that the binding constants for pure 
and contaminated radioactive metal ions are identical for both the free and conjugated 
chelators. Deficiencies with UV spectrophotometry are that chelators and drugs 
conjugated to MAbs can not be accurately determined when their absorptivities are low, 
or occur in the protein absorption region, and that the absorptivity of the 
UV chromophore may change upon conjugation. In addition, radioactivity trace assay, 
UV spectrophotometry can not distinguish between covalently and non-covalently bound 
compounds. The advent of mass spectrometry and the ability to transform large 
molecules into gas-phase ions have led to the use of MS for the characterisation of 
modified-MAbs and it has now become possible to overcome many of the difficulties 
observed with other methods of determining loading values on MAbs. Thus, MS should 
prove to be a routine and accurate methodology, free from many of the limitations 
described for techniques currently utilised.
Chapter 1 Introduction 45
1.6 MONOCLONAL ANTIBODIES AND MASS SPECTROMETRY------------
Traditionally, biochemical analyses of MAbs to generate knowledge of the structure and 
function of these proteins, could only be performed by a combination of several methods 
(63, 209). Thus, SDS-PAGE would be employed to yield an approximate average 
Mi and ion-exchange chromatography or isoelectric focussing techniques to ascertain the 
total number of glycoforms present in the molecule, ie. the number of sets of otherwise 
identical polypeptide chains with unique attached oligosaccharides. The exact 
composition of the individual glycans would be determined by physicochemical analysis 
of the carbohydrates released by chemical or enzymatic reaction (209). Overall, such 
detailed analyses are time consuming and hence are not performed routinely.
The analysis of MAbs has required the development of new analytical techniques to 
manage both the increasing complexity of the therapeutic entities and the intensifying 
regulatory scrutiny (210). While no single method to date is adequate for the complete 
analysis of complex glycoproteins, modem mass spectrometric methods coupled with 
chemical methods can be used to derive useful structural information of MAbs and their 
derivatives (63). MS analysis of the individual polypeptide chains as both intact and 
fragmented species has allowed for examination of minor populations of MAb variants 
and sources of microheterogeneity (210).
To date there is a total of fifteen papers in the literature (42, 60, 63,209-220) in which 
mass spectrometric techniques have been applied to the analysis of intact MAbs, 
recombinant MAbs, MAb fragments and their glycoprotein components. Eleven of the 
papers involve ESI-MS (42, 60, 210, 212-216, 218-220), two involve MALDI-MS 
(63,211), one report uses ESI-MS and MALDI-MS to confirm the predicted amino acid 
sequence and carbohydrate structure of a MAb (217) and the remaining paper compares 
the analysis of MAbs by ESI-MS and MALDI-TOF-MS (209). Only five of the papers 
(60, 63, 211-213) were reported prior to the commencement of this study (in early 
1993), of which three (60, 212, 213) used ESI-MS for the analysis of the MAbs or
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MAb fragments. The following discussion traces the history of mass spectrometry of 
MAb fragments, intact MAbs and modified MAbs.
The first mass spectrum of a MAb Fab fragment was reported in 1991 by Feng and 
colleagues (212). The article describes the analysis of a range of high molecular mass 
proteins, including a MAb Fab fragment on a low resolution Sciex API i n  triple 
quadrupole mass spectrometer (m/z range of 0~2400). The ESI spectrum of the 
F ab fragm ent revealed the presence of two components of molecular mass 
47 643.1±0.6 Da and 47 542.9±0.5 Da, respectively. The mass difference of 100.2±0.6 
Da was believed to be due to either a Val or Thr loss (99.1 and 101.1 Da, respectively) 
caused by papain cleavage of the MAb at adjacent sites. The ambiguity encountered in 
this example could probably have been solved by increasing the instrument resolution, 
however, the resolving power of the instrument was limited. These investigators were 
therefore unable to conclusively determine if the second minor component in the 
Fab spectrum was due to the loss of a Thr or Val residue. *
Also in 1991 two reports were published detailing matrix-assisted UV-laser 
desorption/ionisation mass spectrometry (MALDI-MS) of intact MAbs and modified 
MAbs (211, 221). Eisenhut and co-workers (211) described the use of MALDI-MS to 
determine the number of covalently bound BAT ligands that were conjugated to a MAb 
[BAT = bis(aminoethanethiol) 6-(4T- (4M-carboxyphenoxy)butyl)-2, 10-dimercapto-2, 
10-dimethyl-4, 8-diazaundecane]. The centroids of the unconjugated MAb and 
BAT-conjugated derivative differed by 730 Da indicating that approximately 1.7 BAT 
ligands had been bound per MAb molecule. The broader peak width of the conjugated 
MAb spectrum was attributed to the statistical distribution of un-, mono- and 
di-substituted products.
In a more detailed analysis, Siegel and colleagues (63,221) evaluated MALDI-MS for the 
characterisation of a range of native and chemically-modified MAbs. The molecular
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masses of intact MAbs were measured and the average mass of the carbohydrate 
estimated from the difference between the MALDI mass and the mass of the protein as 
determined from the translated amino acid sequence. The loading of chelators and 
anticancer drugs conjugated to MAbs was determined from the mass difference between 
the conjugated and unmodified protein. The loading results obtained by MALDI-MS 
were consistent in most cases with measurements obtained by radioactivity trace assay or 
UV spectrophotometry. Unmodified and conjugated MAbs were reduced and analysed to 
determine the distribution of carbohydrate and chelator between the light and heavy 
chains. These investigators concluded that MALDI-MS can be used as an alternative and 
additional method to analytical techniques in general use for determining the loading of 
substances conjugated to large molecules
Feng and Konishi were the first investigators to demonstrate that ESI-MS could be used 
for the analysis of glycoproteins up to 200 kDa including a number of intact MAbs (60). 
The ESI mass spectra of the MAbs analysed on a Sciex API E l triple quadrupole 
instrument all produced charge distribution profiles in the high m/z range (2000-2400), 
however, in each case the distribution of charge states appeared to extend beyond the 
mass range (m/z 2400) of the analyser and only the low intensity portion of distribution 
was monitored (ie. charge states 62+ to 72+). In addition, the resolution of the instrument 
was insufficient to resolve MAb carbohydrate microheterogeneity. Nonetheless, the 
average molecular mass of three murine IgG MAbs were determined from the ESI 
mass spectra.
The charge distribution profiles of the MAbs appeared in the m/z range >2000, much 
higher than those of the majority of the proteins studied by ESI-MS prior to this study. 
The observed high m/z charge distribution profiles can not be attributed solely to the lack 
of chargeable sites in the MAbs as the charge distribution profiles of ESI spectra of 
separated light and heavy chains range from m/z 1200-1600, indicating that the 
constituent chains have sufficient protonation sites. A previous study (212) revealed that
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the charge distribution profile of a MAb Fab fragment is also at a high m/z range, although 
not as high as for the intact MAb. These data suggested that the unique structural 
arrangement of an IgG molecule and the interactions between the constituent chains are 
responsible for shifting the charge distribution profile to a higher m/z (low charge state) 
range and that this is probably due to reduced proton accessibility for inner 
chargeable sites.
As stated above, the ESI-MS instrument used in the study of intact MAbs by Feng and 
Konishi (60) could not resolve the carbohydrate microheterogeneity of intact MAbs. 
Jiskoot and co-workers (213) demonstrated on a VG BIO-Q ESI instrument that the mass 
heterogeneity of MAbs (due to the variation in glycosylation patterns) could be 
ascertained if the protein was proteolytically digested and the reduced and alkylated 
25 kDa Fc fragment assessed by ESI-MS. The apparent molecular mass of Fc subunits 
as determined by SDS-PAGE was approximately 31 kDa, however, the molecular masses 
observed by ESI-MS for the two Fc fragments studied ranged from 24.8 to 25.9 kDa and
25.7 to 26 kDa, respectively. The mass discrepancy between these techniques was 
attributed to the aberrant migration of the glycosylated Fc fragment in SDS-PAGE due to 
inefficient binding of SDS to the glycoprotein (222). The ESI spectra obtained for the 
reduced and alkylated MAb Fc subunits were clearly different from one another, 
illustrating the utility of ESI-MS for the identification of different Fc preparations. The 
resolution of the technique also permitted the detection of several components, which 
were attributed to carbohydrate heterogeneity.
In 1993, Feng and Konishi (214) reported a CID study of multiply-charged 150 kDa 
MAb ions using a Sciex API III triple quadrupole mass spectrometer. The charge 
distribution profile of the intact murine IgGi MAb was again truncated as reported in 
earlier studies (60). CID of the MAb produced a secondary charge-state ion distribution 
series (11+ to 14+) consistent with the mass of the MAb light chain, indicating that the 
interchain disulphide bridge that links the light and heavy chains had been collisionally
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ruptured. Cleavage of a disulphide bridge has been shown to be the preferred collisional 
dissociation pathway of disulphide-bridged dimeric peptides (223). The presence of a 
MAb fragment comprised of two heavy chains bound to one light chain or a MAb 
fragment comprised of two heavy chains only, were not detected in the 
MS-MS spectrum. It was surmised by these workers that the charge-state distribution for 
these species were either above the m/z range of the instrument, or that insufficient 
charging on the proteins may have prevented their detection. The 75 kDa fragment 
consisting of one heavy and one light chain was also not observed. Inter-heavy chain 
linkages in a murine IgGi MAb consists of three disulphide bridges whose cleavage 
would demand a much higher energy input. Production of the 50 kDa heavy chain would 
be even less likely as this would require cleavage of the three inter-heavy chain disulphide 
bridges and one additional inter-light chain-heavy chain disulphide bridge. The MAb CID 
study demonstrated that multiply-charged macrosized ions as large as 150 kDa can be 
fragmented by collisions with argon gas, however, the structural information generated 
was rather limited.
In 1994, three reports appeared in Volume 66 of Analytical Chemistry detailing the use of 
ESI-MS for the characterisation of MAbs and MAb fragments (42, 210, 215). In the first 
of these publications Verentchikov and co-workers (42) became the first researchers to 
report the complete ESI mass spectrum of an intact MAb with no truncation of the lower 
charge states (at higher m/z). An ESI source was coupled to a reflecting 
time-of-flight (TOF) mass spectrometer with orthogonal ion injection and this was used 
to demonstrate the m/z spectrum of an intact MAb extending beyond m/z 2400. 
The spectrum revealed that the charge-state distribution ranged from approximately 
m/z 2200 to 3500, the most abundant charge state (ie. 50+) was centred at m/z 3000 and 
that only a small fraction of the distribution was below m/z 2400.
In the second of these reports, Lewis and colleagues (210) provided a detailed ESI-MS 
analysis of the recombinant humanised MAb (hu-anti-TAC) using a Perkin-Elmer-Sciex
Chapter l Introduction 50
API III triple quadrupole mass spectrometer, capillary reversed-phase liquid 
chromatography mass spectrometry (LC-MS) and tandem MS. Disulphide-reduced and 
trypsin-digested samples of the MAb were analysed by LC-ESI-MS and it was 
demonstrated that two forms of biantennary carbohydrate structures were present in the 
MAb which were consistent with those reported for the human IgGi framework. In 
addition, the N-terminus of the heavy chain was found to be modified by conversion of 
Glu to pyroglutamic acid and partial removal of the C-terminal heavy chain lysine residue 
was evident. This information was confirmed by mass calculations of tryptic peptides 
followed by MS-MS sequencing. These investigators clearly demonstrated that the high 
sensitivity of ESI-MS, when combined with capillary chromatography LC-MS and 
tandem MS, can provide detailed information of the protein structure of high molecular 
mass proteins such as MAbs.
Finally, the third report published in Volume 66 of Analytical Chemistry detailed the use 
of ESI-MS by Bourell and colleagues to confirm the amino acid sequences of a range of 
recombinant Fab and F(ab’)2 fragments of the humanised huMAb4D5 anti-pl85HER2 
antibody (215) and to corroborate the identity of the variant MAb fragment. On-line 
reversed-phase high-performance LC-MS was coupled to a Perkin-Elmer-Sciex API HI 
triple quadrupole mass spectrometer and in most instances the spectra obtained by 
LC-MS infusion were markedly improved due to the removal of non-specific salt adducts 
resulting in increased sample purity. The measured masses of the recombinant Fab and 
F(ab')2 fragments were in excellent agreement with predicted masses, however, the 
charge-state distribution profile for the intact subunits were truncated due to the low m/z 
range of the Sciex instrument. Disulphide reduction to yield the component subunits of 
the Fab and F(ab')2 fragments provided additional confirmation of the correct amino acid 
sequence and unlike the intact species the charge-state distribution of the fully reduced 
MAb fragments were within the m/z range of the instrument. These data clearly 
demonstrated that ESI-MS can be used routinely to measure the masses of purified 
proteins as large as 100 kDa, with an accuracy of <0.02%.
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In 1995, the complete ESI mass spectrum of the B72.3 MAb (171) using a Fisons 
VG Quattro™ triple quadruple  instrument (m/z 4000) and a Fisons VG AutoSpec™ 
magnetic sector mass spectrometer (m/z 8000) (216) were reported. This publication is 
based on the work described in this thesis and was the first report of a complete ESI 
mass spectrum of an intact MAb since the initial account by Verentchikov and colleagues 
(42). Further details are given in Chapter 3.
Also in 1995, two reports were published in which the complementary techniques of 
ESI-MS and MALDI-MS were used to extensively characterise two humanised MAbs. 
In the first of these, Ashton and colleagues studied the intact MAb CAMPATH 1H, the 
deglycosylated species, and a range of MAb fragments (209). The ESI spectra were 
measured with either a VG BioQ or a VG Quattro™ II quadrupole mass spectrometer, 
both having a m/z range of 4000 and the MALDI spectra were all obtained using a 
VG TofSpec instrument. The ESI mass spectra of the glycosylated species gave 
complex patterns of molecular masses due to carbohydrate heterogeneity, whereas the 
MALDI mass spectra of the glycosylated species gave single molecular mass values 
comparable to the mean molecular mass calculated from the ESI results. The molecular 
masses determined for the non-glycosylated species supported the known amino acid 
sequence for the MAb and defined the cleavage sites for the enzymatic fragmentations.
In the second report, the complete amino acid sequence and site-specific carbohydrate 
structure of a recombinant MAb directed against respiratory syncytial virus (RSHZ19) 
was extensively characterised by Roberts and co-workers (217). A Perkin Elmer-Sciex 
API-ID triple quadrupole mass spectrometer was used for all ESI mass spectra and the 
laser desorption spectra were measured on a VG TofSpec instrument ESI-LC-MS was 
used for peptide mapping and selective identification of glycopeptides, and Edman 
degradation and MS-MS were used to define the sequences of selected peptides. 
MALDI-MS was used to characterise endo- and exoglycosidase digests of isolated 
glycopeptides to identify the glycosylation-site peptide and define the structures of the
Chapter 1 Introduction 52
carbohydrates at that site. These experiments verified almost all of the light and heavy 
chain amino acid sequences, confirmed the N- and C-termini of both chains, and 
demonstrated the nature and relative extent of heterogeneity at the N- and C-termini of the 
heavy chain. Carbohydrate was found exclusively at N of the heavy chain and there 
was no evidence for a non-glycosylated form of the MAb or for the presence of 
O-linked carbohydrate. The distribution of glycoforms at N of the heavy chain was 
determined by MS of the isolated, tryptic glycopeptide and compared with results 
obtained by high-performance anion-exchange chromatography and high-resolution gel 
permeation chromatography of oligosaccharides released by hydrazinolysis. The 
sequences and linkages of individual glycan species were determined by MALDI-MS by 
monitoring the results of a series of controlled digestions with specific exoglycosidases. 
This study illustrated some of the unique capabilities that MS provides for identifying 
sites and structures of modifications such as glycosylation, N-terminal blocking groups, 
and C-terminal proteolytic clipping. These investigators clearly demonstrated that the 
primary structure of MAbs may be extensively characterised through a combination of 
LC-ESI-MS and MALDI-MS, supplemented as necessary with Edman degradation and 
MS-MS studies. ,
In 1996, two reports were published which arose from the work described in this thesis. 
The ESI mass spectrum of a modified MAb Fab fragment was reported (218). 
Chemically-derivatised MAb fragments had not been investigated by ESI-MS prior to the 
commencement of this study (in early 1993). ESI-MS was also used to examine the Fab, 
F(ab')2 and deglycosylated Fc fragments obtained from the murine IgGi B72.3 antibody 
MAb following digestion with papain, in an attempt to determine the sites of cleavage and 
thus to clarify the mode of action of this enzyme on MAbs (220). These studies 
illustrated the power of ESI-MS for characterising chemically-modified proteins of high 
molecular mass, as well as providing a rapid and sensitive technique for assessing protein 
fragments produced from proteolytic digestion of intact MAbs. The details of the work 
giving rise to these two publications are given in Chapters 3 and 4.
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Huang and colleagues have reported the ESI mass spectra of an intact MAb in which the 
heterogeneity of the glycosylation pattern is clearly resolved (219). To detect the type of 
microheterogeneity observed with MAbs, it is necessary to achieve a mass resolution that 
resolves approximately 150 Da (the average mass of a monosaccharide) in the 
mass-to-charge range of 150 000 Da (the average molecular mass of MAbs) after 
deconvolution of the multiply-charged envelopes. MAbs carry ~50 charges, thus the 
actual mass resolution required is ~3 miz units. The Finnigan MAT TSQ 7000 triple 
quadrupole mass spectrometer used in this study was tuned for adequate mass resolution 
to detect different glycosylated forms of the MAbs without significant loss of sensitivity. 
As predicted, a mass resolution of 3 m/z units resolved multiple peaks in each charge 
state due to the heterogeneity of the MAb. Peaks corresponding to individual hexose 
sugar (162 Da) or fucose deletions (146 Da) were clearly identified. These investigators 
suggested that it is possible for a quadrupole instrument to measure 150 kDa 
glycoproteins and resolve the individual glycosylation patterns on the intact MAb. It 
would appear that the optimisation of the mass spectrometer in high mass-to-charge range 
is crucial for the characterisation of MAbs, but also it would appear that it is important to 
introduce these large proteins into the ESI source through a HPLC if this is feasible. 
This process eliminates the formation of salt adduct ions, and thus the resolution was 
markedly improved. This was further supported as these investigators found that the 
multiply-charged ion envelope for MAbs remained congested due to adduct ion formation 
even when samples were carefully dialysed against water prior to infusion into the 
source.
In conclusion, it can be seen from the array of publications that have appeared in the 
literature in the last six years since the first report of mass spectrometry analysis of a 
MAb fragment (212), that the field of mass spectrometry has become, and undoubtedly 
will continue to be, an important area of research for the ongoing characterisation of 
MAbs, MAb fragments and derivatised MAbs. It can be expected that mass spectrometry 
will also continue to play an important role in the quality control and product analysis of 
pharmaceutical-based MAbs.
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1.7 OUTLINE OF THIS STUDY---------------------------------------------------------------
The early part of this chapter describes a brief outline of the history and development of 
mass spectrometry for the analysis of biological samples culminating in the development 
of the 'soft' ionisation techniques, electrospray ionisation mass spectrometry (ESI-MS) 
and matrix-assisted laser desorption ionisation mass spectrometry (MALDI-MS). 
ESI-MS, which is the major concern of this thesis, is described in more detail including a 
description of the instrumentation and the mechanisms that have been proposed to 
account for ion formation. The application of ESI-MS in the analyses of proteins 
including covalent interactions, such as post-translational modifications and chemical 
derivatisation of proteins; a key aspect of this study, are outlined. In addition, the study 
of non-covalent interactions and higher-order protein structure by ESI-MS are discussed 
briefly. Tandem mass spectrometry is described and application of MS-MS to modified 
peptides and proteins is highlighted with a few key examples (the applications of MS-MS 
to peptide characterisation are now so extensive that a comprehensive coverage would not 
be practical).
The latter part of this chapter deals with the structure, development, purification and 
fragmentation of monoclonal antibodies (MAbs). The use of MAbs as pharmaceuticals 
eg. radioimmunoconjugates, is described in detail, including the available methods for 
derivatisation of MAbs. The discussion in Section 1.6 provides a comprehensive review 
of the literature to date concerning mass spectrometry (ESI-MS and MALDI-MS) of intact 
MAbs, MAb fragments and modified MAbs. Several key points that emerge which are 
relevant to the work described in this thesis. Firstly, there have been no studies of 
chemically-derivatised MAbs and few examples of MAb fragments analysed by ESI-MS. 
Most of the MAb studies have been concerned with confirmation of amino acid sequences 
of MAbs or location of the carbohydrate moiety on the MAb heavy chain by mass alone 
or in conjunction with protein digests and tandem MS. Further, only one of these reports 
had been published prior to the commencement of this study.
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The major aim of this work was, therefore, to use ESI-MS to examine a range of MAbs, 
MAb fragments, modified MAb fragments and other chemically-modified proteins as part 
of a broader study aimed at establishing ESI-MS as a method for the characterisation of 
radioimmunoconjugates. To this end the specific aims of this project were:
(i) to optimise instrument and experimental parameters for the ESI analysis of 
monoclonal antibodies and antibody fragments ie. Fab, F(ab')2 and Fc;
(ii) to characterise the structure(s) of specific chemically-modified proteins and 
antibodies, and;
(ii) to explore the utility of ESI-MS and tandem MS for the investigation and 
characterisation of covalent ligand-protein interactions in general.
The VG Quattro™ triple quadrupole mass spectrometer used for the analysis of native 
and modified proteins, MAb fragments and intact MAbs and the VG AutoSpec™ 
magnetic sector mass spectrometer used in the characterisation of intact MAbs are 
described in detail in Chapter 2. This chapter also outlines the techniques for generation 
of MAbs and MAb fragments as well as the procedures utilised for the chemical 
derivatisation of the proteins, some of which required adaptation to suit either the proteins 
under investigation and/or subsequent ESI analysis.
The optimisation of ESI analysis of the murine IgGi B72.3 MAb (171) and a range of 
other MAbs using both the instruments described in Chapter 2 is discussed in Chapter 3. 
The difficulties encountered in characterising intact MAbs cf. smaller proteins are 
detailed. The optimum ESI conditions for intact antibodies are also compared with MAb 
fragments. In addition, ESI-MS analyses of the reduced and/or deglycosylated MAb and 
MAb fragments allowed the available sequence information for the B72.3 monoclonal 
antibody to be compared to data obtained from ESI-MS. The final section of this chapter 
describes the optimisation of papain digestion for the generation of MAb fragments.
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Characterisation of native MAbs and MAb fragments was only one aspect of this study. 
ESI-MS was to be used for the analysis of a range of chemically-modified peptides and 
proteins (which were used primarily for method development) and ultimately 
chemically-modified MAbs and fragments. Chapter 4 details the derivatisation of small 
peptides and lower molecular mass proteins by a range of common, readily-available, 
protein modification reagents. The information gleaned from these studies was then 
extended to the larger MAb fragments and ultimately to intact MAbs. The potential of 
these modifying reagents for use in the production of radioimmunoconjugates is 
discussed. Chapter 4 also discusses the use of ESI-MS for characterising antibody-based 
pharmaceuticals and also for determining the purity of the derivatised proteins prior to 
use in vivo.
Finally, Chapter 5 outlines a series of low-energy MS-MS experiments on singly- and 
doubly-charged ions performed on a modified amino acid and modified peptides to 
determine firstly, if it is possible to locate and confirm the site(s) of chemically-induced 
modification and secondly, what influence the commonly-used modifying groups have on 
the fragmentation observed in MS-MS spectra.
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CHAPTER 2
INSTRUMENTATION AND EXPERIMENTAL PROCEDURES
2.1 MATERIALS --------------------------------- :________________________________
The following materials were purchased from Sigma Pty. Ltd. (St. Louis, MO, USA): 
hen egg-white lysozyme (HEL), horse heart myoglobin, polypropylene glycol 3000 
(PPG), diethylenetriam inepentaacetic acid anhydride (cDTPA), anhydrous 
dim ethylsulphoxide (DMSO), l-(3-dim ethylam inopropyl)-3-ethylcarbodiim ide 
hydrochloride (EDC), mercuripapain (2x crystallised suspension in 70% ethanol), 
cysteine-HCl, 1,4-dithiothreitol (DTT), L-lysine-HCl, N-acetyl histidine, glutathione 
(y-Glu-Cys-Gly), p-Glu-His-Pro peptide, p-Glu-His-Gly-NH2 peptide, bovine serum 
albumin (BSA), human serum albumin (HSA), sodium bicarbonate (NaHCÛ3), 
ammonium bicarbonate (NH4HCO3), Folin and Ciocalteu's phenol reagent, Trizma® 
hydrochloride, Trizma® base, sodium hydroxide (NaOH), sodium carbonate (Na2CÛ3) 
and pristane (2,6,10,14-tetramethylpentadecane).
l,3,4,6-tetrachloro-3a-6a-diphenylglycoluril (Iodogen®) iodination reagent and 
N-hydroxysuccinimidobiotin (NHS-biotin) were purchased from Pierce (Rockford, IL). 
iV-glycosidase F (PNGase F) was purchased from Boehringer (Manneheim, Germany).
[Co(diAMsarH2)](N03)2 (diAMsar = l,8-diamino-3,6,10,13,16,19-hezaazabicyclo- 
(6.6.6) icosane) and [(T|5-C6H7) Fe(CO)3]BF4 (Fed+) were gifts from Dr Stephen Ralph 
and Professor Leon Kane-Maguire, respectively, of the Department of Chemistry, 
University of Wollongong, Australia.
Acetonitrile (HPLC grade), methanol (HPLC grade), dichloromethane (DCM), 
trifluoroacetic acid (TFA), sodium chloride (NaCl), formic acid (HCOOH), ammonium 
acetate (CH3COONH4), sodium iodide (Nal), copper sulphate (CUSO4.5H2O) and
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ammonium sulphate (NH4SO4 ) were purchased from Ajax Chemicals, Auburn, 
Sydney, Australia.
Sodium dihydrogen orthophosphate (NaH2P0 4 .2 H2 0 ), disodium hydrogen 
orthophosphate (anhydrous) (Na2HP0 4 ), disodium ethylenediaminetetraacetic acid 
(Na2EDTA) and sodium tartrate were purchased from BDH Chemicals Pty. Ltd., 
Kilsyth, Victoria. Sodium dodecyl sulphate (SDS) was purchased from 
Bio-Rad Laboratories Incorporated, Hercules, CA.
The synthetic peptides (refer to Table A1 in Appendix A for the one letter codes of the 
amino acids) cGMP protein kinase substrate (cGMP - RKRSRKE, Mr 958.58), human 
angiotensin I 4-10 (YIHPFHL, Mr 925.48), iV-acetylated aB crystallin C-terminal 
peptide (Ac-EEKPAVTAAPKK, Mr 1309.72), luteinising hormone releasing hormone 
(LHRH - EHWSYGLRPG, Mr 1182.56) and [Cysn ]-LHRH (EHWSYGLRPGC, 
Mr 1285.57) were obtained from Auspep Pty. Ltd., Parkville, Victoria, Australia.
The B72.3 murine MAb hybridoma cell line was purchased from the American Type 
Culture Collection (ATCC), USA.
Murine B72.3 monoclonal antibody (MAb) was produced 'in-house' or purchased from 
Bioquest Limited (Sydney, NSW, Australia). Murine MAb X was supplied by Dr Rikki 
Waterhouse, Biomedicine and Health Program, ANSTO from a sample provided by the 
National Institute of Health, USA. The chimaeric 14.18 MAb and the murine 
9.2.27 MAb were supplied by Dr Richard Lambrecht, University of Tübingen, 
Germany.
All water used for experimental purposes was of Milli-Q™ grade.
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2.2 PRODUCTION AND PURIFICATION OF MURINE B72.3 MAb--------
2.2.1 Animal Ethics—------------------------------------- ---------------------------------------------
All animal experimental procedures were approved by the Australian Nuclear Science and 
Technology Organisation (ANSTO) Animal Care and Ethics Committee (ACEC), in 
compliance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes.
2.2.2 Animal Care-----------------—— ---------------------------------------------------------------
Experiments were performed using 6 to 9 week old male and/or female Balb/c mice raised 
on a commercial chow diet (YSF Pty. Ltd., Young, NSW, Australia) together with water 
ad libitum. Animals were housed in groups at 21±1°C under a 12h:12h light/dark cycle.
2.2.3 Production of Ascitic Fluid---------------------------------------------------------------
Ascitic fluid (or ascites) is the intraperitoneal fluid which accumulates in animals that have 
developed a peritoneal tumour. The tumour is induced by the injection of hybridoma 
cells into the peritoneum, where they continue to grow and secrete high concentrations of 
the MAb specific to the tumour (158).
Balb/c mice were pre-treated with 0.5 mL pristane (2,6,10,14-tetramethylpentadecane) 
injected intraperitoneally (i.p.) with a hypodermic glass syringe fitted with a  26Gx^" 
needle (Terumo Corporation, Tokyo, Japan). Pristane acts as an irritant to the mice, 
which respond by secreting monocyte and lymphoid cells into the peritoneum creating an 
ideal environment for the growth of the hybridoma cells (158). Pristane also severely 
depresses the normal immunological function of the animal (224). Seven to fourteen 
days after pristane pre-treatment, 5xl05 to 5xl06 B72.3 hybridoma cells suspended in 
0.1 mL 50 mM sodium phosphate buffered saline (PBS, pH 7.2) were injected i.p.
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Animals were monitored twice daily (early morning and early evening) for the appearance 
of abdominal swelling indicative of accumulated ascitic fluid. Within one to six weeks 
following the injection of the cells, when the mice were noticeably large but before they 
had difficulty moving, the animals were sacrificed by cervical dislocation and the ascitic 
fluid drained from the peritoneum. Ascitic fluid was centrifuged at 1500xg for 5 minutes 
at 4°C to form a pellet of hybridoma and red blood cells. The supernatant was removed 
and clarified (to remove fat) by centrifugation at 10 OOOxg for 10 minutes at 4°C. 
Clarified ascitic fluid was stored at -20°C until required.
2.2.4 Purification o f B72.3 Monoclonal Antibody----------------------------------------
The B72.3 MAb was precipitated from the ascitic fluid by the slow addition of saturated 
ammonium sulphate at 4°C to a final concentration of 50% (v/v). After stirring for 
30 minutes, the precipitate was collected by centrifugation at 10 OOOxg for 10 minutes at 
4°C and the supernatant removed. The protein pellet was re-dissolved in 50 mM PBS 
(pH 7.2) at one quarter the original ascites volume and filtered through a 0.22 pm syringe 
filter (Millipore Corporation, Bedford, MA).
The B72.3 MAb was separated from murine serum albumin, transferrin and 
immunoglobulin M (IgM) on a high pressure W aters 625 HPLC system 
(Waters Associates Incorporated, Milford, MA) with a 600x21.2 mm BioSep Sec 3000 
size exclusion column (Phenomenex, Torrance, CA) equilibrated at a flow rate of 
3 mL/min with 50 mM PBS (pH 7.2). The BioSep Sec 3000 size exclusion column was 
calibrated prior to injection of ascitic fluid with Bio-Rad protein standards 
(Bio-Rad Laboratories Incorporated, Hercules, CA). A least squares standard curve of 
Mr versus column retention time was constructed and from this the retention time of the 
B72.3 MAb was calculated to be ~45 minutes. The amount of eluted MAb was 
determined by the protein assay method of Lowry et al. (225), as described in 
Section 2.4. The purity of the MAb was verified by sodium dodecyl sulphate
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polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing conditions (226). 
Purified B72.3 MAb (1 mg/mL) was stored at -20°C until required.
2.3 ENZYMATIC DIGESTION OF MONOCLONAL ANTIBODIES----------
2.3.1 Preparation of Fab and Fc Fragments------------------------------------------------
Papain (2 mg/mL) was diluted in the digestion buffer (75 mM NaCl, 2 mM Na2EDTA 
and 75 mM sodium phosphate plus 10 mM cysteine-HCl, pH 7.0) and activated for 
2 minutes at 37°C before addition to the B72.3 MAb. Fragments were prepared by 
dialysing MAb (10 mg/mL) into the digestion buffer containing 10 mM cysteine-HCl and 
then digesting with 0.5 to 10% papain (w/w) for 90 minutes at 37°C. This procedure is a 
modification of the method of Brown et al. (227).
2.3.2 Preparation of Ffab'fo Fragment------------------------------------------------------------
In a variation of the method of Milenic et al. (228), papain (2 mg/mL) was diluted in the 
digestion buffer and activated for 2 minutes at 37°C (as above). Cysteine was removed 
from the activated papain by Centricon ultrafiltration tubes (Amicon, Lexington, MA). 
Papain digestion was similar to that described above (Section 2.3.1), however for the 
production of the F(ab')2 fragment cysteine-HCl was not added to the digestion buffer.
2.3.3 Separation of Fab, F(ab*)2 and Fc Fragments-------------------------------------
B72.3 F ^  or F(ab’)2 fragments were separated from undigested MAb, Fc fragment and 
papain on a medium pressure BioLogic™ system (Bio-Rad Laboratories Incorporated, 
Hercules, CA) with a HR 5/5 Mono Q™ anion exchange column (Pharmacia, Uppsala, 
Sweden) equilibrated at a flow rate of 1 mL/min with Buffer A (5 mM sodium phosphate 
buffer, pH 8.0). Proteins were detected by the change in absorbance at 280 nm (A28o)* 
The MAb fragments were eluted with a program of 100% Buffer A for 5 minutes, 
followed by a linear gradient of 0-42% Buffer B (300 mM sodium phosphate buffer, 
pH 8.0) for 11 minutes and 100% Buffer B for 3 minutes. The column could be reused
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for further separations after re-equilibration in Buffer A for 5 minutes. This procedure 
was adapted from the method of Clezardin et al. (229). B72.3 Fab or F(abf)2 fragments 
were eluted in the void volume, and papain, undigested MAb and Fc fragment were 
retained on the column and eluted consecutively as the percentage of 300 mM sodium 
phosphate buffer was increased. The amount of Fab, F(ab')2 and Fc fragments produced 
were determined by the protein assay method of Lowry et al. as described in 
Section 2.4 (225). -
2.4 LOWRY METHOD OF PROTEIN QUANTITATION (2 2 5 )------------------
Sodium tartrate (1 g) and Q 1SO4.5H2O (0.5 g) were dissolved in 500 mL water. 
Na2CC>3 (10 g) dissolved in 500 mL water was added slowly to the copper/tartrate 
solution. The copper/tartrate/carbonate mixture was added to 5% SDS (w/v) and 
0.8 M NaOH in the ratio of 1:2:1 (Reagent A). Folin-Ciocalteu's phenol reagent (2 N) 
was diluted 1:5 with water (Reagent B).
Standards of BSA (20, 40, 60, 80 and 100 jig/m L) and unknow n sam ples 
(-5-100 |ig/mL) were prepared. Reagent A (1 mL) was added to each protein sample, 
mixed and incubated at room temperature for 10 minutes. Reagent B (500 |iL) was then 
added to each sample, mixed immediately and incubated at room temperature for 
30 minutes. The absorbance of each sample was then determined at 750 nm (A750) on 
UV 265 UV-visible recording spectrophotometer (Shimadzu Corporation, Kyoto, 
Japan). A least squares curve of the A750 of standard protein samples versus protein 
concentration was constructed and from this the concentration of the unknown samples 
were determined.
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2 .5  CHEM ICAL MODIFICATION R E A C T IO N S ---------------------------------------
2.5.2 Conjugation o f  [(r\5-C6H 7) Fe(CO)3]+ (Fed*)---------------------;--------------
N-acetyl histidine, p-Glu-His-Pro peptide, p-Glu-His-Gly-NH2 peptide, glutathione and 
LHRH (1 m g/m L) in water were each reacted at an equim olar ratio with 
[(tj5-C6H7) Fe(CO)3]BF4 (Fed+) and [Cysn ]-LHRH (1 mg/mL) was reacted at 2-fold 
molar ratio with the ligand. Prior to the addition of the Fed+ ligand, the pH of the peptide 
solutions were adjusted with 0.1 M NH4OH or 0.1 M CH3COOH.
2.5.2 Biotinylation------------------------------------------------------------------------------------------
L-Lysine-HCl, cGMP protein kinase substrate peptide, aB  crystallin C-terminal peptide, 
HEL, B72.3 Fab fragment or B72.3 MAb (all 1 mg/mL in 50 mM sodium bicarbonate 
buffer, pH 8.5) were reacted at 1-, 2-, 5- and/or 8-fold molar ratios with NHS-biotin 
dissolved in anhydrous DMSO (1% v/v). Samples were incubated at room temperature 
for 30 minutes (230). Excess NHS-biotin was removed by ultrafiltration.
2.5.3 lo d in a tio n -----------------------------------------------------------------------------------------
A ratio of 10 |Lig of oxidative agent (Iodogen®) per 100 fig of angiotensin, HEL or B72.3 
Fab fragment was used in each iodination reaction. A solution of Iodogen® (0.5 mg/mL) 
in DCM was added to the reaction vessel and the solvent evaporated to coat the tube with 
oxidative agent. The angiotensin, HEL or B72.3 Fab fragment (all 5 mg/mL in 10 mM 
sodium phosphate buffered saline, pH 7.2) were added to the coated reaction tubes with 
varying molar ratios of Na127I. Samples were reacted at room temperature for 
10 minutes before terminating the reaction by decanting the mixture from the reaction 
tube into a clean test tube (231).
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2.5.4 Conjugation of Diethylenetriaminepentaacetic A cid ---------------------------
All the DTPA m odification procedures were adaptations of the method of 
Paik et al. (232), however, it was found that this procedure required optimisation for 
individual samples.
25.4. a Conjugation of DTPA to L-hysine and cGMP Peptide--------------------------------
cDTPA dissolved in anhydrous DMSO was reacted with either L-lysine or cGMP 
(2 mg/mL) in 100 mM sodium bicarbonate buffer (pH 8.3) at the molar ratio Of peptide 
to cDTPA of 1:1 and 1:10, respectively. The percentage of DMSO for these reactions 
was 10% v/v. Samples were reacted at room temperature for 60 minutes.
25.4. b Conjugation of DTPA to Proteins----------------------------------------------------------
cDTPA dissolved in anhydrous DMSO was reacted with myoglobin or B72.3 
Fab fragment (2-20 mg/mL) in 100 mM sodium bicarbonate buffer (pH 8.3) at the molar 
ratio of protein to cDTPA of 1:10 or 1:100. The concentration of DMSO for these 
reactions was also 10% v/v. Samples were reacted at room temperature for 60 minutes. 
Hydrolysed free DTPA, excess DMSO and other salts were removed by ultrafiltration.
25.4. C Chelation o f Metal Ions by DTPA----------------------------------------------------------
A range of metal salts such as CUCI2.H2O, C0SO4.7H2O, L1CI3, Ga(N03)3.H2 0 , 
T1(N03)3.3H20 were added to hydrolysed DTPA (1.0 mM) at final concentrations of 
0.4 to 1.4 mM. .
25.4. d Chelation o f Metal Ions by DTTA-modified Proteins----------------------------------
Q 1Q 2.H2O, C0SO4J H 2O, InCl3, Ga(N03)3.H20, T1(N03)3.3H20 were also added to 
DTPA modified myoglobin at final concentrations of 0.5 to 10 mM. Samples were 
incubated at room temperature for 30 minutes and excess metal salts removed by 
ultrafiltration.
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2.5.5 Conjugation o f Cage Complexes — --------------------------------------------------
A 100-fold molar excess of EDC and a 1000-fold molar excess of [Co(diAMsarH2)] 
(N 0 3)2 (233) were added to HEL (10 mg/mL) in 75 mM phosphate buffer (final pH 
4.75) and incubated at 37°C for 60 minutes. Excess EDC and [Co(diAMsarH2)] (NC>3)2 
were rem oved by ultrafiltration. This procedure is based on the method of 
Conrad et al. (234), albeit only a ten fold molar excess of EDC was used to conjugate 
Co(diA M sar)3+ to cytochrome c. Samples were incubated at room temperature for 
30 minutes.
2.5.6 Reduction o f Disulphide Bridges---------------------------------------------------------
B72.3 MAb, deglycosylated B72.3 MAb, Fab or F(ab')2 fragments were each dissolved 
at 20 mg/mL in reduction buffer (100 mM Tris, 1 mM disodium EDTA, pH 8.3) and 
reduced with 20 mM DTT for 60 minutes at 37°C. Samples were flushed with N2 and 
sealed prior to incubation. This procedure was adapted from the method of 
Stanworth et al. (169). '
2.5.7 Carbohydrate Removal from Glycoproteins---------------------------------------
B72.3 MAb or Fc fragment (10 mg/mL) in sodium phosphate buffered saline (pH 7.2) 
was deglycosylated with 1 unit of N-glycosidase F per 100 p.g protein at 26°C for 
60 hours (209).
2.5.8 N-Terminal Protein Sequencing----------------------------------------------------------
N-terminal amino acid sequencing of the B72.3 Fab fragment digested with 5% (w/w) 
papain (Chapter 3, Section 3.3.2) was performed on an Applied Biosystems Procise 494 
pulsed liquid-phase protein sequencer. A piece (ca . 3x3 mm) of ProBlott™  
(polyvinylidene difluoride membrane) was wet with methanol, washed in water and 
added to an aliquot of the protein solution containing approximately 10 pmol of protein. 
The ProBlott™ was left overnight to passively adsorb the protein then washed with water
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to remove any buffer salts and air dried prior to being placed in the Procise sequencer. 
The sequencer employed standard procedures.
2.6 DESALTING AND STORAGE
Modified L-lysine, cGMP, angiotensin or A-acetylated aB  crystallin C-terminal peptide 
were each injected directly into the ESI source and desalted on-line by peptide trap 
cartridges (Michrom BioResources Incorporated, Auburn, CA). A schematic 
representation of the peptide trap cartridge is shown in Scheme 2.1. The reaction mixture 
is loaded onto the trap and desalted with water plus 2% formic acid. The peptide is








Schem e 2.1  Schematic representation of the peptide trap cartridge (Michrom BioResources 
Incorporated, Auburn, CA) used to desalt modified peptides injected directly into the ESI
source.
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retained on the cartridge and the salts are removed to waste. The desalted peptide is 
released from the trap by 50% aqueous methanol and enters the ESI source for analysis. 
All other protein samples were desalted either using Nanosep™ 10K microconcentrators 
(Filtron Technology Corporation, Northborough, MA), Centricon-30 or Centricon-10 
ultrafiltration tubes (Amicon, Lexington, MA). Reduced protein samples were desalted 
with water containing 1 mM DTT to prevent reoxidation of reduced cysteine residues.
It is essential for ESI-MS analyses that stabilising buffer salts are removed prior to 
analysis as the presence of salt in the sample both lowers ESI ionisation efficiency and 
can reduce the accuracy of the mass measurement. Further, desalting reduces the 
tendency for excess unreacted materials to form non-specific non-covalent adducts often 
observed by ESI-MS (discussed further in Chapter 3, Section 3.2.2).
Desalted material was lyophilised in a Speed Vac (Savant, Farmingdale, NY) and stored 
at -20°C until required.
2.7 INSTRUMENTATION--------------------------------------------------------------- =-----------
2.7.1 Quattro™ Triple Quadrupole Mass Spectrometer---------------------------------
A VG Quattro™ triple quadrupole mass spectrometer (VG Biotech, now Micromass, 
Altrincham, UK) was used for the majority of experiments, except where indicated. This 
was equipped with an electrospray ionisation source, a quadrupole-hexapole-quadrupole 
mass analyser configuration and has a 4000 mass range for singly-charged species. A 
schematic of the triple quadrupole mass spectrometer is shown in Figure 2.1. The 
solvent for the spray was delivered through fused silica capillary tubing via an ISCO 
SFC-500 syringe pump (Lincoln, NE) at a flow rate of 5-10 pL/min. Nebulising gas 
(N2) flowing concurrent to the stainless steel capillary in the probe at a flow rate of 
-1 0  L/h was used to assist in the production of a stable spray. A dry, warm, 
counter-current nitrogen bath gas at a flow rate of ~350 L/h at atmospheric pressure was 
employed to aid evaporation of the electrospray solvent. The electrospray probe tip
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potential was usually 3.5 kV with 0.5 kV on the chicane counter electrode (see 
Figure 1.1, schematic representation of the electrospray ionisation source for further 
information). All spectra were acquired in positive ion mode (ES+) by multi-channel 
analysis (MCA) at a rate of 1 second per 100 m/z units and typically, data from 
10-20 scans were summed to obtain representative spectra.
Figure 2.1 Schematic representation of triple quadrupole mass spectrometer, equipped with an 
electrospray ionisation source.
2.7.2 Tandem Mass Spectrometry (M S-M S)---------- ------------------------------------
For MS-MS experiments, argon collision gas was used at a pressure corresponding to 
approximately 30% transmission of the incident ion beam. The laboratory collision 
energy (£iab) was varied from 0-25 eV as indicated in the text. Other parameters are as 
shown in Table 2.1. During MS-MS experiments the resolution in MSI was set to a 
minimum to allow maximum transmission of the ESI signal into MS2.
2.7.3 A uto  Spec™  Magnetic Sector Mass Spectrom eter------------------------------
A VG AutoSpec™ magnetic sector mass spectrometer (VG Analytical, now Micromass, 
Wythenshawe, UK) equipped with an electrospray interface, was also used for analysis 
of some of the intact MAbs. The electrospray interface on this instrument consists of a 
three stage, differentially pumped arrangement to transfer ions formed at the tip of the 
spray probe into the high vacuum necessary for mass analysis. A schematic of the
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P A R A ME T ER S SETTING
SOURCE
Capillary 3.0-3.5 kV
HV Lens (chicane counter electrode) 0.3-0.5 kV
Cone (Skimmer potential) 20-150 V (sample dependent)
Lens 1 50-80 V
Lens 2 0-10 V
Lens 3 35-50 V




HM Resolution 4.0-15.0 (sample dependent)
Energy Filter 6.0
Ion Energy 2.0
Ion Energy Ramp 0.0
Lens 5 200-250 V
Lens 6 0-10 V




Collision 5-20 eV (K switch off)
Ion Energy 1-2
Ion Energy Ramp 0.0
Lens 7 250-300 V
Lens 8 130-160 V
Lens 9 60-80 V
MS2 photomultiplier 650 V
Table 2.1 Typical tuning parameters for positive ESI-MS and MS-MS of proteins and peptides.
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interface is given in Figure 2.2. Declustering, which is primarily controlled by the 
differential voltage between the sampling cone and the skimmer, is assisted by a flow of 
warm gas. For the experiments here, N2 was employed as both the bath and nebuliser 
gas. The electrospray source was maintained at 60°-80°C. All of the data presented here 
were acquired on an AutoSpec™ fitted with the standard point detector, and a high field 
magnet having 8000 mtz range at 4 kV accelerating voltage. Spectra were acquired in 
positive ion mode at a resolving power of 1 0 0 0  to 2 0 0 0  (1 0 % valley).
F igure 2.2  Schematic representation of the AutoSpec™ mass spectrometer electrospray interface. 
Details of operation are outlined in the text
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2.8 CALIBRATION AND SAMPLE A N A L YSIS ------------- ------------------------
2.8.1 Quattro™ Triple Quadrupole Mass Spectrometer------- —-------------------
The mass range of the Quattro™ instrument was calibrated with myoglobin 
(20 pmol/pJL), HEL (30 pmol/jitL), ammoniated PPG (1 |Lig/jLLl) or Nal (~1 nmol/pL) 
depending on the nt/z range of the sample to be analysed. A typical ESI mass spectrum 
of myoglobin (subtracted and smoothed) obtained at a resolution of 1 Da 
(peak width-at-half peak height) and transformed to a mass scale is shown in Figure 2.3. 
The resultant myoglobin calibration is given in Figure 2.4.
Modified peptide and protein samples were analysed by ESI-MS without further 
chromatographic purification. This is a key feature of the method enabling analysis of 
reaction mixtures to determine the individual species and their relative abundance directly 
by ESI-MS. Protein samples modified by cDTPA were dissolved in 1% aqueous formic 
acid (pH 2.5). B72.3 F(ab')2  fragment was dissolved in 50% formic acid due to the 
insolubility of this protein in 50% aqueous acetonitrile. Diethylenetriaminepentaacetic 
acid anhydride samples conjugating metal ions were dissolved in water alone (pH 2.9). 
All other protein samples were dissolved in 50% aqueous acetonitrile plus 1% formic acid 
(pH 2.5). Samples were injected via a loop injector (Rheodyne 7125) and delivered to 
the instrument in 50% aqueous methanol at a flow rate of 5-10 pL/min. Ten microlitres 
of sample was injected for each analysis. HEL, myoglobin, Fc fragments and reduced 
protein samples were dissolved at a concentration of 20 pmol/pL, Fab and F(ab')2  
fragments at 5 to 10 pmol/pL, and the MAbs required a concentration of 1 to 10 pmol/pL 
for optimum sensitivity. Similarly, the potential on the first source skimmer also required 
tuning for each protein. The skimmer potential for the MAbs was 150 V, and 50-100 V 
was used for the other proteins as indicated in the text. Typical tuning parameters for all 
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Figure 2.3  ESI-MS analysis of horse heart myoglobin. Skimmer potential 50 V, protein 
concentration 20 pmol/pL:
(A) ESI spectrum (baseline subtracted and smoothed) and
(B) Transformed to a mass scale.
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Figure 2 .4  Typical calibration obtained for MSI on VG Quattro™ triple quadrupole mass 
spectrometer using horse heart myoglobin.
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2.8,2 AutoSpec™ Magnetic Sector Mass Spectrometer----------------------------------
The mass range of the magnetic sector instrument was calibrated with ammoniated PPG 
(1 Hg/pl). All MAb samples were dissolved in 50% aqueous acetonitrile plus 1% formic 
acid (pH 2.5) at a concentration of 2-5 pmol/|nL. Proteins were injected via a loop 
injector (Rheodyne 7125) and delivered to the instrument in 50% aqueous methanol plus 
1% acetic acid at a flow rate of 20 pL/min. Twenty microlitres of sample was injected for 
each analysis.
2.9 DATA PROCESSING -----------------------------------------------------------------------
2.9.1 Quattro™ Triple Quadrupole Mass Spectrometer---------------------------------
The ESI spectra were baseline-subtracted with either a linear or fitted polynomial 
subtraction. The subtracted spectra were smoothed twice, with the degree of smoothing 
based on the peak width-at-half-peak height according to the 'mean' mathematical 
smoothing method. Smoothed data were converted to peak-top data from which the true 
mass was calculated. The mtz values for individual peaks are determined at the centre of 
each peak at 80% height following smoothing. The m h  scale in the raw 
baseline-subtracted spectra were converted to exact molecular masses using the transform 
function of the MassLynx™ software (Cambridge, UK). The uncertainty in the masses 
are calculated from the range of masses generated by this function (based on mean mass 
and deviations of individual components). Transformed spectra were smoothed by twice 
the peak width-at-half-peak height. For the more complex spectra, in which there were 
multiple overlapping charge states (eg. modified Fab fragment), molecular masses and 
uncertainties were determined by deconvoluting the raw baseline-subtracted spectra using 
the more sophisticated maximum entropy (MaxEnt™) method (54,57).
All MS-MS peptide fragment ions were assigned according to the nomenclature 
recommended by Roepstorff and Fohlman (137) (see Chapter 1, Section 1.4, 
Scheme 1.1).
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2.9.2 AutoSpec™ Magnetic Sector Mass Spectrometer----------------------------------
The ESI spectra of the intact MAbs were smoothed twice, with the degree of smoothing 
based on the peak width-at-half-peak height Smoothed data were converted to peak-top 
data from which the true mass was calculated and the m/z values for individual peaks are 
determined at the centre of each peak at 80% height following smoothing. The 




MONOCLONAL ANTIBODIES AND ANTIBODY FRAGMENTS
3.1 IN TR O D U C TIO N -------------------------------------------------------------------------------
While the utility of ESI-MS for the characterisation of monoclonal antibodies (MAbs), 
antibody fragments and recombinantly engineered antibodies is now well established 
(42,209, 210, 212-218), prior to the commencement of this study (in early 1993) only 
one report of ESI of an intact MAb had appeared in the literature (212). These 
investigators used an instrument with a low m/z range (m/z 2400) which as will be 
shown here, is of limited use for the characterisation of intact MAbs as only the higher 
charge state (ie. lower m/z) species are detected. This chapter describes the optimisation 
of ESI analysis of the murine IgGi B72.3 MAb (171) and a range of other MAbs using a 
VG Quattro™ triple quadrupole instrument and a VG AutoSpec™ magnetic sector 
instrument with higher mass ranges (im/z 4000 and m/z 8000, respectively). The 
optimum ESI conditions for intact antibodies are also compared with those for smaller 
proteins such as MAb F(ab')2, Fab and Fc fragments. In addition, ESI-MS of reduced 
and/or deglycosylated MAb and MAb fragments revealed sequence information for the 
B72.3 monoclonal antibody which could not be determined from spectra of the intact 
protein. The final section of this chapter describes the optimisation of papain digestion 
for the generation of F(ab')2* Fab and Fc fragments.
3.2 MONOCLONAL ANTIBODIES-----------------------------------------------------------
3.2.1 Optimisation o f Monoclonal Antibodies by ESI-M S-------------------------
One of the major tasks in this study was to determine the optimum conditions for 
analysing MAbs by ESI-MS, including such parameters as protein concentration, 
skimmer potential, the distribution of charge states and calibration of the appropriate 
m/z range. This task initially proved to be difficult as many of the experimental
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parameters required for observation of these large proteins by ESI-MS were markedly 
different to those for proteins of lower mass. A readily available monoclonal antibody, 
the murine IgGi B72.3 MAb (171) was used as a model for the investigation of the 
appropriate ESI conditions for characterising intact MAbs. The B72.3 MAb was thought 
to be a suitable model since there is a significant amount of information available on this 
protein including its DNA sequence (190, 235) and carbohydrate structure (236). The 
information gained from characterising this particular MAb by ESI-MS was then applied 
to a range of other MAbs, including a mixture of two monoclonal antibodies, to ascertain 
if the optimised ESI conditions determined for the B72.3 MAb could be extended to other 
members of this class of protein.
The first of the experimental parameters that required careful optimisation on the 
VG Quattro™ triple quadrupole instrument was the concentration of the MAb used for 
the ESI analyses. The dependence of the intensity of the ESI ion signal on the 
concentration of injected sample are shown in Figure 3.1 for the B72.3 MAb at protein 
concentrations of (A) 0.5 pmol/|iL, (B) 1 pmol/jiL, (C) 5 pmol/pL (D) 10 pmol/jiL and 
(E) 20 pmol/|iL (total 10 pL injected for each analysis). The absolute intensity scale is 
the same in each case. The intensity of the ESI signal increased with increasing 
concentration to reach a maximum for the solution with a concentration of 5 pmol/jiL. 
For 10 pmol/pL solution, however, the intensity was approximately half of that observed 
with 5 pmol/|iL and at 20 pmol/pL the signal is extremely weak. From these experiments 
it was concluded that the minimum concentration of the B72.3 MAb that could be 
successfully analysed on the quadrupole instrument was 1 pmol/pE (total 10 jllL  injected) 
and the concentration range over which a strong MAb signal could be detected was 
1-10 pmol/^iL. Above 10 pmol/fiL suppression of the ESI response became evident with 
increasing concentration of MAb and below 1 pmol/|iL the ESI response became 
increasingly weak. A similar dependence of concentration has been noted for smaller 
proteins run in our laboratory, however, the actual concentration range for MAbs is 
smaller. For instance, the optimum concentration for proteins of ~Mr 20 kDa such as
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hen egg-white lysozyme, horse heart myoglobin and bovine eye lens crystallins are in 
the range of 20-30 pmol/fiE. *
Figure 3.1 Electrospray mass spectrum of the intact murine B72.3 monoclonal antibody at a 
skimmer potential of 150 V and at concentrations of injected protein ranging from 
0.5 pmol/|iL to 20 pmol/pL. Note that the maximum signal intensity is observed at a 
concentration of 5 pmol/pL and thereafter decreases with increasing concentration of 
the MAb.
The phenomenon of suppression/saturation of ESI response at high concentrations is well 
known (237) and arises from a combination of rates of desolvation and con-transport 
efficiency. Kebarle and Tang (237) have derived a relationship between ESI ion 
intensities (I) and the molar conductivity (A,m°) and concentration (C) of the analyte as
shown in Equation 1.
I -  (^m°C)n ...1
where: n = 0.2-0.3
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That for a given I  there appears to be an inverse relationship between concentration and 
the mass of the ion suggests that the molar conductivity of the large MAb proteins is 
higher than that of the lower mass proteins. This is not unexpected since they have a 
greater number of charged side chains at a given pH and probably a lower degree of 
solvation. It is known, for example, that with cations (say comparing the alkali metal 
cations), the smaller the cation, the lower the molar conductivity because of the higher 
degree of solvation of the small cations (238).
The second important experimental factor for the successful analysis of MAbs by 
ESI-MS was the potential on the first source skimmer. Figure 3.2 shows the B72.3 
MAb at a concentration of 5 pmol/jiL and skimmer potentials of (A) 100 V, (B) 150 V 
and (C) 200 V (total 10 fiL injected for each analysis). At a skimmer potential of 200 V, 
the intensity of the ion signal is relatively weak, with only the 48+ to 40+ charge states 
evident. At 150 V, charge states 51+ to 40+ were present and at 100 V the charge states 
63+ to 41+ were observed. It was interesting to note that the distribution profile for the 
B72.3 MAb at 100 V ranged from m/z 2200 to mil 3700, whereas at a potential of 150 V 
the distribution range was much narrower {mlz 2700 to m/z 3700). Although there were 
fewer charge states evident at 150 V, the signal intensity for the 46+ and 47+ charge states 
were greater than at 100 V. At a skimmer potential of 50 V (data not shown), the ESI 
signal ranged from mlz 2400 to mlz 4000 but the charge states could not be resolved. 
These experiments indicated that the intact MAb required a relatively high potential on the 
first source skimmer ie. 150 V compared with 50 V for the 50 kDa and 25 kDa MAb 
fragments (see Sections 3.3.2 and 3.3.6) and other smaller proteins run in our 
laboratory. This is most likely a simple ion optical effect with the larger protein species 
and higher mlz ions requiring higher focussing potentials to be transmitted through the 
source skimmer region. A similar effect has been noted on our instrument for 
singly-charged synthetic polymers, whereby higher mass oligomers are only observed at 
higher skimmer potentials (239).
Chapter 3 Monoclonal Antibodies 79
Figure 3.2  Electrospray mass spectrum of the intact murine B72.3 monoclonal antibody at a 
protein concentration of 5 pmol/pJL and at potentials on the first source skimmer of 
100, 150 and 200 V.
The final experimental parameter that was markedly different in the analyses of MAbs 
compared to smaller proteins and antibody fragments was the distribution of charge 
states. At a skimmer potential of 150 V and a protein concentration of 5 pmol/}iL 
(total 10 jiL injected), the charge-state distribution for the B72.3 MAb was centred at 
m/z 3125 (z = 47). This is approximately twice the maximum m/z value observed with 
the 25 kDa Fc fragment (see Figure 3.25) which is centred at m/z 1288 (z = 20). In the 
first ESI-MS study of an intact MAb by Feng and Konishi (60) it was suggested that it is 
the unique structural arrangement of an IgG molecule and the interactions between the 
constituent chains that are responsible for shifting the charge distribution profile to a 
higher m/z (low charge state) range. This is a reasonable observation as presumably 
proton accessibility to inner chargeable sites is reduced due to the more compact structure 











































































Figure 3.3  Electrospray mass spectrum of ammoniated polypropylene glycol (PPG) 3000 at a 
concentration of 1 pg/pL and a skimmer potential of 200V.
(A) baseline subtracted and smoothed data,
(B) centroided data at 80% peak height.
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In addition to the parameters discussed above, the calibration of the high mlz range is 
extremely important if accurate masses are to be achieved for intact 150 kDa MAbs. For 
example, if the mlz value determined by ESI for the 50+ charge state is 2 mlz units higher 
or lower than expected then this equates to a mass difference of 100 Da (±0.07%). Thus 
precise calibration of the triple quadrupole mass spectrometer is also a major contributor 
to obtaining accurate ESI spectra of intact MAbs. The standard chosen for calibration of 
the higher region of the instrument ie. mlz 2000-4000, was ammoniated polypropylene 
glycol 3000 (PPG). At a skimmer potential of 200 V and at a concentration of 1 |ig/|iL 
the PPG produced a series of peaks ranging across this mlz region. The ESI spectrum of 
ammoniated PPG is shown in Figure 3.3, (A) subtracted and smoothed data 
(B) centroided data at 80% peak height. Successful calibration was achieved by 
comparison of the centroided mlz values with that of the reference file and in most 
instances 33 to 34 of the 35 possible reference values were matched.
3.2.2 Data Processing o f Monoclonal Antibodies-------------------------------------
Once the three parameters of protein concentration, skimmer potential and charge-state 
distribution had been carefully optimised and the high mlz region of the instrument had 
been successfully calibrated, the next step in the analysis of intact MAbs was related to 
the software processing of the spectra. This is particularly important for these large 
proteins. The spectra shown in Figures 3.1 and 3.2, above, have all been baseline 
subtracted and 'smoothed* by the value obtained from the peak width-at-half peak height 
which enables an average molecular mass to be then determined. The spectra in 
Figure 3.4 shows the 6 most intense charge states of the B72.3 MAb at a skimmer 
potential of 150 V and a protein concentration of 5 pmol/f-iL (A) baseline subtracted and 
unsmoothed  data and (B) baseline subtracted and smoothed by twice the peak 
width-at-half peak height. As it can be seen from Figure 3.4A, it would be extremely 
difficult to derive an average molecular mass for the MAb from unsmoothed data due to 
the complex nature of these proteins.
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Figure 3.4 Electrospray mass spectrum of the 6 most intense charge states (49+ to 44+) of the 
B72.3 MAb at a concentration of 5 pmol/pL and a skimmer potential of 150V.
(A) baseline-subtracted data (unsmoothed),
(B) baseline-subtracted and smoothed data 
(twice the peak width-at-half peak height).
F igure 3 .5  Electrospray mass spectrum of the intact murine B72.3 monoclonal antibody at a 
skimmer potential of 150 V and a protein concentration of 5pmol/pL.
(A) 51+ charge state (m/z 2881),
(B) 41+ charge state (m/z 3586 note the degree of tailing on the high m/z of the 
peak).
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A predominant feature of the ESI spectra of intact MAbs is that the peaks become 
increasingly broad and asymmetric as the charge state decreases (m/z increases). The 
peak widths-at-half peak height for the 51+ and the 41+ charge states of the B72.3 MAb 
shown in Figure 3.5 are 22.5 and 29.5 m/z units, respectively and the 41+ charge state 
shows an increase in the tailing on the high m/z side of the peak. There are a number of 
reasons to account for these observations. Firstly, the same number of isotopic species 
exist within each peak of the spectrum, however, as the charge state increases and 
m/z decreases these isotopic species are confined to a smaller m/z range. For instance, 
the isotopic distribution within a singly-charged species would occur over twice the 
m/z range compared with the doubly-charged species. However, isotopic broadening is 
not the major contributor to the increasing width of the peaks at high m/z as MAb 
fragments do not exhibit the same effects as observed with the intact MAbs (see Sections
3.3.2 and 3.3.6). The second contribution to peak width is attributed to the 
heterogeneity arising from glycosylation (240) which also causes broadening of the 
peaks in the ESI mass spectrum of the intact MAb and can result in large uncertainties in 
mass measurement, however, this does not account for the -m/z dependence of the peak 
broadening. Further, the increase in asymmetry of peaks with lower charge is not 
evident with the antibody fragments including the glycosylated Fc fragment (see 
Figure 3.25). The third contribution to peak broadening with the intact MAb is in part 
due to increasing proportions of non-specific salt adducts as the charge state decreases, 
which are present even after extensive dialysis (216). These are more pronounced at 
higher m/z as the salt adducts appear to block accessible charge states. A recent report on 
ESI-MS of intact MAbs by Huang and co-workers (219) has shown that peak 
broadening due to the formation of salt adduct ions can be markedly reduced if these 
large proteins are introduced on-line into the ESI source via a HPLC. A final 
contribution to peak broadening, particularly at high m/z, may be due to poor desolvation 
of these species in the ESI source.
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In the data processing of MAbs the mass calculation is based on the peak centres at 
80% of the peak height in an attempt to minimise the effect of this asymmetry. Shown 
in Figure 3.6 is the 47+ charge state (smoothed by twice the peak width-at-half peak 
height) overlaid with centroided data at (A) 20%, (B) 50% and (C) 80% of the peak 
height. As the centroiding parameter was reduced the m/z ratio of the centroided peak 
was moved to a lower m/z value, thus at 20% of the peak height m/z = 3125.5, at 50% 
m/z = 3126.0 and at 80% m/z = 3126.7. For the 47+ charge state, a m/z difference of
1.2 between centroiding the data at 20% and 80% of the peak height equates to a mass 
change of ~50 Da. Thus, it is apparent that the mass calculation can be dramatically 
altered by varying the centroiding parameters. In addition to the above processing 
parameters for determining the average molecular mass of the intact MAb, only the most 
intense charge states were used in the mass calculation ie. peaks below 20% of the height
Figure 3.6  Electrospray mass spectrum of the 47+ charge states of the B72.3 MAb at a 
concentration of 5 pmol/pL and a skimmer potential of 150 V. Data has been 
subtracted and smoothed by twice the peak width-at-half peak height. Overlaid on the 
smoothed spectrum is the centroided data at 20%, 50% and 80% peak height.
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of the most intense charge state were not included in the calculation. The parameters 
outlined above for processing the spectra of MAbs have been successfully used for 
analysis of smaller proteins and MAb fragments and in general this has resulted in 
derived molecular masses to within 0.05% of predicted masses generated from the 
known translated DNA sequences.
From the above discussion, it can be seen therefore that the optimisation of ESI-MS of 
intact MAbs is by no means a simple task. Optimisation requires the careful integration of 
a range of conditions, including tuning of the instrument and appropriate skimmer 
potentials as well as sample preparation and concentration. The presence of an ESI signal 
is only, however, interpretable if the m/z range is carefully calibrated. Furthermore, the 
software data processing of the ESI spectra also requires special attention if accurate 
molecular masses are to be achieved from the data.
3.2.3 B72.3 Monoclonal Antibody--------------------------------------------- — -----------
The complete ESI mass spectrum of the intact murine B72.3 IgGj MAb showing charges 
states 56+ to 37+ is illustrated in Figure 3.7. The average molecular mass determined for 
this MAb on the VG Quattro™ triple quadrupole mass spectrometer was 146 931±44 Da 
and only the 9 most intense charge states ie. 51+ to 43+ were included in the calculation. 
This is approximately 3% higher than the mass of 143 475 Da calculated from the DNA 
sequence (190, 235), which is consistent with the known degree of glycosylation of the
IgG class of MAb (159). The average molecular mass of the MAb determined from the
438translated DNA sequence (with the loss of K from both the MAb heavy chains, 
discussed in Section 3.2.5) (190, 235) and the known glycosylation pattern (236, 240) is 
146 689 Da. The mass determined from the ESI spectra is therefore in close agreement 
with the predicted average mass of the MAb.
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Figure 3 .7 Electrospray mass spectrum of the intact murine B72.3 monoclonal antibody, skimmer 
potential 150 V, protein concentration 5 pmol/pL. Note that the m/z range of the 
protein extends to 4000.
The B72.3 MAb has also been extensively investigated by MALDI-MS (63) in a study 
conducted in 1991 by Hillenkamp and co-workers. The molecular masses obtained for 
the B72.3 MAb by MALDI-MS (63), ESI-MS and the DNA sequence (190, 235) are 
shown in Table 3.1. As can be seen the mass obtained from MALDI-MS is higher by 
-500 Da than the mass obtained from ESI-MS in this study. In addition the error in mass 
measurement is significantly larger than that observed with the ESI data. The reason for 
this is that the range of molecular mass values observed in ESI-MS are based on the 
variation in masses determined from each charge state and thus are generally lower than 
error values observed with MALDI-MS, which are calculated from the width of 
singly-protonated peaks on the lower resolution TOF instruments. It has been shown 
with MALDI-MS that when proteins are bound either to other proteins or small molecules 
there is a shift to a higher m/z (117) and the presence of matrix adduct peaks on the
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protonated protein molecules is thought to contribute to lower mass accuracy in MALDI 
for high mass proteins (241).
TECHNIQUE AVERAGE MOLECULAR 
MASS (Da)
ESI-MS (Quattro™) 146 931±44 ‘
MALDI-MS (63) 147 470±190
DNA sequence (190, 235) 143 475*
DNA sequence (190, 235) 146 689
+ estimated glycosylation pattern
Table 3.1 Average molecular masses of the intact murine B72.3 MAb as determined by ESI-MS,
MALDI-MS, DNA sequence and DNA sequence plus estimated carbohydrate component.
* Molecular mass of non-glycosylated B72.3 MAb.
Once the ESI-MS conditions and the software processing were optimised for the 
B72.3 MAb, these same parameters were used for the analysis of a range of other MAbs, 
including the deglycosylated B72.3 MAb and it was found that the instrument conditions 
and sample preparation were similar for all the other MAbs studied. The only major 
difference that was observed was the charge-state distribution profiles varied slightly with 
some of the MAbs. In general, however, all the MAbs analysed required the same 
ESI-MS conditions determined for the B72.3 MAb.
3.2.4 D eglycosylated B72.3 M onoclonal A ntibody-------------------------------------
In order to determine if some of the contribution to the peak width observed in the 
spectrum of the intact B72.3 MAb was due to the heterogeneous nature of glycosylation, 
the carbohydrate portion was enzymatically removed from the MAb heavy chains. 
Removal of the carbohydrate side chain from the Ch2 region (see Chapter 1, 
Section 1.5.2, Figure 1.4) of the B72.3 MAb was achieved by treatment of the MAb 
with A-glycosidase F (Chapter 2, Section 2.5.7). Oligosaccharides attached to 
asparagine (N) ie. A-linked sugars, are released after proteolysis with A-glycosidase F, 
an enzyme that cleaves the p-aspartylglycosylamine linkage of all known types of
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asparagine-linked sugars and converts the attachment site Asn (N) to Asp (D) by 
glycosidase-mediated hydrolysis (242). Carbohydrate removal should markedly decrease 
the heterogeneous nature of the MAb as only the homogeneous protein core is retained for 
analysis, thereby allowing the direct comparison of the molecular mass obtained by ESI- 
MS with the known DNA sequence of the antibody.
Figure 3.8 illustrates the ESI mass spectrum for the intact deglycosylated B72.3 MAb
showing charges states 58+ to 41+. The average molecular mass determined for the
deglycosylated MAb was 143 541+16 Da which compares favourably with the mass of
143 477 Da determined from the translated DNA sequence (again taking into account the 
438
loss of K from both the heavy chains, see Section 3.2.5, and the conversion of Asn 
to Asp) (190, 235).
Figure 3.8 Electrospray mass spectrum of the deglycosylated murine B72.3 monoclonal antibody, 
skimmer potential 150 V, protein concentration 5 pmol/pL. The carbohydrate portion 
was enzymatically released from the heavy chains by the action of /V-glycosidase F.
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F igure 3 .9  Electrospray mass spectrum of the murine B72.3 MAb reduced by 20mM DTT and 
transformed to a mass scale. Skimmer potential 50 V, protein concentration 
20 pmol/pL.
(A) Light chain,
(B) Glycosylated heavy chain (carbohydrate pattern is as indicated).
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The peak width-at-half peak height for the deglycosylated B72.3 MAb were 
approximately 11 m/z units compared to 25 m/z units for the intact glycosylated MAb 
indicating that the carbohydrate heterogeneity does contribute significantly to the peak 
width in the spectrum of the MAb. As was observed with the intact protein, the peak 
widths for the lower charge state species (higher m/z) were also broader than the peaks at 
lower m/z, with a significant tailing on the high m/z side of the peaks. As was stated 
previously, this is probably due to non-specific salt adducts which are blocking accessible 
protonation sites or to poor desolvation of the lower charge state species. The 
distribution of charge states for the deglycosylated MAb is centred at m/z 2991 (z = 48) 
compared with the glycosylated B72.3 MAb (Figure 3.7) which is centred at m/z 3125 
(z = 47). It is possible that removal of the carbohydrate portion from the MAb exposes 
otherwise concealed protonation sites, thus the charge-state distribution profile has moved 
to a lower m/z range than was observed for the intact glycosylated protein.
3.2.5 Reduced B72.3 Monoclonal Antibody-----------------------------------------------
In an effort to gain further structural information on the B72.3 MAb, the protein was
reduced with dithiothreitol (DTT) to break the intra-chain and inter-chain disulphide
bridges and the resultant mixture analysed by ESI-MS. Figure 3.9 shows the ESI mass
spectrum of the reduced B72.3 MAb (A) light chain and (B) glycosylated heavy chain
both transformed to a mass scale. The mass of the light chain determined by ESI-MS
was 23 588±2 Da which is in very close agreement with the mass of 23 590 Da calculated
from the translated DNA sequence (190, 235). The transformed ESI-MS spectrum
shown in Figure 3.9B indicates the presence of three major components labelled A, B
and C. The predominant peak in the spectmm (Component A) has an average molecular
mass of 49 629±8 Da which is consistent with the amino acid sequence of the heavy
1 437 438chain (Heavy Chain: Q -» G , less K ) (235) plus the core carbohydrate portion 
(2 A-acetylglucosamine, 3 mannose, 1 fucose) with the addition of two 
A-acetylglucosamine units (calculated Mv 49 610 Da). The other major peaks at 
49 629±8 Da (Component B) and 49 949±13 Da (Component C) correspond closely to
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the addition of 1 and 2 hexose units, respectively. The addition of a single hexose 
residue increases the overall mass of the glycoprotein by 162 Da.
The carbohydrate structure of murine IgG is an asparagine linked oligosaccharide of the 
biantennary complex type (236), however, instead of a single oligosaccharide, an array 
of structurally related yet distinct oligosaccharides is expressed. It has been reported that 
94% of murine oligosaccharides have a fucosylated core and that 80% have either no 
additional residues or a single galactose residue. Based solely on mass, the proposed 
carbohydrate composition for the B72.3 MAb therefore appears to have the same 
carbohydrate structure as that elucidated by Mizuochi and co-workers (236).
3,2,6 Reduced Deglycosylated R72.3 Monoclonal A ntibody -----------------------
As noted above, it is difficult to directly assess the protein portion of the MAb due to the 
heterogeneous nature of these glycoproteins. Thus, removal of the carbohydrate and 
subsequent reduction of the deglycosylated MAb can provide information on the protein 
structure of the heavy chain of the MAb. Figure 3.10 shows (A) the ESI spectrum of the 
deglycosylated and reduced B72.3 MAb. Figure 3.10 (B) and (C) show the intact 
reduced light chain and the reduced deglycosylated B72.3 heavy chain, respectively, both 
transformed from a m/z to a mass scale. The ESI mass spectrum of the deglycosylated 
and reduced MAb (Figure 3.10A) shows a series of peaks ranging from 56+ to 33+ which 
are due to the deglycosylated heavy chain. The second minor series of peaks ranging 
from 21+ to 16+ are attributed to the reduced light chain. In Figure 3.1 OB there is a 
component at a mass of 23 583±6 Da which is due to the reduced B72.3 light chain 
(icf. 23 590 Da determined from the DNA sequence) (190, 235) and in Figure 3 .10C the 
component of mass 48 173±5 Da is attributable to the deglycosylated heavy chain minus 
the C-terminal K residue and with the conversion of Asn (N) to Asp (D) due to the 
release of the carbohydrate moiety. It has been reported that MAbs processed during 
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Figure 3.10 Electrospray mass spectrum of the deglycosylated murine B72.3 MAb reduced by 
20 mM DTT. Skimmer potential 50 V, protein concentration 20 pmol/pL.
(A) ESI spectrum (baseline subtracted and smoothed),
(B) Light chain (transformed to a mass scale),
(C) Deglycosylated heavy chain (transformed to a mass scale).
heavy chains due to carboxypeptidase B (CPB) activity (243). The presence of proline 
adjacent to the penultimate glycine would presumably prevent further attack by CPB. A 
similar phenomenon has been observed with the C-terminal loss of serine from aA- and 
PB2-crystallin from carboxypeptidase A (CPA) activity (244). These two proteins have 
Pro-Ser-Ser at their C-termini. In this case, however, the presence of proline adjacent to 
the penultimate serine prevents further attack by CPA. From the DNA sequence 
(190, 235) the expected mass for the deglycosylated heavy chain is 48 294 Da. Thus the 
mass determined by ESI-MS is in excellent agreement with that predicted from the
438
sequence, less K (48 166 Da).
It can be seen therefore, that the structure of a MAb can be carefully probed by ESI-MS 
and sequences verified by use of reducing agents to disassociate MAb subunits and
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enzymes that release the carbohydrate from the protein. In this way structural information 
otherwise unattainable from classical techniques can be achieved. ESI-MS is therefore an 
indispensable tool for characterisation of intact MAbs.
3.2.7 Other Monoclonal Antibodies-----------------------------------------------------------
The conditions and instrument parameters utilised for the analysis of the B72.3 MAb and 
deglycosylated B72.3 MAb were extended to a range of other MAbs, with very little 
variation of the experimental conditions. All the MAbs studied were predominantly from 
murine sources, however, one of the proteins was a chimaeric MAb which as discussed in 
Section 3.2.6.C, is predominantly human in nature but the variable region is murine 
in origin.
3.2.7.a Monoclonal Antibody X --- —------------------------------------------------------------------
MAb X is a murine IgGi antibody that reacts against the TAG-72 antigen and is termed a 
'second generation' MAb. 'Second generation' MAbs have nearly an order of magnitude 
higher affinity constant in comparison to their 'first generation' counterparts such as the 
B72.3 MAb (245). Illustrated in Figure 3.11 is the ESI mass spectrum for the intact 
murine MAb X showing the charge states 57+ to 39+ and the average molecular mass 
determined for this MAb was 145 613+55 Da. The potential on the first source skimmer 
was 150 V and the concentration of the protein was 5 pmol/pL. The m/z distribution for 
this particular MAb ranged from m/z 2500 to m/z 3900, which is similar to the m/z range 
for the B72.3 MAb (m/z 2600-4000). The average molecular mass of MAb X was -1300 
Da (which equates to a m/z difference of 28 for the 47+ charge state) less than the mass 
determined for the B72.3 MAb and as shown in Section 3.2.6.d, this variation in mass is 
sufficiently different to allow the resolution of these two MAbs in a mixture.
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Figure 3.11 Electrospray mass spectrum of the intact murine monoclonal antibody X, skimmer 
potential 150 V, protein concentration 5 pmol/pL.
3.2.7.b 9.2.27 Monoclonal Antibody------------------------------------------------------------------
The 9.2.27 MAb belongs to the murine IgG2a subclass of antibodies and reacts against a 
melanoma-associated proteoglycan antigen termed NG2. Figure 3.12 illustrates the ESI 
mass spectrum for the intact 9.2.27 monoclonal antibody showing charges states 
62+ to 40+. The average molecular mass determined for this MAb on the triple 
quadrupole instrument was 147 203±85 Da and the m/z region over which charge state 
profile was distributed ranged from m/z 2300 to m/z 3600. This is in the same 
m/z region as the deglycosylated B72.3 MAb (ie. lower than the m/z region observed for 
the intact B72.3 MAb) which implies that the 9.2.27 MAb may have a less compact 
three-dimensional structure than the B72.3 MAb, thereby enabling protonation of more 
sites in the MAb. This appears to be also reflected in the total number of observed charge 
states in the spectra of these two MAbs. Twenty two charge state species were observed 
for the 9.2.27 MAb whereas three less than this (19 in total) were observed in the 
spectrum of the intact B72.3 MAb.
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Figure 3.12 Electrospray mass spectrum of the intact 9.2.27 monoclonal antibody. Skimmer 
potential 150 V, protein concentration 5 pmol/pL.
3.2.7.C Chinicene 14.18 Antibody------------------ —------------------ - “
There are two major problems with the clinical use of murine MAbs directed against 
human tumour-associated antigens. Firstly, such antibodies are recognised as foreign 
molecules by the human immune system and evoke a human anti-mouse antibody 
(HAMA) response (246). Secondly, the Fc portion of a murine MAb may not be able to 
activate human complement and effector cells as efficiently as the human Fc portion. 
These difficulties led to the development of chimaeric mouse/human antibodies which are 
prepared by splicing mouse genes coding for the variable (V) regions of the antibody 
molecule with human genes encoding the constant regions (Figure 3.13).
Figure 3.14 illustrates the ESI mass spectrum for the intact chimaeric 14.18 (Chl4.18) 
MAb showing charges states 61+ to 42+. Chl4.18 reacts with the disialoganglioside 
GD2 on the surface of tumour cells of neuroectodermal origin (248). The average
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Figure 3.13  Construction of a ’humanised' and a 'chimaeric' antibody from a mouse antibody. White 
indicates sequences originating from human sources and black indicates sequences 
originating from murine sources. The CDR's present in the mouse antibody are in red. 
Adapted after Coghlan (247).
molecular mass determined for the MAb from the 17 most intense charge states 
(ie. 60+ to 44+) was 147 920±71 Da. It was interesting to note that the spectrum 
determined for this monoclonal antibody contained a second series of charges states 
ranging from 35+ to 26+. The average molecular mass determined for this series was 
66 554±19 Da (calculation based on the 33+ to 26+ charge states) and would appear to be 
due to the presence of human serum albumin (HSA) in the sample. To confirm that the
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series of peaks at lower m/z were due to the presence of albumin, a sample of HSA was 
mixed with the B72.3 MAb and run at 150 V. The ESI spectrum of the B72.3/HSA 
mixture (data not shown) was similar to that observed for the Chl4.18 MAb 
(Figure 3.14), adding impetus to the fact that the series of charge states at lower m/z in 
the Chl4.18 sample were due to the presence of HSA. The Chl4.18 MAb sample was 
also assessed by non-reducing SDS-PAGE (data not shown) and two protein bands were 
evident, one at ~ 150 kDa due to the MAb and one band at ~ 6 6  kDa, which appeared to 
confirm the presence of albumin in the preparation.
Figure 3 .14  Electrospray mass spectrum of the intact chimaeric 14.18 (Chl4.18) monoclonal 
antibody, skimmer potential 150 V, protein concentration 10 pmol/pL.
The presence of the albumin contaminant in the Chl4.18 MAb sample was curious as the 
purity of the MAb had been checked previously by a range of methods, since this was an 
actual preparation injected into a patient for clinical trial. The most likely explanation is 
that the syringe used for injection of the MAb into the patient was contaminated with 
HSA and this in turn contaminated the sample vial since the preparation is normally
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injected twice using the same syringe. Nonetheless, it is clear from the spectrum of the 
Chi 4.18 MAb that ESI-MS is a powerful technique for characterising 
pharmaceutical-based MAbs and determining their purity.
3.2.7.d Mixture of B72.3 MAb and MAb X----------------------------------------------------------
To assess the capability of ESI to distinguish between mixtures of one or more MAbs, an 
equimolar mixture of two different MAbs (B72.3 and MAb X) was prepared and 
analysed by ESI on the triple quadrupole as shown in Figure 3.15. The mass of the 
B72.3 MAb was 146 765+54 Da (determined from the 10 most intense charge states) and 
the mass of the murine MAb X was 145 198±124 Da (determined from the 6 most 
intense charge states). In this case, the masses of these two MAbs were sufficiently 
different (ie. 1250 Da) to allow the resolution of the two series of components in the 
mixture since the individual ions were separated by 25 m/z for the 50+ charge state and
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Figure 3.15 Electrospray mass spectrum of an equimolar mixture of the intact murine B72.3 MAb 
and monoclonal antibody X. Skimmer potential 150 V, protein concentration of each 
MAb was 5 pmol/|iL.
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two distributions are clearly evident. If the masses of the individual MAbs had been 
closer to one another it is likely that the charge-state distribution profiles would have 
overlapped and as a consequence, once the spectrum had been smoothed, the two series 
of peaks may have merged into one component. If the mass difference between the two 
MAbs, however, was only 600 to 700 Da ie. 12 to 14 m/z units for the 50+ charge state, 
then it would become difficult to resolve two such MAbs, as the charge distribution 
profiles would overlap given that the width of the peaks in MAb spectra are typically 25 
m/z units. Thus it would appear that it is possible to resolve two MAbs in a mixture, 
provided that the masses of the proteins differ by at least 600 Da.
Once the ESI-MS conditions and the data processing for a range of MAbs had been 
successfully determined on the triple quadrupole instrument, these optimised conditions 
were extended to the analyses of MAbs on the AutoSpec™ magnetic sector mass 
spectrometer. There have been no reports of a MAb analysed on a sector instrument 
except that arising from this study (216).
3.2.8 A utoSpec™ Mass Spectrometry o f  M onoclonal A ntibodies----------------
Three of the MAbs characterised on the triple quadrupole mass spectrometer were chosen 
for analysis on the AutoSpec™ to ascertain if intact MAbs could also be analysed on a 
sector instrument. The AutoSpec™ has an extended mass range (m/z 8000) and is 
therefore ideal for the analysis of intact MAbs as in some instances the complete ESI 
spectrum of a MAb extended beyond the m/z range of the quadrupole instrument 
(ie. above m/z 4000). A MAb concentration of 5 pmol/jiL was initially chosen, as this 
concentration was found to produce the most intense signal on the Quattro™ instrument. 
The potential on the sampling cone, which is the equivalent of the skimmer potential on 
the Quattro™, was again higher than that observed for the analyses of smaller proteins 
(eg. 25 to 35 V for intact MAbs cf. 20 to 25 V for horse heart myoglobin). This is 
consistent with the optimised conditions determined for MAbs on the quadrupole mass 
spectrometer. The m/z range of the sector instrument was calibrated from m/z 2000 to
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4500 with ammoniated polypropylene glycol 3000 and the data processing of the spectra 
was similar to the processing of the spectra obtained on the Quattro™. All spectra were 
smoothed by twice the peak width-at-half peak height, the smoothed data centroided at 
80% of the peak height and the average molecular mass of the MAbs determined from the 
centroided data.
The first MAb to be characterised on the AutoSpec™ magnetic sector instrument was the 
B72.3 MAb. The concentration of the protein injected into the ESI source was 
5 pmol/}iL and the potential on the sampling cone was optimised at 25 V. The spectrum 
in Figure 3.16 shows the charge states ranging from 56+ to 34+. The most intense charge 
state was at m/z 3342 (z = 44) cf. Quattro™ in which the most intense charge state was at 
mlz 3125 (z = 47), and peaks due to lower charge states were observed up to at least 
m!z 4500, albeit with relatively low intensity. The mass determined for the B72.3 MAb 
was 147 021±77 Da (calculation based on the 44+ to 50+ charge states)
F igure 3 .16  Electrospray mass spectrum of the intact murine B72.3 monoclonal antibody analysed 
on the VG AutoSpec™ magnetic sector mass spectrometer. Sampling cone 25 V and 
protein concentration 5 pmol/pL.
Chapter 3 Monoclonal Antibodies 99
cf 146 931+44 Da on the Quattro™ (43+ to 51+ charge states). Only the higher charge 
state peaks (ie. above 43+) were used in the mass calculation as inclusion of lower charge 
states (ie. below 44+) resulted in an average molecular mass significantly higher than that 
determined from the Quattro™ instrument. The reason for the observed increase in mass 
with decreasing charge state has been discussed in the Section 3.2.2 and has been 
attributed to non-specific salt adduction to the MAb. The observed decrease in mass 
accuracy for the lower charge states may be alleviated by on-line introduction of the MAb 
into the ESI source by HPLC, which has been shown to markedly decrease salt adduction 
to these large proteins (219).
The other two MAbs to be analysed on the AutoSpec™ mass spectrometer were the 
'second generation' MAb X and the Chl4.18 MAb. The latter MAb sample also 
contained a significant proportion of human serum albumin, as was shown in the 
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Figure 3.17 Electrospray mass spectrum of the intact murine monoclonal antibody X analysed on the 
VG AutoSpec™ magnetic sector mass spectrometer. Sampling cone 33 V and protein 
concentration 5 pmol/|lL.
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4000
Figure 3.18 Electrospray mass spectrum of the intact Chl4.18 monoclonal antibody analysed on the 
VG AutoSpec™ magnetic sector mass spectrometer. Sampling cone 25 V and protein 
concentration 2 pmol/pL.
SDS-PAGE. The protein concentration for MAb X was 5 pmol/pL and the optimum 
potential on the sampling cone was 33 V. The concentration of the MAb/HSA mixture 
was optimised at 2 pmol/jLiL and the potential employed was 25 V. The mass spectra of 
these two MAbs are illustrated in Figures 3.17 and 3.18. The average molecular mass of 
MAb X (Figure 3.17), the Chl4.18 MAb and HSA (Figure 3.18) were 145 712±47 Da 
(calculated from the 44+ to 51+ charge states), 147 966±46 Da (calculated from the 46+ to 
56+ charge states) and 66 429±36 Da (calculated from the 31+ to '55+ charge states), 
respectively. These masses compared favourably to those determined from the spectra 
obtained on the Quattro™ instrument. The experimental conditions and the average 
molecular mass determined by ESI-MS for the three MAbs characterised by AutoSpec™ 
MS are summarised in Table 3.2.






















































B72.3 25 5 147 021±77 146 931±44
MAbX 33 5 145 712±47 145 613±55
Chl4.18 25 2 147 966±46 147 920±71
HSA 25 2 66 429±36 66 554±19
Table 3.2 Summary of the experimental conditions required for the analyses of two MAbs and a 
MAb/HSA mixture on the VG AutoSpec™ magnetic sector mass spectrometer. Masses 
are compared to those determined from the VG Quattro™ triple quadrupole instrument.
There were a number of differences observed between the spectra obtained on the 
Quattro™ instrument compared to that obtained on the sector instrument. At least 5 to 10 
more charge states were observed on the AutoSpec™ for all three MAbs than those 
observed in the spectra obtained on the Quattro™ instrument. In particular, the spectrum 
of the HSA contaminant shown in Figure 3.18, showed approximately 3 times as many 
charge states as was observed with this same sample when analysed on the triple 
quadrupole instrument (29 charge states cf. 10 charge states). In addition, due to the 
extended mass range of the sector instrument, more of the lower charge states were 
evident than can be observed with the Quattro™ (maximum m/z 4000). Also the most 
intense charge states for the proteins characterised on the AutoSpec™ were lower charge 
states than the most intense charge states for the same proteins on the Quattro™.
It can be seen, therefore, that the AutoSpec™ magnetic sector instrument can also be 
successfully used in the ESI analysis of intact MAbs, however, non-specific salt 
adduction observed with the lower charge states remains a significant problem in 
determining accurate average molecular masses for these 150 kDa proteins. The problem 
of salt adduction was overcome in this study by using only the masses determined from 
the higher charge states in the calculation of the average mass. Non-specific salt 
adduction to the lower charge states may be alleviated, as mentioned above, by on-line
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desalting by HPLC and introduction of the MAb directly into the ESI source. The 
average molecular masses determined by ESI-MS of the MAbs characterised in this study, 









B72.3 146 689 146 931±44 147 021±77
Deglycosylated B72.3 143 477 143 541±16 -
MAbX - 145 613±55 145 712±47
9.2.27 - 147 203±85 -
ch l4 .18 - 147 920±71 147 966±46
B72.3/MAb X mix 146 689 146 773±54 -
- 145 165±139 -
Table 3.3  Summary of the molecular masses determined for the characterised monoclonal 
antibodies on the VG Quattro™ triple quadrupole instrument and the AutoSpec™ 
magnetic sector instrument.
Once the ESI-MS conditions for assessment of monoclonal antibodies had been fully 
examined and established, whether the analysis was by the Quattro™ triple quadrupole or 
the AutoSpec™ magnetic sector instmment, the next task of this study was to assess the 
fragments of the B72.3 MAb that are produced from papain digestion of the intact protein. 
This again proved to be a difficult task as papain digestion produced fragments of masses 
that were initially difficult to assign with respect to the DNA sequence of the protein. 
Nonetheless, analysis of papain-produced MAb fragments, when used in conjunction 
with N-terminal Edman sequencing and deglycosylation experiments, provided a great 
deal of information regarding the structure of the MAb and the mode of action of the
enzyme.
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3.3 MONOCLONAL ANTIBODY FRAGMENTS  — —_____________________
3.3.1 Introduction ---------------------—_______________________________________
Monoclonal antibodies (MAbs) labelled with radionuclides have found widespread use in 
the in vivo diagnosis and therapy of a range of carcinomas (249). MAb fragments offer a 
number of advantages over the intact protein for imaging and therapy since they have 
rapid pharmacokinetics and reduced non-specific binding that are often associated with 
the glycosylated Fc portion of the immunoglobulin (228). *
The analysis of intact MAbs by ESI-MS can be a difficult task as noted in the previous 
sections, requiring the optimisation of a range of instrument and sample parameters. To 
overcome some of the difficulties with assessing intact proteins, MAbs can be 
enzymatically digested and the resultant fragments analysed by ESI-MS. MAb fragments 
are smaller in mass and therefore the unit resolution and thus mass accuracy is markedly 
improved. In addition, carbohydrate heterogeneity which is difficult to resolve in the ESI 
analysis of the intact protein can be observed by analysing the smaller 25 kDa 
glycosylated Fc fragment.
The protease digestion of MAbs to generate homogeneous, immunoreactive fragments is 
not always a straightforward process (170, 228). It is apparent from the number of 
studies that have been performed on enzymatic digestion of monoclonal antibodies that 
the parameters required for enzymatic fragmentation must be meticulously examined for 
each antibody and can vary considerably for different types and subclasses of MAbs 
(228). Classically, the enzymes pepsin and papain have been employed in thé digestion 
of MAbs to a bivalent F(ab')2 molecule (two antigen binding sites) with a molecular mass 
of approximately 100 kDa (250), or the univalent Fab (one antigen binding site) and 
Fc molecules each with a molecular mass of approximately 50 kDa (170) (see Chapter 1, 
Section 1.5.5, Figure 1.6). However, following pepsin digestion the resulting 
fragments may not be immunoreactive and some immunoglobulins such as murine IgGi 
MAbs are resistant to cleavage by this enzyme (170). Nonetheless, it is possible to
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cleave murine IgGi with papain under controlled conditions to F(ab')2 and Fc fragments 
(Figure 1.6). This can be achieved by preactivating the enzyme with lOmM cysteine, 
followed by separation of the activated papain from the excess cysteine. The presence or 
absence of lOmM cysteine during digestion determines whether the Fab or F(ab')2  will 
predominate (170, 227). Papain is a nonspecific sulphydryl protease that hydrolyses 
most peptide bonds to some extent, although the relative rates of hydrolysis may differ 
by several orders of magnitude. It has been reported that the most susceptible peptide 
bonds appear to be the bond next-but-one to the carboxyl group of phenylalanine (251) 
and peptide bonds at basic amino acids and lysine or glycine (252).
The separation profile of the B72.3 F ^  fragment from papain, undigested B72.3 MAb 
and Fc fragment is shown in Figure 3.19. A similar profile is observed when the F(ab')2
Figure 3.19  Profile of the papain-digested fragments of the B72.3 MAb separated on a HR 5/5 Mono 
Q anion-exchange column using a BioLogic™ chromatography system. The void peak 
(A) contains either Fab or F(ab')2 fragments. Papain, undigested MAb (B) 
and Fc fragments (C) are eluted consecutively as the percentage of ionic salt 
is increased. *
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F igure 3 .20  Electrospray mass spectra of the B72.3 Fab fragment (MAb digested with 5% papain).
Skimmer potential 50 V, protein concentration 20 pmol/p,L. Insets show mlz data 
transformed to a mass scale.
(A) 'Papain-resistant' B72.3 MAb,
(B) 'Papain-sensitive' B72.3 MAb.
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fragment is generated. The B72.3 MAb fragments were separated from undigested MAb 
and papain on a medium pressure BioLogic™ system (Bio-Rad Laboratories 
Incorporated, Hercules, CA) with a HR 5/5 Mono Q™ anion exchange column 
(Pharmacia, Uppsala, Sweden) (Chapter 2, Section 2.3.3).
3.3.2 B72.3 Fab Fragment-------- ---------------------------—— ________________________
The optimum instrument parameters and sample concentration for the MAb fragments 
were found to be markedly different to those determined for intact MAbs, as described in 
Section 3.2.1. The concentration range for the 50 kDa B72.3 Fab fragment over which a 
strong ESI signal was observed was determined to be 10-20 pmol/pL and the potential on 
the first source skimmer was optimised at 50 V. The mlz distribution ranged from 1000 
to 1900, approximately half the mlz range observed for the intact MAbs.
The ESI mass spectra of the B72.3 Fab subunit, following digestion with 5% papain 
(w/w) are shown in Figure 3.20A and 3.20B. These fragments were produced from two 
different batches of the B72.3 MAb (discussed below). Shown inset is the ESI data 
following transformation from a mlz to a mass scale. The average molecular mass of the 
major species (A) in Figure 3.20A, calculated from the raw data was 47 261±5 Da. 
Based on the translated DNA sequence of the B72.3 MAb, the expected mass of the
4 A j i  4 A A 4
Fab fragment is 47 264 Da (Light Chain: D C plus Fd Fragment: Q -» C ) 
(190, 235). Thus the mass determined from ESI is in excellent agreement, with the 
theoretical mass. The three components (labelled B, C and D) in Figure,3.20A are 
attributed to cleavages in other regions of the MAb heavy chain. These data are 
summarised in Table 3.4 and the proposed cleavage sites of papain are given in 
Scheme 3.1.
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NSWTD QDSKD STYSM SSTLT LTKDE YERHN SYTCE ATHKT
210
STSPI VKSFN RNEC
Scheme 3,1 Translated DNA sequence of the B72.3 monoclonal antibody (190,235).
(A) Heavy chain,
(B) Light chain.
The proposed sites of cleavage by papain (P) and caiboxypeptidase B (C) are indicated.

























. 1 214 1 221 
Light Chain: D —» C + Fj Fragment: Q —> C
1 214 1 218 
Light Chain: D —> C + Fj Fragment: Q —> C
1 214 4 219 
Light Chain: D —> C + Fj Fragment: L -» K
1 214 4 217 
Light Chain: D -> C + Fj Fragment: L -> G
Table 3.4  Summary of data for the B72.3 Fab Fragment1 (see Figure 3.20A).
1 'Papain-resistant' MAb digested with 5% (w/w) papain.
81 136
2 Assuming oxidation of heavy chain M or M (ie. with the addition of 32 Da, see Section 3.3.3).
The average molecular mass determined from Figure 3.20B (inset) was 46 521±5 Da. 
From the translated sequence of the MAb, the minimum possible mass for the 
Fab fragment is 46 775 Da (Light Chain: D 1-* C214 plus Fj Fragment: Q1-» C216) 
(190, 235) implying that the B72.3 MAb may have been further cleaved by papain 
(discussed below). A mass difference such as this would not be readily detected by 
conventional techniques. SDS-PAGE, for example, would be unable to discriminate 
between the masses of 46 521 Da and 46 775 Da. This clearly illustrates the power of 
ESI-MS for determining small changes in mass on large proteins.
The apparent difference in susceptibility to cleavage by papain from batch to batch of the 
B72.3 MAb may be due to such factors as the age of the animals used to produce the 
MAb in vivo. Of the four different batches of B72.3 used in this study, only one 
appeared to be resistant to this apparent further cleavage. These four batches included 
two that were prepared and purified by Bioquest Limited, one that was produced and 
purified in our laboratory (all referred to throughout as 'papain-sensitive') and the only 
'papain-resistant' batch which was produced 'in house' and purified by Bioquest 
Limited. Normal variability in the carbohydrate content of monoclonal antibodies from 
batch to batch has also been reported (63). Over digestion of the 'papain-sensitive' 
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F igure 3.21  Electrospray mass spectra of B72.3 Fab fragment produced from the digestion of 
'papain-sensitive' MAb with 0.5% papain (w/w) and reduced with 20mM DTT. 
Skimmer potential 50 V, protein concentration 20 pmol/pA.
(A) ESI mass spectrum with data transformed to a mass scale shown inset,
(B) MaxEnt™ deconvoluted spectrum.
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to cleave the MAb. Similar data as shown in Figure 3.20A were obtained when 
0.5% papain (data not shown) was utilised for the ’papain-sensitive' batch of 
B72.3 MAb. Thus the possibilities of either an error in the DNA sequence which has 
been translated to errors in the amino acid sequence or digestion of the MAb in vivo can 
be excluded. In addition, the ’papain-resistant' batch of MAb appeared to be relatively 
unaltered by varying concentrations of papain. The ’resistant’ B72.3 MAb was digested 
at 1, 2.5, 5 and 10% papain (w/w) with little change in the reaction products. The 
apparent further cleavage of the Fab fragment (in some cases) was explored further by 
reduction with DTT and N-terminal sequencing.
3.3.3 Reduced B72.3 Fab Fragment---------------------------------------------------------
In an attempt to confirm the proposed sites of papain digestion, the Fab fragments were
reduced with DTT to separate the light chain from the Fd fragment Figure 3.21 shows
the ESI spectra of the reduced, 'papain-sensitive' B72.3 Fab fragment digested with
0.5% papain (w/w). Illustrated in Figure 3.21 A is the ESI mass spectrum with the
m!z data transformed to a mass scale shown inset and Figure 3.2IB shows the ESI data
transformed to a mass scale using the more sophisticated maximum entropy (MaxEnt™)
method (54, 57). The average molecular mass of the components (A and C) in
Figure 3.21 A (inset) were 23 357±1 and 23 912+4 Da, respectively. These correspond
1 218
to the translated DNA sequence masses of 23 355 Da (Fd Fragment: Q - » C )
1 223
(190,235) and 23 900 Da (Fd Fragment: Q -> C ) (190, 235). The major component
/
(B) of mass 23 579±4 Da corresponds with the translated DNA sequence mass of
1 220
23 580 Da (Fd Fragment: Q ->•P ) (190, 235) (Scheme 3.1), but there is no evidence 
of the light chain (23 590 Da) in the transformed spectrum. It is interesting to note that 
the charge-state distribution, as shown in the raw data (Figure 3.21A) is non-Gaussian, 
rather there appears to be two separate distributions.
Deconvolution of the ESI raw data (Figure 3.2 IB) by the MaxEnt™ algorithm (54,57) 
revealed that the component at 23 579 Da (shown in Figure 3.21 A inset) was comprised
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of two overlapping peaks of masses 23 586+0.3 Da (light chain) and 23 578±0.6 Da 
(Fd fragm ent), that were difficult to resolve in the transform ed spectrum 
(Figure 3.21 A inset). Reduction of 'papain-resistant' Fab fragment of mass 47 264 Da 
(Figure 3.20A), should produce the light chain (23 590 Da) and the Fd fragment 
(23 683 Da), however, as indicated by the deconvoluted data, the Fd fragment has a 
mass of 23 578 Da (expected mass Fd Fragment: Q -* P is 23 580 Da) (190, 235).
Therefore it can be assumed that during the reduction procedure the peptide bond
220 221 221 
between P and C has been cleaved resulting in the loss of the C residue from














(Scheme 3.1) (190, 235)
A 23 355 23 357±1
1 218
Fd Fragment: Q —> C
B 23 580 23 579±4
1 220
Fd Fragment: Q —» P
C 23 900 23 912±4
1 223
Fd Fragment: Q —> C
5% PAPAIN5 A 22 897 (22 929)3 22 929±2
4 217
Fd Fragment: L —» G
B 23 000 (23 032)3 23 032±3
4  218
Fd Fragment: L C
C 23 128 (23 160)3 23 161±3
4 219
Fd Fragment: L -» K
D 23 590 23 588±2
1 214
Light Chain: D -» C *
T able 3.5 Summary for reduced B72.3 Fab fragment (see Figure 3.21).
, 81 136
3 Assuming oxidation of heavy chain M and M .
4 'Papain-sensitive' MAb digested with 0.5% (w/w) papain.
5 'Papain-sensitive' MAb digested with 5% (w/w) papain.
Figure 3.22 shows the ESI spectrum of reduced Fab fragment produced from digestion of 
the 'papain-sensitive' B72.3 MAb cleaved with 5% papain (w/w). The average 
molecular mass of the major species (D), shown inset, was 23 588±2 Da. The reduced 
mass of the B72.3 MAb light chain determined from the translated DNA sequence is 
23 590 Da (190, 235). The data from ESI is in excellent agreement with the known
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sequence of the light chain. This implies that although the Fab fragment has been further
cleaved by papain (Figure 3.20B), the light chain is completely intact Thus it is likely
that loss of an amino acid(s) by cleavage with papain occurred on the Fd fragment This
was confirmed by N-terminal Edman sequencing which revealed that the first seven
residues of the light chain (DIQMTQS) (Scheme 3.1) were in agreement with the known
amino acid sequence (190,235). Similar analysis of the Fd fragment revealed the loss of
the first three residues (QVQ). Taking this into account, the calculated mass for the
F d fragm ent should be 22 897 Da (Fd Fragment: L4-* G 217) (190, 235)
(c /. 22 929±2 Da by ESI). The discrepancy of 32 Da between the predicted and
observed masses is most likely a result of oxidation of the two methionine residues in the 
81 136Fd fragment (M and M ). Oxidation of methionine residues could have occurred 
during enzymatic cleavage of the MAb, however, since the digestion was performed
________________________________ m/z ___________________________
F igure 3.22  Electrospray mass spectrum of B72.3 Fab fragment produced from the digestion of 
'papain-sensitive' MAb with 5% papain (w/w) and reduced with 20mM DTT. Shown 
inset is the ESI data transformed to a mass scale, skimmer potential 50 V, protein 
concentration, 20 pmol/pL.
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under reducing conditions it is likely that the oxidation occurred during sample 
introduction/ionisation process as has been reported previously for other proteins (253).
It is interesting that the intact ’papain-resistant' Fab fragment (which we presume is more 
tightly folded) does not undergo methionine oxidation (Figure 3.20A). The evidence for 
both enhanced methionine oxidation and N-terminal cleavage suggests that the 
'papain-sensitive' MAb is a less-folded protein. These data are consistent with a similar 
report of two conformational forms of human 7G globulin that have been distinguished
by their differing behaviour on incubation with papain (254). Analysis of the 0.5% 
papain digest for the same reduced 'papain-sensitive' Fab fragment (Figures 3.21 A and 
3.2IB) does not show oxidation of methionine residues. This discrepancy can be 
reconciled as follows. It is plausible that the loss of QVQ from the overdigested 'papain­
sensitive' Fab fragment disrupts the integrity of the protein and results in partial 
unfolding of the fragment, thereby exposing the methionine residues to oxidation in the 
ESI source. Although the same 'papain-sensitive' MAb was digested with 0.5% papain 
and then reduced, no loss of QVQ occurred, thus the three-dimensional structure of the 
protein was maintained and the methionine residues were not exposed to oxidation.
In addition to the two major components (A and D) in Figure 3.22 (inset), there are two 
components of mass 23 032±3 Da (B) and 23 162±3 Da (C). Assuming loss of QVQ 
from the N-terminus of the Fd fragment, then the calculated masses from the siequence of 
the protein are 23 000 Da (Fd Fragment: L4-» C 218) (190, 235) and 23 128 Da
4 219 .(Fd Fragment: L -> K ) (190,235). Again, however, there are discrepancies m mass 
of 32 Da and 33 Da, respectively, most likely as a result of methionine oxidation. These 
data are summarised in Table 3.5.
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3,3 .4  B72.3 F (ab ,)2  F ra g m e n t----- -------------------------- —_____________________
The 50 kDa univalent Fab fragment discussed in Section 3 .3 . 2  is only one of the non- 
glycosylated fragments that can be produced from enzymatically digesting intact MAbs. 
Under appropriate experimental conditions a bivalent 1 0 0  kDa F(ab')2  fragment can also 
be generated. In the ESI-MS analysis of the B72.3 F(ab')2  fragment, the protein 
concentration was optimised at 10 pmol/jiL and the optimum skimmer potential was 
determined to be 100 V. The m!z distribution ranged from 1800 to 2800 which is higher 
than for the Fab fragment, but lower than that observed for MAbs. Illustrated in 
Figure 3.23 is the F(ab’) 2 fragment of the ’papain-sensitive' B72.3 MAb digested with 
5% papain, in the absence of a reducing agent, and showing the charge states 34+ to 51+. 
The mass of 94 553±36 Da determined from ESI compares favourably with the mass of 
94 523 Da (Light Chains: D 1-» C214 plus F^ Fragments: Q1-» C221) (190, 235). This is 
determined from translation of the DNA sequence assuming that symmetrical cleavage
F igure 3.23  Electrospray mass spectrum of the ’papain-sensitive’ B72.3 F(ab')2 fragment digested 
with 5% papain (w/w) (in the absence of cysteine) showing charge states 34+ to 51+. 
Skimmer potential 100 V, protein concentration 10 pmol/pL.
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. 221
has occurred at the C-terminus of C of the two MAb heavy chains. No apparent over 
digestion of the MAb occurred in this reaction, even though 5% papain (w/w) was used. 
This tends to imply that the presence of a reducing agent in other reactions may cause the 
B72.3 MAb to become partially unfolded thereby exposing more regions to attack by the 
enzyme (Figure 3.20B).
3.3.5 Reduced B72.3 F(ab' ) 2  Fragment----------------------------------------------------------
221To confirm that cleavage of the B72.3 MAb had occurred at C of both the heavy 
chains, without the loss of any residues from the N-terminus of the Fd fragment, the 
'papain-sensitive' F(ab')2  subunit was reduced with DTT. Figure 3.24 shows the ESI 
spectrum of the reduced 'papain-sensitive' B72.3 F(ab')2  fragment transformed to a mass 
scale. The data were similar to that observed on reduction of the 'papain-sensitive' 
B72.3 Fab fragment that had been digested with 0.5% papain (Figure 3.21A inset) and is
F igure 3 .24  Electrospray mass spectra of ’papain-sensitive' B72.3 F(ab')2 fragment shown in 
Figure 3.21, reduced by 20mM DTT and transformed to a mass scale. Skimmer 
potential 50 V, protein concentration 20 pmol/jxL.
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, 220 221 
consistent with cleavage at P , with loss of the C-terminal C during the
reduction procedure.
3.3.6 B72.3 Fc Fragm ent--------------------------------------------------------------------------
The final MAb fragment that was investigated in this study was the 25 kDa Fc fragment 
which contains the carbohydrate portion of the protein and is responsible for the 
heterogeneous nature of MAbs. The optimum concentration for ESI analysis of the
25 kDa reduced Fc fragment of the B72.3 MAb was 20 pmol/|nL (total 10 pL injected) 
and the potential on the first source skimmer was optimised at 50 V. These figures are 
typical for other proteins of this size run in our laboratory and the observed 
m/z distribution from 1000 to 1700 is also fairly typical for a protein of this 
molecular mass.
The ESI spectrum of the reduced 'papain-resistant' B72.3 Fc subunit is shown in 
Figure 3.25. Charge states 16+ to 23+ are given, with an expanded view of 19+ charge 
state shown inset. The transformed ESI-MS spectrum shown in Figure 3.26 indicates 
the presence of three major components labelled A, B and C. The predominant peak in 
the spectrum (Component A) has an average molecular mass of 25 728±2 Da which is 
consistent with the amino acid sequence of this fragment (Heavy Chain Fragment: 
T 224-> G437, less K438) (235) plus the core carbohydrate portion
(2 A-acetylglucosamine, 3 mannose, 1 fucose) with the addition of two 
A-acetylglucosamine units. The other major peaks at 25 890+2 Da (Component B) and
26 054±4 Da (Component C) correspond closely to the addition of 1 and 2 hexose 
units, respectively.
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F igure 3 .25  Electrospray mass spectrum of the reduced 'papain-resistant' Fc fragment of the 
B72.3 monoclonal antibody, skimmer potential 50 V, protein concentration 20 










|  N-Acetylgalactosamine 
®  Mannose 
D> Galactose










^  I M M | M 1111 M i |
26500 26750 27000
F igure 3 .26  Electrospray mass spectrum of the reduced 'papain-resistant' Fc fragment of the 
B72.3 monoclonal transformed to a mass scale. Glycosylation patterns are as indicated.
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3.3.7 Deglycosylated Fc Fragment------------------------------------------------------------
To determine the sites of papain cleavage with respect to the Fc fragment, the 
carbohydrate was removed from this subunit in the same fashion as the intact MAb 
(Section 3.2.4). Illustrated in Figure 3.27 is the ESI mass spectrum of the 
deglycosylated Fc fragment (charge states 24+ to 15+) produced from digestion of the 
'papain-resistant' B72.3 MAb cleaved with 5% papain (w/w). Shown inset is the ESI 
data transformed to a mass scale. Removal of the carbohydrate from the Fc fragment 
markedly reduces the heterogeneity of the protein, thus enabling the sites of cleavage by 
papain to be determined. The major component (D) in Figure 3.27 (inset) has a mass of 
24 284±2 Da. From the translated DNA sequence the mass of 24 280 Da (Heavy Chain:
437 438i -» G ) (235) ie. less the C-terminal residue K , corresponds closely to the mass
determined from electrospray. Note that the major cleavage sites for the Fd and
221
Fc fragments do not coincide as papain has cleaved on the C-terminal side of C
223 .(Fd fragment from the ’papain-resistant’ Fab fragment) and C (’papain-resistant’ 
Fc fragment) (Scheme 3.1) leaving the dipeptide (I C ) which would be dialysed 
from the reaction mixture when the samples were prepared for ESI-MS analysis of the 
fragments. The three components (A, B and C) are also in close agreement with the 
masses determined from the translated DNA sequence. These data are summarised in 
Table 3.6 and the proposed sites of papain cleavage and carboxypeptidase B activity are 













A 23 814 23 817±2
224 T 432
Heavy Cham: T —» L
B 23 903 23 907±5
218 427
Heavy Chain: C H
C 24 178 24 183±3
225 437
Heavy Chain V —» G
D 24 280 24 284±2
224 437
Heavy Chain: T —» G
T able 3.6. Summary of Data for the Deglycosylated B72.3 Fc Fragment6 (see Figure 3.27). 
6 ’Papain-resistant’ MAb digested with 5% (w/w) papain.
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Figure 3 .27  Deglycosylated ’papain-resistant’ Fc fragment of the B72.3 monoclonal antibody, 
skimmer potential 50 V, protein concentration 20 pmol/pL. The inset shows the 
electrospray mass spectrum transformed to a mass scale. Note that component B at a 
mass of 23 907 Da is unlabelled in the transformed spectrum (inset).
3.4 CONCLUSIONS------------------------------------------------------------------------ --------
The results from this chapter clearly show that ESI-MS is an important and versatile 
analytical technique for the assessment of monoclonal antibodies as indicated by the 
successful analyses of a range of different antibodies on a VG Quattro™ 
triple quadrupole instrument and a VG AutoSpec™ magnetic sector instrument ESI-MS 
has also proven to be useful for determining the purity of a MAb which is extremely 
important, for example, in the quality control of antibody-based pharmaceuticals. This 
was demonstrated in one instance by the resolution of albumin from the antibody and 
also in the resolution of two MAbs in a mixture. In addition, ESI-MS has proven a 
valuable technique for assessing the mode and site of action on a MAb of the protease 
papain. When used in conjunction with reducing agents and carbohydrate-releasing 
enzymes a remarkable amount of structural information can be determined from a MAb.
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If the sequence of the MAb was unknown, structural information could be achieved 
using the above methods in conjunction with peptide mapping.
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CHAPTER 4
CHEMICALLY-MODIFIED PEPTIDES AND PROTEINS
4.1 INTRO D U CTIO N --------------------------------------------------------------------------------
Radioimmunospecific pharmaceuticals, in which radionuclides are incorporated into a 
monoclonal antibody (MAb) or genetically engineered proteins, are contemporary 
approaches to diagnostic and therapeutic treatment of cancer (249, 255). Methods for 
labelling antibodies include: (i) direct labelling and (ii) indirect labelling with the use of 
bifunctional chelators. Many of the factors limiting clinical applications of 
radioimmunoconjugates, eg. human anti-mouse antibody (HAMA) response, have been 
overcome by the use of antibody fragments and the development of recombinant forms of 
MAbs (246); however, the chemistry involved in modification of MAbs remains a 
significant limiting factor in the development of radioimmunoconjugates for clinical use. 
For the on-going development of radioimmunoconjugates it is vital to establish loading 
values of chelators on the proteins (ie. average numbers of moles of chelator bound to the 
protein), to characterise the nature of the ligand binding and to have a method for 
determining the purity of the resulting radiopharmaceutical.
As discussed in Chapter 1, Section 1.5.7 the current techniques available for assessment 
of loading conditions of MAbs are most commonly based on UV spectroscopy (208) and 
radioactivity trace assays, (200) each of which have limitations. ESI-MS has the 
potential to be used as an alternative technique for establishing loading values of chelators 
and radioisotopes bound to MAbs, as well as for confirming the purity of antibody-based 
pharmaceuticals. As noted in the previous chapter, there have now been a number of 
published reports on ESI-MS of monoclonal antibodies, antibody fragments and 
recombinantly engineered antibodies (42,60,63,209,210,212-219); however, the only 
report of ESI mass spectra of a chemically-modified antibody (220) is based on the work 
described in this thesis. Further, there have been relatively few reports of ESI-MS for
Chapter 4 Chemically-modified Peptides and Proteins 120
characterisation of chemically-modified proteins, although chemically-derivatised MAbs 
have been successfully characterised by MALDI-MS in a study by Hillenkamp and 
colleagues (221).
One of the goals of this study was to characterise a range of novel ligands for 
development of new radioimmunoconjugates. A shift in the research priorities of the 
industry partner (ANSTO), meant no such ligands became available in time for inclusion 
in this study. Hence the initial work on this aspect of the project focussed on the 
derivatisation of small peptides and lower molecular mass proteins by a range of 
common, readily-available, protein modification reagents. The peptides were used 
primarily to generate representative samples for tandem mass spectrometry studies as 
described in Chapter 5. Modification of the peptides and model proteins required the 
optimisation of labelling and reaction conditions as well as careful desalting of the 
reaction products for subsequent ESI-MS analysis. The information obtained from 
modification of these proteins was then extended to the larger MAb fragments and 
ultimately to intact MAbs.
4.2 CONJUGATION OF l(r)5-C6H 7) Fe(CO)3]+ (Fed*)------------------------------
Dienyl cations of the type [(T|5-C6H7) Fe(CO)3]+ (Fed+) are chemically robust and very 
efficient electrophiles, attacking a wide range of nucleophilic substrates to give 
substituted diene products, thus providing a class of reagents for the selective labelling of 
peptides and proteins (256, 257). Cysteine sulphydryl and histidine nitrogen groups 
(imidazole ring), in particular, are highly preferred targets. Fed+ was chosen for this part 
of the study because of the potential to generate a rhenium dienylcation analogue, which 
in turn would allow the introduction of rhenium radioisotopes into protein conjugates.
It has been shown that addition of Fed+ to cysteine residues is favoured at pH 5, whereas 
conjugation to histidine is favoured at pH >7 (256). The increased reaction at a higher 
pH presumably arises from partial deprotonation of the imidazole side-chain which
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enhances its nucleophilicity. The mechanism of Fed+ addition to both cysteine and 
histidine residues is shown in Scheme 4.1. The addition of a Fed+ molecule increases 
the overall mass of the peptide or protein by 218 Da and this is readily detected in the ESI 
mass spectra.
Schem e 4 .1  Addition of [Cn5-C6H7) Fe(CO)3]+ (Fed+) to either a cysteine or histidine residue in a 
protein to produce the protein-Fed conjugate. Each addition of a Fed+ moiety increases 
the overall mass of the protein by 218 Da.
Fed+ was conjugated to a range of small peptides, containing either a histidine (H) and/or 
a cysteine (C) residue and the masses of the organometallic-peptide conjugates 
determined by ESI-MS. The ESI spectra of the histidine-containing peptides N-acetyl 
histidine (Mr 197.08), p-Glu-His-Pro (Mr 363.15) and p-Glu-His-Gly-NH2 (Mr 322.14) 
showed protonated molecular ions for the unmodified peptides [peptide+H]+ at mlz 198,
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364 and 323, successively. In addition, the protonated peptide-Fed conjugates 
[peptide+Fed+H]+ were also observed at mlz 416, 582 and 541 in the respective ESI 
spectra. The ESI spectrum of the cysteine-containing peptide glutathione (Mr 306.10) 
showed peaks which were attributed to the protonated unm odified peptide 
[glutathione+H]+ (mlz 307) and the peptide-Fed conjugate [glutathione+Fed+H]+ 
(m/z 526), respectively. The spectrum of the cysteine-containing LHRH peptide 
(EHWSYGLRPG, Mr 1182.56) showed a singly-charged peak at mlz 1184 [LHRH+H]+ 
and doubly-charged peaks at mlz 593 [LHRH+2H]2+ and mlz 702 [LHRH+Fed+2H]2+. 
The ESI spectrum of the [Cysu ]-LHRH peptide (EHWSYGLRPGC, Mr 1285.57), 
which contains both a histidine and cysteine residue gave a singly-charged peak at 
mlz 1286 [peptide+H]+ and doubly-charged peaks at mlz 644 [peptide+2H]2+, mlz 753 
[peptide+Fed+2H]2+ and mlz 862 [peptide+2 Fed+2H]2+. In all of the spectra of the 
peptide-Fed conjugates, the protonated Fed+ adduct [Fed+H]+ was also observed at 
mlz 219. The peptide-Fed bond is known to be highly labile and consequently a low 
skimmer potential of 20 V was employed for analysis of the conjugates. When skimmer 
potentials above 20 V were used the Fed-peptide adducts were not observed in the ESI 
spectra presumably due to the facile cleavage of the Fed-peptide bond. Addition of 
1% formic acid also resulted in a decrease in the proportion of the peptide-ligand 
conjugate, as the peptide-Fed bond is acid labile.
The pH dependence of Fed+ addition to the peptides discussed above is shown in 
Figure 4.1. The data shows that conjugation of Fed+ to histidine occurs at pH <7, 
however, the proportion of Fed+ addition to a histidine containing peptide increased 
markedly when a pH of 7 or greater was employed. Conversely, the MS data shows that 
addition of Fed+ to cysteine residues was quite significant at lower pH. This is 
consistent with NMR and other data regarding the reactivity of Fed+ (256).











Figure 4.1 Ratio of peptide-Fed+ conjugate to peptide at a range of pH (pH of the reaction is shown 
at the end of each bar). Data indicates that for histidine containing peptides, the 
proportion of adduct increased at a pH greater than 1: Adduct formation for peptides 
containing cysteine residues occurred at low pH. .
* Relative to each other.
Fed+ was also conjugated to hen egg-white lysozyme (HEL), which contains a single 
histidine (H 15) and eight cysteine residues. Highly selective and almost quantitative 
addition of Fed+ to the sole histidine residue of HEL has been established by 
2D *H NMR studies using TOCSY (total correlation spectroscopy) in D20  (256), 
however, the adduct was not detected in the ESI mass spectra. The most likely 
explanation for this is that given the protein-Fed bond is very labile, it is necessary to use 
a low skimmer potential to observe the conjugate; however, a skimmer potential of 20 V 
does not provide a sufficient energy to transmit a protein of the size of HEL through the 
source skimmer region and hence enable the ESI mass spectrum to be recorded. At 
50-70 V, there is a strong ESI response for the protein, but at this potential it is likely that
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the Fed+ adduct dissociates. From these experiments it was concluded that while 
ESI-MS analysis of peptide-Fed+ conjugates can be achieved at low skimmer potentials, 
the use of ESI-MS as a technique for the analysis of labile protein-ligand complexes is 
limited. It is possible, however, that the data obtained from ESI-MS of labile reagents 
can give some indication of relative stabilities of different conjugates which can in turn be 
correlated with the stability of the conjugate in vivo. In this case it appears that the 
HEL-Fed complex (which NMR data has shown to be present in solution under the same 
conditions) is less stable than many non-covalent complexes (eg. trypsin inhibitor) (258) 
which are observed in ESI spectra when moderately high skimmer potentials are 
employed. Hence, based on these results, it is unlikely that rhenium analogues of Fed+ 
would be suitable as protein labelling agents for use in vivo.
4.3 BIOTINYLATION R E A C TIO N S ---------------------------------------------------------
Radiolabelled MAbs have been used for both diagnosis and experimental therapy of 
cancer with some encouraging results (259), however, one of the major drawbacks in 
MAb-guided tumour detection is the high background due to non-specific uptake of the 
radiolabelled protein by normal tissues and blood (260). This has led to the development 
of tumour pre-targeting strategies where the MAb and radiolabel are administered 
separately (261-264). Such procedures allow non-localised MAb to clear from 
circulation prior to the administration of the radiolabel. Accumulation of the label in 
normal tissues is thereby reduced and tumour/non-tumour radioactivity ratios are 
significantly improved. In addition, imaging of tumours by radioimmunoscintrgraphy is 
enhanced and the likelihood of normal tissues receiving unnecessary doses of radiation is 
decreased.
One of the most successful pre-targeting strategies to date is based on the avidin-biotin 
system (260). The binding of biotin (vitamin H) by egg-white avidin (Afr ~66 kDa) or 
streptavidin (its non-glycosylated bacterial relative from Streptomyces avidinii, 
Mi -6 0  kDa) is one of the highest affinity biological interactions known (K<j = 10-15 M)
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(265). It is this strong non-covalent interaction that can be used to advantage in 
radiochemical imaging and therapy. The two strategies based on the avidin-biotin system 
that are in common use are the two-step and three-step pre-targeting protocols. One 
two-step approach involves the in vitro conjugation of a molecule of avidin 
(or streptavidin) to the MAb. The conjugate is administered in vivo and allowed to 
localise onto the target. After two to three days, when the amount of circulating MAb is 
sufficiently decreased, radiolabelled biotin is injected to image the tumour. In another 
two-step approach, MAbs conjugated with biotin are administered unlabelled in vivo and 
after two to three days radiolabelled avidin is injected. The three-step protocol involves 
the administration of biotinylated MAb to pre-target the tumour cells, injection of 
unlabelled avidin and finally, administration of radiolabelled biotin. The major 
advantages of pre-targeting strategies are that the immunoreactivity of the MAb is 
preserved throughout the procedure and the tumour/non-tumour ratio is greater than that 
obtained with directly labelled MAbs.
The insertion of biotin into proteins requires an activated group such as the 
hydroxysuccinimide ester form of biotin. N-hydroxysuccinimidobiotin (NHS-biotin) 
reacts specifically with primary amines (generally lysine epsilon groups) on peptides and 
proteins to form stable amide bonds resulting in the release of N-hydroxysuccinimide 
(Scheme 4.2). Each addition of a biotin molecule increases the mass of the protein 
by 226 Da.
ESI-MS was used to study the reaction of NHS-biotin with the amino acid L-lysine and a 
range of lysine-containing peptides and proteins in an attempt to ascertain if it is possible 
to determine the number of biotin groups that have been conjugated to the peptide or 
protein by this technique. The procedure for biotinylation of the model peptides and 
proteins and subsequent ESI-MS analyses was then extended to MAb fragments and 
intact MAbs.
Chapter 4 Chemically-modified Peptides and Proteins 126
Schem e 4.2  Biotinylation of a protein with iV-hydroxysuccinimidobiotin (NHS-biotin) at 
alkaline pH. Each addition of a biotin moiety to a lysine residue or the N-terminus 
increases the overall mass of the protein by 226 Da. '
4.3.1 L -L ysin e -------------------------------------------------------- ----------------------------------
Illustrated in Figure 4.2 is the electrospray mass spectrum of L-lysine modified with 
NHS-biotin at an equimolar ratio. There was no evidence of the protonated unmodified 
lysine at mlz 146.9 [lysine+H]+, implying that the reaction of the amino acid with 
NHS-biotin was complete. The protonated peak is the major component of the spectrum 
of the free amino acid (data not shown). L-lysine has one e-amino group plus a free 
N-terminal amino group, therefore it is possible that a maximum of 2 biotin molecules 
could be conjugated to the amino acid. As shown in Figure 4.2, the singly-charged 
species are evident for the addition of one and two biotin groups to L-lysine at mlz 373.1 
[lysine+biotin+H]+ and mlz 599.1 [lysine+2 biotin+H]+, respectively.
From the data it can be seen that it is possible to clearly observe the addition of biotin on 
the amino acid L-lysine by ESI-MS. A skimmer potential of 50 V was employed in the 
analysis and unlike the peptide-Fed conjugates (discussed above in Section 4.2) in which 
the Fed+ adduct was removed from the peptide at skimmer potentials greater than 20 V, 
the L-lysine-biotin conjugate remained intact The implication from the data is that the 
strength of the covalent bond between the amino acid and the biotin moiety is
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significantly greater relative to the peptide-Fed bond. Loss of the biotin adduct can, 
however, be induced by tandem MS experiments in which fragmentation occurs by 
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F igure 4.2  Electrospray mass spectrum of the biotinylated amino acid L-lysine showing the 
addition of one and two biotin moieties. Skimmer potential 50 V, amino acid 
concentration 200 pmol/pL. L-lysine was reacted at an equimolar ratio with 
NHS-biotin.
4.3.2 cGMP Protein Kinase Substrate Peptide-------------------------------------------
Once the biotinylated L-lysine conjugate had been successfully analysed by ESI-MS the 
biotinylation reaction was then extended to small peptides containing more than a single 
lysine residue. Shown in Figure 4.3 is the cGMP protein kinase substrate peptide 
(cGMP - RKRSRKE, MT 958.58) modified with NHS-biotin at a molar ratio of peptide 
to biotin of 1:2. The data obtained from the conjugation reaction and the percent relative 
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Figure 4.3 Electrospray mass spectrum of the biotinylated cGMP peptide showing the addition of 
one, two and three biotin moieties. Skimmer potential 50 V, peptide concentration 
200 pm ol/pL . Molar ratio of peptide to NHS-biotin was 1:2. Note that the 































cGMP 958.6 nd - 320 4.46
cGMP + Biotin 1184.9 nd - 397 10.44
cGMP + 2 Biotin 1411.2 706 4.06 471 100
cGMP + 3 Biotin 1637.5 819 1.58 546 68.57
Table 4.1 Summary of the covalent conjugation of N-hydroxysuccinimidobiotin (NHS-biotin) to 
the cGMP peptide to produce the cGMP-biotin conjugate.
* Relative to the base peak, nd = not detected.
cGMP has two lysine residues plus a free N-terminal amino group, therefore it would be 
expected that a maximum of three biotin groups could be conjugated to the peptide. The 
doubly- and triply-charged species were observed for the addition of two and three biotin
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groups to cGMP. Only the triply-charged species was observed in the ESI-MS spectrum 
of the unmodified peptide and the peptide with one biotin moiety. As the addition of 
three biotin moieties to the two lysine residues and the N-terminus of the peptide were 
observed at a molar ratio of peptide to NHS-biotin of 1:2, no other molar ratios were 
investigated. The skimmer potential employed was again 50 V and as was stated in 
Section 4.3.1, the peptide-biotin bond was apparently stable under these conditions.
4.3.3 N-Acetylated ccB-Crystallin C-Terminal Peptide-------------------------------
A second synthetic peptide to be biotinylated and analysed by ESI-MS was the 
A-acetylated aB-crystallin C-terminal peptide (Ac-EEKPAVTAAPKK, Mr 1309.72). 
Shown in Figure 4.4 is the ESI mass spectrum of this peptide modified with NHS-biotin 
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F igure 4 .4  Electrospray mass spectrum of the biotinylated N-acetylated aB-crystallin C-termmal 
peptide, skimmer potential 70 V, peptide concentration 200 pmol/pL. Molar ratio of 
peptide to NHS-biotin was 1:2.
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peptide has three lysine residues and the N-terminus is blocked by an acetyl group. Thus 
no more than three biotin molecules could be conjugated to the peptide. The ESI data 
shows a small proportion of the doubly-charged ion [peptide+2H]2+ of the unmodified 
peptide at m/z 656.0. The major species is the doubly-charged ion 
[peptide+biotin+2H]2+ of the peptide plus the addition of 1 biotin molecule at m/z 769.1. 
In addition there are the doubly-charged ions of the species arising from the addition of 
two and three biotin molecules at m/z 882.2 [peptide+2 biotin+2H]2+ and m/z 995.0 
[peptide+3 biotin+2H]2+, respectively.
Biotinylation of the peptide does not appear to affect the protonation of the molecule since 
the same charge state was observed for the unmodified and the modified forms ie. the 
doubly-charged species. It is reasonable to assume that the biotin residue itself may 
accommodate a charge so there is no nett change in the availability of basic sites 
following biotinylation. As with the cGMP peptide, no studies were performed at 
different molar ratios as the maximum number of biotin moieties were conjugated to the 
peptide at the ratio of 1:2. The potential on the first source skimmer in this example was 
70 V and even at this voltage no loss of the biotin adduct was observed. This 
peptide-biotin conjugate was prepared primarily for MS-MS studies discussed in 
Chapter 5 and the relative abundance, in the ESI spectrum, of the three ions arising from 
the peptide plus the addition of the biotin moieties were sufficient for subsequent MS-MS 
analyses. From these results it can be concluded that the conjugation of biotin to the 
amino acid L-lysine, N-acetylated aB-crystallin C-terminal peptide and the cGMP protein 
kinase substrate peptide is a strong covalent interaction which remains intact during ESI 
analyses. Once the biotinylation reaction for the smaller peptides had been investigated 
and the modified products analysed by ESI-MS these reactions were extended to larger 
proteins, with the major impetus focussing on the selective modification of 'exposed 
residues located on the surface of the more compact protein molecules as compared to the 
synthetic peptides.
Chapter 4 Chemically-modified Peptides and Proteins 131
4.3.4 Hen Egg-White Lysozyme----------------------------------------------------------------
The first model protein to be biotinylated and analysed by ESI-MS was hen egg-white 
lysozyme (HEL). Illustrated in 4.5A-C are the ESI mass spectra of HEL following 
biotinylation with NHS-biotin in protein to biotin molar ratios of 1:2 (Figure 4.5A), 1:5 
(Figure 4.5B) and 1:8 (Figure 4.5C). In each case the most abundant ions are due to the 
9+ charge state, and the observed charge states range from 10+ to 5+. This compares 
(or contrasts) with the distribution observed for native HEL under the same solution 
conditions. It is interesting to note that only a few charge states are observed for native 
and modified forms of HEL cfi the B72.3 Fab fragment in which the observed 
charge-state profile ranges from 48+to 25+ (see Chapter 3, Section 3.3.2, Figure 3.20). 
The conformation of a protein in solution is highly dependent upon intramolecular forces 
dictated by the amino acid sequence. With a protein such as HEL, in which several of the 
basic amino acid sites are 'buried' in the globular structure, the number of accessible 
protonation sites is decreased and consequently the number of observed charge states is 
also decreased (266). In addition to this, there are fewer basic residues (19 potential 
protonation sites in HEL) than the Fab fragment which has a total of 48 possible sites 
for protonation.
Figure 4.6A-C shows the spectra corresponding to Figure 4.5A-C following 
transformation from a m/z to a mass scale. Figure 4.6A clearly shows a peak due to the 
native HEL (14 306±2 Da) and a peak due to the addition of 1 biotin (14 532±2 Da) 
which is the most abundant species under these conditions. Peaks corresponding to the 
addition of 2 biotins (14 758+2 Da), 3 biotins (14 986+1 Da), 4 biotins (15 211+3 Da) 
and 5 biotins (15 438±5 Da) are also evident in this spectrum. As the ratio of biotin to 
protein was increased the distribution of molecular species shifted to higher masses. 
With a 1:5 HEL to biotin ratio, the most abundant species is HEL plus 2 biotins 
(Figure 4.6 B) and with a 1:8 ratio, HEL plus 4 biotins is the most abundant 
(Figure 4.6C). In this case there is also a peak due to the addition of 6  biotins
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Figure 4.5 Electrospray mass spectra of biotinylated hen egg-white lysozyme (HEL), skimmer 
potential 70 V, protein concentration 20 pmol/pL. Conjugation reaction was at pH 8.5. 




(▼) HEL, (♦ )  HEL+1 Biotin, (•)  HEL+2 Biotin, (*) HEL+3 Biotin, 
(A) HEL+4 Biotin, (f) HEL+5 Biotin, ( ■ ) HEL+6 Biotin.
(15 665±3 Da) and the native protein is no longer evident. There is no indication of 
more than 6 biotin molecules being incorporated into HEL at the molar ratios employed 
here (Figure 4.6C). The molar incorporation of biotin into HEL can be estimated by 
dividing the relative intensity of each peak in the transformed mass spectrum by the total 
intensity of the peaks in the spectrum, assuming the ionisation efficiency for each species 
is comparable (267). This approach indicates that when the ratio of HEL to biotin was 
1:2, 1.3 molecules of biotin were incorporated per molecule of HEL. This increased to
1.8 and 3.7 for the ratios of 1:5 and 1:8 respectively. Note that the small peaks 50+1 Da 





































I I I I M I I I I I I I
15750 16000
Chapter 4 Chemically-modified. Peptides and Proteins 133
Figure 4 .6  Electrospray mass spectra of biotinylated HEL transformed to a mass scale, skimmer 




and thus may be due to a non-specific adduct or an impurity in the lysozyme itself rather 
than a product arising from reaction with NHS-biotin. The observed mass difference of 
approximately 50 Da does not correspond to any commonly observed metal ion or 
solvent adduct
The molar incorporation of biotin into HEL was also studied under different reaction 
conditions. In these experiments the pH, initial concentration of HEL (Figure 4.7A-B) 
and incubation time were each varied independently. The incorporation of biotin into the 
protein at pH 5 was markedly reduced from that observed at pH 7 and pH 8.5 as shown 
in Figure 4.7A. This would be as expected as biotin is known to conjugate to lysine 
e-amino groups. Thus at a higher pH the lysine side chains would be deprotonated and
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F igure 4 .7  Molar incorporation of biotin into HEL versus molar ratio NHS-biotin added, 
at varying:
(A) pH,
(B) Initial Concentration of HEL.
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therefore available for conjugation to the ligand. Altering the initial concentration of HEL 
also markedly affected the molar incorporation of biotin into the protein. Increasing the 
concentration of the protein decreased the number of biotin molecules conjugated to the 
protein even when the relative molar ratios were the same, as shown in Figure 4.7B. 
One explanation for this observation might be that as the concentration of HEL is 
increased, the number of HEL molecules occupying the same volume also increases, so 
that many of the lysine side chains are not available for reaction with NHS-biotin as they 
are shielded from exposure to the solvent by other HEL molecules. Altering the time of 
incubation (15, 30 and 60 minutes) (data not shown) had little effect on the incorporation 
of biotin into HEL. After 15 minutes, there was no substantial increase in the number of 
biotin molecules being incorporated.
One feature of note with the plots shown in Figure 4.7 is that there is a linear relationship 
between the molar ratio of biotin added and molar incorporation of biotin at varying pH 
or initial concentration of HEL. This tends to imply that the ionisation efficiencies for 
each biotinylated species is unaltered from the native unmodified form. Consistent with 
this is the observation that biotinylation of the protein does not appear to affect the 
protonation of the molecule since the same charge states were observed for the 
unmodified and the modified forms (ie. 10+ to 5+). Thus modification of the lysine side 
chains either does not appear to block accessible protonation sites on the protein, or 
causes the protein to unfold making other sites available. Alternatively, the biotin residue 
itself may accommodate a charge so there is no nett change in the availability of basic 
sites following biotinylation. The data obtained for peptides would tend to support this 
view (see Sections 4.3.2 and 4.3.3).
HEL was chosen as the initial model protein for this study as there is substantial literature 
available concerning the accessibility of the amino acid residues in this protein (268). 
Crystal structure analysis of HEL has revealed that all six lysine residues are on the 
surface of the protein and are therefore available for reaction with derivatising
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agents (268) and as seen in Figure 4.6C all six residues appear to have been conjugated
when a 8  molar excess of biotin was used. The possibility of NHS-biotin reacting with
the other amino groups on the protein (ie. N-terminus) can not be totally excluded on the
basis of this data, however, in this example there is no spectral evidence for the
incorporation of a seventh biotin molecule, but as was observed with the amino acid
L-lysine and the cGMP peptide (both with a free N-terminal amino group) it is possible
for biotin to react with this moiety. The lack of evidence of a seventh biotin moiety being
incorporated into HEL may be due either to the inaccessibility of the N-terminal residue
or that the ratio of HEL to biotin was insufficient to add a seventh biotin molecule to the
protein. Given that no such incorporation was observed at the molar ratios employed
and/or with longer incubation times, however, the latter possibility is considered less
likely. It has been reported, again from crystal structure studies of HEL, that the
40 . . .
a-amino N-terminal group is involved in a hydrogen bond to T and is partially shielded 
from the solvent (268). Thus, in light of this information it can be presumed that under 
the reaction conditions used for the conjugation experiments, it is the N-terminus of HEL 
that is unavailable for reaction with NHS-biotin rather than one of the lysine side chains. 
This could have been examined further by experiments involving tryptic digestion of the 
modified HEL with LC-MS and MS-MS of the resultant fragments but this was not 
thought to be warranted for the preliminary aspect of the work.
From the data on the biotinylation of HEL a number of conclusions can be made. It is 
clearly evident from these series of experiments that it is possible to observe successive 
increases in mass of 226 Da on a protein such as HEL and the spectra show that as the 
molar ratio of protein to biotin was increased a shift to higher masses was observed. The 
same charge states were observed whether HEL was unmodified or modified by biotin 
thereby implying that no protonation sites are blocked as a consequence of the addition of 
the biotin moiety and/or alternate sites are made accessible. No more than six biotins 
were conjugated to the protein which is consistent with crystal structure analysis of HEL 
having six exposed lysine residues and a 'buried' N-terminus, thus ESI-MS is a valuable
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tool for relating modified proteins to known crystal structure data. The incorporation of 
biotin into HEL was unaltered by incubation times greater than 15 minutes therefore 
implying that the reaction is rapid and reaches completion after a short period of time. 
The molar incorporation of biotin into HEL was markedly altered by pH and initial 
concentration of HEL, however, in all cases a linear relationship was observed between 
molar incorporation of NHS-biotin and molar ratio of NHS-biotin added. The observed 
linear relationship may imply that the ionisation efficiency of the modified protein 
remained unaltered from the native protein.
4.3,5 B72.3 F ^  Fragm ent-------- ---------------------------------— -----------------------------
The next stage in the analyses of biotinylated proteins was to modify a MAb fragment. 
The B72.3 Fab fragment was biotinylated at varying molar concentrations in an attempt to 
ascertain if it was possible to observe successive additions of the 226 Da biotin moiety on 
such a large protein. Prior to this investigation, there had been no report of 
chemically-derivatised MAb fragment by ESI-MS. It appears that two types of 
Fab fragment are produced from papain digestion of the intact B72.3 MAb (as was 
discussed in Chapter 3, Section 3.3.2), which we have proposed to be related to two 
conformational forms of the MAb (220). The Fab fragment produced from the 
'papain-resistant' and 'papain-sensitive' batches of the MAb (digested with 5% papain) 
were biotinylated with varying molar ratios with NHS-biotin to determine if there was 
any differences in these two conformers with respect to the number of biotin moieties 
incorporated into the fragment. The ESI-MS transformed spectra of biotinylated 
'papain-sensitive' Fab fragment at ratios of protein to NHS-biotin of 1:2, 1:5 and 1:8 is 
shown in Figure 4.8A-C and biotinylated 'papain-resistant' Fab fragment is shown in 
Figure 4.9A-C. Due to the large number of overlapping charge states the ESI spectra 
were deconvoluted to a mass scale using the MaxEnt™ algorithm (54, 57). These spectra 
all clearly show the successive increase in mass of only 226 Da on the 50 kDa protein 
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Figure 4.8 Electrospray mass spectra of biotinylated 'papain-sensitive' Fab fragment converted to a 
mass scale using MaxEnt™ deconvolution software, skimmer potential 75 V, protein 




increase in mass on a protein of this size. The data from ESI-MS of the biotinylated 
'papain-sensitive' and 'papain-resistant' B72.3 Fab fragments are summarised in 
Table 4.2. The masses of the 'papain-sensitive' fragment are 32 Da greater than the 
translated DNA sequence as oxidation of the heavy chain M and M is presumed to 
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F igure 4 .9  Electrospray mass spectra of biotinylated ’papain-resistant' Fab fragment con voted to a
mass scale using MaxEnt™ deconvolution software, skimmer potential 50 V, protein 




In Figure 4.8A-C, an average of 1.9 biotin molecules were incorporated into the 
'papain-sensitive' B72.3 Fab fragment when the ratio of protein to biotin was 1:2. This 
increased to 4.2 and 6.7 for the ratios of 1:5 and 1:8 respectively. It is interesting to note 
that even at a Fab to biotin ratio of 1:2, the native protein is no longer evident This 
suggests a 100% molar incorporation of biotin since there is no purification stage 
between chemical modification and analysis. In Figure 4.9A-B, an average of 
0.71 biotin molecules were incorporated into the 'papain-resistant' Fab fragment when 
the ratio of protein to biotin was 1:2. This increased to 1.6 and 3.1 for the ratios of 1:5 
and 1:8 respectively.






Fab Fragment1 46 5093 nd nd nd
+ 1 Biotin 46 7353 46 772±13 nd nd
+ 2 Biotin 46 9623 47 002±13 46 994±12 nd
+ 3 Biotin 47 1883 47 216±13 47 220±12 nd
+ 4 Biotin 47 4143 47 413±16 47 448±19 nd
+ 5 Biotin 47 6413 nd 47 666117 47 672111
+ 6 Biotin 47 8673 nd 47 890120 47 902116
+ 7 Biotin 48 0933 nd nd 48 118127
+ 8 Biotin 48 3193 nd nd , 48 348113
+ 9 Biotin 48 5463 nd nd 48 558115
+ 10 Biotin 48 7723 nd nd 48 788112
Fab Fragment2 47 264 47 28016 47 27017 nd
+ 1 Biotin 47 490 47 516113 47 50619 47 501122
+ 2 Biotin 47 717 47 739123 47 732117 47 750119
+ 3 Biotin 47 943 nd 47 962122 47 964121
+ 4 Biotin 48 169 nd nd 48 192113
+ 5 Biotin 48 396 nd nd 48 421117






Assuming oxidation of heavy chain M and M
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The percent relative abundance of the 'papain-sensitive' and 'papain-resistant' 
Fab fragments biotinylated at varying molar ratios of protein to NHS-biotin are illustrated 
in Figure 4.10, with the number of conjugated biotins incorporated into the fragments 
shown at the end of each bar. This diagram suggests an increased reactivity of the 
'sensitive' fragment (shown in black) towards the ligand as compared to the 
'resistant' fragment (shown in white). In particular it shows that as the ratio of protein 
to NHS-biotin was increased, considerably more derivatisation of the 
'sensitive' fragment occurred than was observed with the 'resistant' fragment.
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% RELATIVE ABUNDANCE*
Figure 4 .10  Relative intensities of biotinylated ’papain-resistant' (□ ) and 'papain-sensitive' (■) 
B72.3 Fab fragment modified at ratios of protein to NHS-biotin of (from left to right) 
1:2, 1:5 and 1:8. The number of conjugated biotin moieties are indicated at the end 
of each bar.
* Relative to the base peak.
It should be noted that since the ’papain-resistant' fragment is heterogeneous in nature 
due to non-specific cleavages by papain (see Chapter 3, Section 3.3.2), the calculations 
of molar incorporation of biotin does not include the additions of biotin to the minor 
components. This is because it is very difficult to determine if a particular component 
observed in the spectrum is due to, for example, Fragment 1 plus two biotin or 
Fragment 2 plus one biotin, as the masses for these two species are approximately the 
same and can not be differentiated in the spectrum. In contrast, the 'papain-sensitive' 
Fab fragment is relatively homogeneous prior to derivatisation by biotin and conjugation 
of the ligand to minor digestion products is not apparent, however, this would not
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account for the large differences apparent in Table 4.10. Thus it is likely that, to a large 
extent, the observed differences in molar incorporation of biotin arise because the 
'papain-sensitive1 Fab fragment is less tightly folded than the 'papain-resistant' subunit 
and this is reflected in the increased chemical reactivity of the 'sensitive' fragment 
towards NHS-biotin. A more 'relaxed' three-dimensional conformational structure 
would allow for greater exposure of lysine residue side chains to the solvent and 
subsequent modification by NHS-biotin. Conversely, a more rigid structure would 
hinder solvent access to some lysine residues and subsequent derivatisation, even 
allowing for the effects of additions to the minor products. It is clear from the data that 
the total number of biotin molecules conjugated to the 'papain-sensitive' Fab fragment 
(up to 10 biotin moieties) was greater than the 'papain-resistant' fragment (a maximum 
of 5 biotin moieties) which is again consistent with a more 'relaxed' protein conformation 
for the 'sensitive' fragment.
An alternative method to direct modification of MAb fragments is to alter the intact MAb 
with a ligand of choice, enzymatically digest the protein to Fab and Fc subunits, and 
analyse the proteins by ESI-MS to determine the loading values of the ligand on the 
individual fragments. This procedure has the advantage of providing information 
regarding the number of biotin moieties that have been conjugated to the Fab fragment and 
their proportions when the modified intact MAb is to be used in radioimaging or therapy. 
It is not possible to observe successive additions of biotin on an intact MAb by ESI-MS, 
and consequently only an average estimate can be determined (discussed below in 
Section 4.3.7), thus modification of the intact protein, digestion and analysis of MAb 
fragments provides a more accurate means of determining the number of ligands that have 
been conjugated to the protein. .
The B72.3 MAb was modified with NHS-biotin at a ratio of protein to biotin of 1:5, the 
MAb digested with 5% papain (w/w), the fragments separated chromatographically and 
the biotinylated Fab subunit analysed by ESI-MS. The resultant modified protein is
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shown in Figure 4 .1 1 . When the MAb is digested with papain and modified at a ratio of 
1:5, the major component is the fragment plus 1 biotin (47 506±9 Da), however, when 
the MAb is modified with biotin at the same molar ratio, then digested with papain, the 
major component is the fragment plus 2 biotins (47 738±11 Da). This would be as 
expected, as modification of the intact MAb would result in the addition of biotin 
molecules to the Fc fragment which is then removed by digestion, thereby decreasing the 
proportion of biotin molecules conjugated to the Fab regions of the MAb. The 
biotinylated Fc fragment was also characterised by ESI-MS (data not shown), however, 
due to the heterogeneous nature of this fragment the ESI spectrum obtained was complex 
and uninterpretable.
Figure 4.11 Electrospray mass spectra of biotinylated ’papain-resistant’ Fab fragment converted to a 
mass scale using MaxEnt™ deconvolution software. B72.3 MAb was modified with 
NHS-biotin at a molar ratio of protein to biotin of 1:5, prior to digestion with 
5% papain (w/w). Skimmer potential 50 V, protein concentration 20 pmol/pL.
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The B72.3 Fab fragment has a total of 28 lysine residues ( 1 1  in the light chain plus 17 in 
the Fd fragment) (190, 235) and although the precise location of these residues in the 
three-dimensional structure of the protein had not been investigated in this study, it is 
known that in general charged residues such as lysine are rarely found in the interior of 
globular protein molecules (91). The generality of this observation, which initially 
emerged from the examination of the crystal structure of sperm whale myoglobin (269), 
has been amply supported by subsequent crystallographic studies on a number of 
proteins. Lysine side chains located on the outer 'exposed' surface of the 
three-dimensional configuration of proteins appear to have considerable freedom of 
motion and are therefore amenable to chemical derivatisation, without the protein 
incurring major conformational changes as a result of the introduced modification. 
Evidence for this is provided by X-ray diffraction data (269, 270) as well as by 
NMR studies in solution (91). Although the above generalisation holds for many 
proteins, it is reasonable to assume that not all of the lysine residues in the Fab fragment 
are exposed to the solvent (and subsequent derivatisation), as the protein is composed of 
two subunits closely associated through a combination of inter- and intra-chain disulphide 
bridges and non-covalent interactions. Thus, it is feasible that some of the lysine 
residues may be shielded from modification as a direct result of these interactions.
As for the biotinylation experiments with HEL, a number of conclusions can be made 
concerning the derivatisation of the B72.3 Fab fragment. The most important observation 
from these studies is that ESI-MS can be used to observe successive additions of a small 
ligand such as biotin on a large 50 kDa protein, however, due to the large number of 
overlapping charge states in the spectrum of the modified Fab fragment it is necessary to 
deconvolute the ESI spectrum to a true mass scale using the MaxEnt™ algorithm 
(54, 57). As was observed with the biotinylated HEL, the spectra of the modified 
Fab fragment also showed that as the ratio of protein to biotin was increased, a shift to 
higher masses was evident. In addition, the same charge states were apparent whether 
the Fab fragment was unmodified or modified by biotin, again implying that there is no
F igure 4.12  Electrospray mass spectra of deglycosylated, biotinylated and reduced B72.3 converted to 
a mass scale using MaxEnt™ deconvolution software, skimmer potential 50 V, 
protein concentration 20 pmol/fiL. Ratio of protein to NHS-biotin was 1:5.
(A) Light chain,
(B) Deglycosylated heavy chain (note that the components at mass 48 171 Da 
and 49 309 Da have been magnified by a factor of 4 and 1.5, respectively).
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nett change in the number of available protonation sites as a result of the addition of the 
biotin moiety. The conjugation of biotin by the two different conformers of the 
Fab fragment was markedly different as a greater number of biotin moieties were 
conjugated to the 'relaxed', or 'papain-sensitive', fragment compared to the number 
incorporated by the tightly folded, or 'papain-resistant', fragment. Modification of the 
intact MAb, digestion by papain and analysis of the Fab fragment provided an alternative 
means for characterising the number of biotin groups attached to the Fab subunit when the 
intact MAb is derivatised, however, analysis of the Fc subunit proved to be difficult due 
to the heterogeneous nature of that fragment. These series of experiments clearly 
demonstrate the utility of ESI-MS for determining the number of biotin moieties 
incorporated into a 50 kDa Fab fragment.
4.3.6 D eglycosylated and R educed B 7 2 .3 --------------------------------------------------
Due to the heterogeneous nature of the carbohydrate portion of the B72.3 MAb it is 
difficult to observe additions of biotin on the glycosylated fragments of the MAb. To 
overcome this problem the carbohydrate component of the B72.3 MAb was enzymatically 
removed by AT-glycosidase F (Chapter 2, Section 2.5.7) and the deglycosylated MAb 
modified with biotin at a protein to NHS-biotin ratio of 1:5. The modified MAb was 
reduced with DTT to separate the light and heavy chains and the protein injected directly 
into the ESI source without prior separation of the MAb chains. It has already been 
shown by ESI-MS that it is possible to detect a small ligand (ie. biotin) on a 50 kDa 
Fab fragment (Figures 4.8 and 4.9), thus it should be possible to observe the addition of
biotin on the 50 kDa deglycosylated heavy chain.
The ESI spectra of the biotinylated light chain and the biotinylated deglycosylated heavy 
chain transformed to a mass scale by the MaxEnt™ algorithm (54, 57) are illustrated in 
Figures 4.12A and 4.12B, respectively. The mass of 23 586+4 Da is in excellent 
agreement with the mass of the reduced B72.3 light chain as determined from the 
DNA sequence (ie. 23 590 Da) (190, 235). In addition to the native light chain, there is
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a peak due to the addition of 1 biotin group at 23 811+2 Da. The mass of the 
B72.3 heavy chain (less the C-terminal K residue, plus the conversion of Asn to Asp) 
as determined from the translated DNA sequence is 48 166 Da (190, 235). As shown in 
Figure 4.12B, there is a component at a mass of 48 171+8 Da which can be attributed to 
the unmodified deglycosylated heavy chain. There are also peaks due to the addition of 
1 biotin (48 413+6 Da), 2 biotin (48 641+10 Da), 3 biotin (48 860±6 Da), 4 biotin 
(49 087±9 Da) and 5 biotin (49 309±8 Da) groups to the protein. It is interesting to note 
that the spectrum of the biotinylated deglycosylated heavy chain is 'cleaner' than any of 
the ESI spectra of the biotinylated Fab fragment. This can be attributed to the 
homogeneity of the deglycosylated heavy chain as compared to the Fab fragment which is 
heterogeneous in nature due to non-specific cleavages of the intact MAb by papain.
An average of 0.35 biotin molecules were incorporated into the B72.3 light chain, 
compared to 2.46 biotin molecules incorporated into the heavy chain. That the light chain 
has fewer additions of biotin than the heavy chain suggests that it is less accessible in the 
native conformation of the MAb to derivatisation than the heavy chain. This procedure 
provides an alternative means for assessing labelling efficiency by determining the 
distribution of the ligand between the light and heavy chains of the intact MAb which is 
more readily achievable without the interference of the heterogeneous carbohydrate 
component located on the heavy chain.
Biotinylation of the deglycosylated B72.3 MAb, reduction of the protein and analysis of 
the modified MAb chains by ESI-MS resulted in a spectrum that was complex and could 
again only be interpreted by transformation to a mass scale using the MaxEnt™ algorithm 
(54, 57). The transformed mass scale showed biotin additions to both the reduced light 
chain and the deglycosylated and reduced heavy chain, however, more biotin moieties 
were conjugated to the heavy chain than the light chain implying that the heavy chain is 
more amenable to derivatisation. Modification of deglycosylated MAbs provides an 
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Figure 4.13  Electrospray mass spectrum of intact murine B72.3 monoclonal antibody modified with 
NHS-biotin at a protein to reagent ratio of 1:8.
(A) VG Quattro™ MS
(skimmer potential 150 V, protein concentration 5 pmol/jiL),
(B) AutoS pec™ MS
(sampling cone 25 V, protein concentration 1 pmol/|4L).
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4.3.7 B72.3 Monoclonal Antibody-------------------------------------------------------------
The final protein to be modified by NHS-biotin was the intact and glycosylated B72.3 
MAb. It was presumed prior to assessing the biotinylated MAb by ESI-MS that it would 
not be possible to resolve individual additions of the ligand on the protein since the 
analysis of the native MAb does not resolve the individual glycosylated species. The 
peaks from the intact murine B72.3 MAb (Chapter 3, Section 3.2.3, Figure 3.7) are 
approximately 1100 Da (~25 m/z units) wide due to the heterogeneous glycosylation 
pattern, salt adducts and the large number of isotopic states for a molecule of this size 
(as discussed in Chapter 3, Section 3.2.2). Thus it would not be possible to resolve a 
difference of 226 Da from one biotin molecule which corresponds to ~4 m/z units for the 
50+ charge state and one hexose residue (162 Da, ~3 m/z units). By 'oversmoothing' the 
ESI spectrum an average mass can be determined, as was discussed for native and 
deglycosylated MAbs in Chapter 3 and has also been demonstrated with 
MALDI-MS (63).
Figure 4.13A illustrates the ESI mass spectrum for the intact murine B72.3 monoclonal 
antibody modified at a molar ratio of protein to NHS-biotin of 1:8 and characterised using 
a VG Quattro™ triple quadrupole mass spectrometer. The skimmer potential employed in 
the analysis of the derivatised MAb was 150 V and even at this potential no loss of the 
biotin moiety was observed (this was monitored by scanning the low m/z range in 
separate experiments). It is unlikely that, even at high skimmer potentials, a significant 
amount of internal energy is imparted to the modified MAb ions in the source skimmer 
region since the available energy during collisions in this region would be very small. 
Nonetheless, that no free biotin is observed at low m/z is consistent with the known 
strength of protein-biotin bonds.
The observed charge states in Figure 4.13A were from 56+ to 41+ and the average 
molecular mass determined for the modified MAb was 148 398±39 Da (calculated from 
the 43+ to 50+ charge states). The average molecular mass of the native intact and
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glycosylated B72.3 MAb was 146 689 Da, therefore the mass difference between the 
biotinylated and unmodified MAb was 1709 Da and this equates to the incorporation of 
approximately 8  biotin molecules into the protein. Thus, although individual additions of 
biotin can not be resolved on a protein as large as an intact MAb, it is still possible to gain 
an average estimate of the number of ligands that have been conjugated to the protein. 
Again, however, the underlying assumption is that the relative ionisation efficiency of the 
modified and intact protein is not significantly different.
The biotinylated B72.3 MAb was also analysed on a VG AutoSpec™ mass spectrometer, 
for comparison with the data obtained from the triple quadrupole. The average molecular 
mass determined on the sector instrument was 148 674+70 Da (calculated from the 
43+ to 50+ charge states), with the charge states ranging from 59+ to 34+ 
(Figure 4.13B). As was discussed in Chapter 3, Section 3.2.8 it would appear that the 
average molecular mass determined for a MAb on the sector instrument is always slightly 
higher than the mass determined for the same MAb on the quadrupole instrument and this 
was attributed to non-specific salt adduction to the lower charge state species and/or poor 
desolvation in the ESI source. Nonetheless, the mass determined for the biotinylated 
B72.3 MAb is in close agreement with that determined from the Quattro™ and again 
equates to the addition of approximately 8  biotin moieties to the MAb.
4.3.8 Biotinylation Summary---------------------------------------------------------------------
ESI-MS was successfully used to study the reaction of NHS-biotin with the amino acid 
L-lysine, a range of lysine-containing peptides and proteins, MAb fragments and the 
intact B72.3 MAb. The maximum numbers of biotin groups that were conjugated to the 
amino acid, peptide, protein or MAb fragment were clearly determined by this technique 
as successive increases in mass of 226 Da were evident in the spectra. Individual 
additions of the biotin moiety on the intact MAb could not be resolved, however, and 
only an average estimate of the number of moieties conjugated to the protein could be 
ascertained. It was also apparent from these studies, that the bond formed between the
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peptide or protein and the biotin moiety are sufficiently stable to be analysed by ESI-MS. 
A curious result is that in all the examples examined, addition of biotin to the peptide or 
protein did not alter the observed charge states ie. there is no nett change in the charge on 
the peptide or protein (which is not improbable given that it contains a number of 
potential protonation sites). This suggests either that the biotin moiety itself may 
accommodate the charge or modification of the protein causes other basic sites previously 
'buried' in the core of the protein to become available for protonation.
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4,4 IODINATION REACTIONS----------------- --------------------------------------------------
The next modification reagent that was investigated by ESI-MS was the addition of the 
naturally occurring iodine-127 isotope to peptides and proteins, a procedure referred to as 
direct labelling. Protein radioiodination is well established as a method for direct 
labelling (193) and has guided the development of MAb iodination schemes for several 
decades. Radioiodination offers significant benefits as a protein label and some of the 
advantages of this procedure include the extreme sensitivity of the technique, the 
well-known chemistry and simple labelling conditions and the high specific activities that 
can be achieved (189). The main disadvantage of the radioiodination procedure is that it 
can occasionally damage the protein resulting in loss of antigenic determinants 
ie. with MAbs, or other biological activity (159).
The available methods for direct attachment of iodine to proteins use oxidative agents to 
produce an electrophilic iodine species (I+) thereby enabling iodine to react with aromatic 
groups, with tyrosine residues the major site of iodination (194). The iodination 
procedure used in this study is shown in Scheme 4.3. Iodide (I') was converted to an I+ 
species by oxidation using the water-insoluble compound l,3,4,6-tetrachloro-3a-6a- 
diphenylglycoluril (Iodogen®). The I+ species then undergoes electrophilic addition to 
the phenolic ring of the tyrosine residues. While there are numerous procedures available 
for iodinating proteins, the Iodogen® method is a particularly useful since the proteins are 
not exposed to soluble oxidising agents and therefore are less likely to be subjected to 
oxidative damage.
In keeping with the protocol of labelling peptides and then extending these procedures to 
model proteins and finally MAbs, as was the case with the biotinylation reactions, 
ESI-MS was used to study the reaction of oxidised iodine-127 with a tyrosine-containing 
peptide, a model protein (HEL) and the B72.3 Fab fragment The aim of this part of the 
study was to optimise the reaction conditions for the addition of iodine-127 to. peptides 
and proteins and subsequently to analyse the reaction mixture by ESI-MS.
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Scheme 4.3 Iodination of a protein with naturally occurring isotope iodine-127 (127I). The
iodine-127 is converted to an 127I+ species by the oxidising agent Iodogen™. The 
,27I+ species undergoes an electrophilic addidon to the phenolic ring of tyrosine 
residues in the protein. Each addition of an iodine-127 atom increases the overall mass 
of the protein by 126 Da. For radiolabelling experiments 127I is replaced with 123I, 125I 
or n i l .
4.4.1 H um an A ngiotensin  I  (4-10) P ep tide ------------------------------------------------
The human angiotensin I (4-10) peptide (YIHPFHL, Mr 925.48) was modified with 
Nai27i at a molar ratio of peptide to N a ^ i  0f 1:2, 1:10, 1:50 and 1:100. Angiotensin 
has one Tyr (Y1) residue and thus it would be expected that only two iodine-127 atoms 
could be incorporated into the peptide. Increasing the ratio of peptide to N a127I did not 
markedly alter the proportions of modified peptide and in all reactions, the native peptide 
was the major component. The singly-, doubly- and triply-charged species for the 
unmodified peptide were evident, as were the doubly- and triply-charged species for the 
peptide modified with one iodine-127 atom; however, even when the ratio of peptide to 
Nal27l was 1:100, there was no evidence of the addition of a second iodine-127 atom to 
angiotensin. These data are summarised in Table 4.3. From these data it can be seen that 
it is possible to observe the addition of one iodine-127 atom on the tyrosine-containing 
angiotensin peptide by ESI-MS, although this reaction appears to be inefficient as the 
majority of the peptide remained unmodified and the addition of a second iodine-127 
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Figure 4.14 Electrospray mass spectra of iodinated HEL transformed to a mass scale, skimmer 
potential 70 V, protein concentration, 20 pmol/pL. Molar ratio of protein to 















a) OBSERVED MASS (Da)
1:1 1:2 1:5 1:10 1:50 1:75 1 :100
Lysozyme 14 306 14 306±1 14 307±1 14 306±2 14 308±1 14 306±3 14 307±3 14 306±2
+ Iodine 14 432 14 431±1 14 433±2 14 434±2 14 433±1 14 434±1 14 434±1 14 432±1
+ 2 Iodine 14 558 14 558±4 14 559±3 14 559±2 14 559±2 14 559±1 14 559±1 14 555±2
+ 3 Iodine 14 684 nd nd 14 687±7 14 686±2 14 684±1 14 685±1 14 683±2
+ 4 Iodine 14 810 nd nd 14 814±6 14 813±1 14 811±1 14 811±2 14 810±2
+ 5 Iodine 14 936 nd nd nd nd nd nd nd
+ 6 Iodine 15 061 nd nd nd nd nd nd nd
Table 4.4 Expected and observed masses for iodinated lysozyme at varying molar ratios of protein 
to sodium iodide (Na127I). 
nd = not detected.
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Angiotensin 925.5 464 100 310 69.15
Angiotensin + Iodine-127 1052.4 527 2.65 351 2.97
Angiotensin + 2 Iodine-127 1179.3 nd . nd -
Table 4.3  Summary of the covalent conjugation of sodium iodide-127 (Na127I) to the human 
angiotensin I (4-10) peptide to produce the angiotensin-iodine conjugate. The ratio of 
peptide to Na127I was 1:2.
Relative to the base peak, nd = not detected.
4.4.2 Hen Egg-White Lysozyme-----------------------------------------------------------------
Once the iodination reaction for the smaller peptide had been optimised, the reaction was 
extended to HEL to ascertain if the addition of iodine-127 could be observed on a larger 
protein. ESI-MS spectra were obtained following the reaction of HEL with molar ratios 
of protein to N a127I ranging from 1:1 to 1:100. Figure 4.14 shows the ESI spectrum 
transformed to a mass scale of the reaction mixture of iodine-127 with HEL at a protein to 
Na127I ratio of 1:50. These data, summarised in Table 4.4, demonstrate that even with a 
one hundred fold molar excess of N ai27I there is no evidence of more than four 
iodine-127 atoms being conjugated to HEL.
Figure 4.15A shows the molar incorporation of iodine-127 versus molar ratio of N ai27I 
added to HEL. These values are calculated from the relative intensities of iodinated HEL 
in the ESI spectra. The degree of incorporation initially increases with increasing N ai27I 
up to 1:10 and thereafter levels off to an average incorporation of 2.5 iodine-127 atoms 
per molecule of HEL. The increase appears to be logarithmic since the degree of 
incorporation versus logio molar ratio is roughly linear as shown in Figure 4.15B. 
Figure 4.15C shows the percentage yield of iodinated HEL as a function of moles N a127I 
added to the protein. As shown in Figure 4.15D, the increase again appears to be 
logarithmic since the degree of incorporation versus logio molar ratio is also linear.
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These data indicate that at a molar ratio of protein to N a127I of 1:50 or greater there is a 
96.3% to 98.1% incorporation of iodine-127 into the protein. A key feature of the 
analyses of the derivatised HEL is that purification of the reaction mixture (other than 
removal of buffer salts and excess N a127I) is not necessary between the iodination and 
ESI-MS steps.
As was the case for the biotinylated HEL, the spectra of the iodinated protein showed that 
as the ratio of HEL to Na127I was increased, a shift to higher masses was observed. The 
same charge states (ie. 10+ to 5+) were observed for both the native and modified protein 
thereby implying that no protonation sites are blocked as a consequence of the addition of 
the iodine atoms. This is not unexpected as tyrosine residues are not preferred 
protonation sites. In addition, small changes in the molar ratio of protein to conjugate 
resulted in a change in the distribution of molecular species as well as a change in 
their proportions.
HEL has three tyrosine residues and since each tyrosine has the potential to conjugate two
iodine atoms, so incorporation of up to 6  iodine atoms might be expected. However, it is
. 20
well documented that the two most reactive tyrosine (Y) residues in HEL are Y and
Y . The third residue, Y generally only reacts under extreme conditions (268). As
indicated by the data in Table 4.4, excessive iodination of HEL results in a maximum
incorporation of four iodine atoms which is consistent with an unreactive third tyrosine
residue. This would not be apparent from other methods used for assessment of iodine
. . 53
incorporation which only yield an average figure. Confirmation of an non-reactive Y 
towards iodination would require further structural analysis by additional experiments 
involving enzymatic digestion and LC-MS or MS-MS analysis of the resulting peptides, 
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MOLAR RATIO Na127! ADDED
1 10 100 
Log10 MOLAR RATIO Na127! ADDED
Figure 4.15  Molar incorporation of iodine into HEL versus molar ratio Na127I added.
(A) Linear scale ,
(B) Logarithmic scale
Percentage yield of iodinated hen egg-white lysozyme versus molar ratio Na127I added.
(C) Linear scale
(D) Logarithmic scale
Figure 4.16 Electrospray mass spectrum of murine B72.3 F ab fragment modified with iodine-127 
and transformed to a mass scale (MaxEnt™). Initial protein concentration was 
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4.4.3 B72.3 Fa\j F ragm ent--------------------------------------------------------------------------
After the iodination of a peptide and a larger model protein had been achieved, the 
reaction was extended to the 50 kDa B72.3 'papain-resistant' Fab subunit. The 
'papain-resistant' Fab fragment was modified with iodine-127 in a protein to N a127I ratio 
of (A) 1:10 and (B) 1:100 to determine firstly, if the fragment was amenable to 
iodination and secondly, to ascertain if smaller mass changes could be observed on a 
protein of this size. The peaks from the intact 'papain-resistant' Fab fragment (Chapter 3, 
Section 3.3.2, Figure 3.20A) are approximately 70 Da (~2 m/z units) wide thus a mass 
increase of 126 Da on a protein of this size equates to an increase of ~4 m/z units for the 
35+ charge state. Therefore it can be seen that it is possible to resolve the consecutive 
addition of iodine-127 atoms on a 50 kDa Fab fragment.
The mass spectra of the iodinated 'papain-resistant' Fab fragment transformed to a mass 
scale by the MaxEnt™ algorithm (54, 57) are illustrated in Figure 4.16. In the spectrum 
following reaction in a protein to N a127I ratio of 1:10 (Figure 4.16A) there are intense 
peaks due to the native Fab subunit (47 285±17 Da) and the Fab fragment plus the 
addition of 1 iodine-127 atom (47 412+9 Da). The latter is the most abundant species 
under these conditions. A peak corresponding to the addition of 2 iodine-127 atoms 
(47 536±18 Da) is also evident in this spectrum. As the ratio of N ai27I to protein was 
increased to 1:100 (Figure 4.16B), the most abundant species is again the Fab fragment 
plus 1 iodine-127 atom (47 415±11 Da). In addition, there are peaks due to the 
conjugation of 2 (47 533±7 Da) and 3 (47 662±12 Da) iodine-127 atoms. When the ratio 
of the 'papain-resistant' Fab fragment to N a127I was 1:10, 0.60 atoms of iodine-127 
were incorporated per molecule of Fab and this increased to 1.4 for the ratio of 1:100. As 
mentioned previously, the components of lower mass than the unmodified Fab fragment 
are believed to be due to non-specific cleavages of papain (220). It is highly probable 
that these components have also been modified with iodine-127, however it is difficult to 
determine exactly which fragments have been modified and by how many iodine-127 
atoms without further digestion studies.
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The B72.3 Fab fragment has a total of 21 tyrosine residues (11 located in the light chain 
plus 10 in the Fd fragment) (190,235) and although the location of these residues in the 
three-dimensional structure of the protein has not been investigated, it is known from 
iodination studies of a range of other proteins that at least some of the tyrosine residues 
in a protein are usually amenable to derivatisation (91). It has recently been shown that a 
surprisingly high proportion of tyrosine residues are on or near the surface of protein 
molecules. Iodination of native proteins has been used in an attempt to distinguish 
surface tyrosine residues from those in the interior of the molecule, however, this 
procedure is only valid in a limited number of cases (91). Exposed, or partially exposed 
tyrosine residues, in which the phenolic hydroxyl group is not hydrogen-bonded and 
points towards the solvent, does not always result in the modification of the residue and 
the inability to iodinate certain tyrosine residues is presumed to be the result of steric 
hindrance. Thus unlike modification of lysine residues, a similar generalisation can not 
be made regarding the reactivity of tyrosine residues.
The reactivity of oxidised iodine-127 towards tyrosine residues appears to be lower than 
the reactivity of NHS-biotin towards lysine residues and this may be related to the 
location of the amino acids in the three-dimensional structure of the Fab subunit, although 
as stated above exposed tyrosine residues may not be amenable to derivatisation due to 
steric hindrance by other residues. At a ratio of Fab fragment to Na127I of 1:10, 2.86% 
of the tyrosine residues were modified assuming no change in the relative ionisation 
efficiency following conjugation with iodine. This increased to 6.67% when the ratio of 
protein to Na127I was 1:100. In comparison, modification of the ’papain-resistant’ 
Fab fragment at protein to NHS-biotin ratios of 1:2, 1:5 and 1:8 resulted in 2.54%, 
5.71% and 11.07% of the lysine residues being modified based solely on the mass
spectra.
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4.4.4 lodination Sum m ary ----------— -----------------------------------------------------------
The most important conclusion that can be made from the iodination studies is that 
ESI-MS can be successfully used to observe the reaction of iodine-127 with a 
tyrosine-containing peptide, a larger model protein and a 50 kDa MAb fragment. The 
number of iodine-127 atoms that were conjugated to the peptide, protein or MAb 
fragment were clearly determined by this technique as successive increases in mass of 
126 Da were evident in the spectra. In these examples, the resolution required is greater 
than with biotin which has nearly twice the mass, however, it is well within the limits of 
what can be achieved with a quadrupole instrument. As was observed with the 
biotinylated species, it was necessary to use the MaxEnt™ algorithm (54, 57) to 
deconvolute the ESI spectrum of the modified 'papain-resistant' Fab fragment to a true 
mass scale. The spectra of the iodinated species also showed that as the ratio of protein 
to iodine was increased, a shift to higher masses was evident and the same charge states 
were apparent whether the protein was unmodified or modified. Since it is unlikely that 
modified tyrosine residues would be protonated, this indicates that, at least in the case of 
the proteins, the iodination reaction does not significantly alter the conformation of the 
protein in solution. Comparison of the relative reactivities of NHS-biotin and iodine-127 
indicated that as a percentage of the total number of residues that can be potentially 
modified, more lysine residues are derivatised by NHS-biotin than tyrosine residues are 
modified by iodine-127 and this may be a reflection of the accessibility of the appropriate 
residues by the derivatising reagent. The utility of ESI-MS for determining the number 
of iodine-127 atoms incorporated into a 50 kDa Fab fragment is thus clearly
demonstrated.
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4.5 CONJUGATION OF DIETHYLENETRIAMINEPENTAACETIC ACID
The final modification procedure to be investigated by ESI-MS was the indirect labelling 
of proteins. This can be achieved by two different methods, the first of which involves 
the attachment of a radioisotope or metal to a protein by means of a bifunctional chelator 
covalently attached to the protein (90, 271), or secondly by the addition of a metal cage 
complex via the use of a coupling agent (discussed below in Section 4.6). Bifunctional 
chelators react with functional groups on the protein to form a covalent bond between the 
protein and the chelator, and the conjugated ligand is then free to complex a metal ion or 
isotope without altering the conformation or functionality of the protein. Carboxylic acid 
anhydrides are common acylating agents for introducing such chelators into proteins and 
this is known to occur primarily at the e-amino group of lysine residues (272, 273). 
Acylation of the hydroxyl group of tyrosine, the sulphydryl group of cysteine and the 
imidazole group of histidine by carboxylic acid anhydrides has also been reported (273). 
The N-acylated product from reaction with the e-amino group of lysines is particularly 
stable, however, other acylated products are unstable and usually revert spontaneously to 
the starting amino acids.
Conjugation of the bifunctional chelator diethylenetriaminepentaacetic acid (DTPA) to 
proteins or MAbs can be achieved by one of two different acylation methods either using 
the DTPA carboxycarbonic mixed anhydride procedure (274) or the cyclic DTPA 
dianhydride (cDTPA) technique (275-277). The former conjugation reaction can be 
difficult since the DTPA carboxycarbonic mixed anhydride is thermally unstable and 
hydrolyses very rapidly. In contrast, cDTPA is sufficiently stable to enable these 
derivatives to be isolated for subsequent identification, however, a number of side 
reactions can occur when this method is employed. Since the ligand is bicyclic, two or 
more protein molecules may become linked during the reaction, resulting in higher 
molecular mass dimers and multimers of the proteins (205). When cDTPA reacts with an 
amino group of a protein, an intermediate (A) is transiently formed as shown in 
Scheme 4.4. There are three possible fates for the intermediate (A). The desired DTTA
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conjugate (B) is formed via the pathway in which the remaining anhydride moiety in 
(A) is hydrolysed to regenerate two carboxymethyl groups and give the end product (B). 
If the anhydride moiety of (A) encounters an amino group on a neighbouring protein 
molecule prior to hydrolysis, the cross-linked species (C) results. Similarly if the 
anhydride moiety of species (A) reacts with a second amino group present in the same
Schem e 4 .4  Schematic representation of products from the reaction of cDTPA with a protein, after 
Carney et al. (278).
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protein molecule, an intramolecular cross-link (D) forms (278). Once DTPA has been 
conjugated to MAbs, the immunoconjugate can be labelled with a range of metallic 
radionuclides eg. i n In or 99mTc an(j usecj for biodistribution studies or 
radioimmunodetection of tumours (279).
In this study the cDTPA method (275-277) was used to conjugate DTPA to the amino 
acid L-lysine, cGMP protein kinase substrate peptide (cGMP), horse heart myoglobin and 
the Fab fragment of the B72.3 monoclonal antibody. The modified proteins were 
characterised by ESI-MS to determine the number of DTPA molecules conjugated to the 
peptide or protein. In addition, the utility of ESI-MS for the characterisation of the 
chelation of a range of metal ions by the resultant protein-DTTA conjugate has been 
demonstrated. The interaction of metal ions with peptides and proteins have been studied 
by ESI-MS (111, 280), however, to our knowledge there have been no reports of 
metal-ligand-protein interactions which are relevant models for radioimmunoconjugates.
4.5.1 Coordination o f  M etal Ions by Hydrolysed D T P A -----------------------------
Prior to the ESI-MS analyses of the protein-DTTA conjugates, the interactions of the 
DTPA ligand itself with a range of metal ions was investigated. Previous studies have 
demonstrated the utility of ESI-MS for the characterisation of the coordination of metal 
ions by cryptand ligands (281) and for the determination of relative affinities of alkali 
metal chlorides for a cryptate and crown ether (282). The addition of cDTPA to water 
results in the hydrolysis of the two anhydride moieties to form the free carboxylic acid of 
diethylenetriaminepentaacetic acid (DTPA). Since DTPA is an octadentate ligand it can 
bind a metal ion through a maximum of five deprotonated carboxylate groups and three 
tertiary amino groups (283). Hydrolysed DTPA was used to coordinate a range of metal 
ions and the resultant ligand-metal conjugates characterised by ESI-MS to determine if the 
ligand-metal complexes are maintained during the electrospray process.
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Figure 4.17  Electrospray mass spectra of DTPA showing the coordination of In3+ ion by the DTPA 
molecule. Skimmer potential 50 V, concentration of DTPA, 1.0 mM. Final 




The ESI spectra obtained following coordination of naturally occurring indium-115 by 
DTPA are shown in Figure 4.17. The concentration of the DTPA was 1.0 mM and the 
final concentrations of InCl3 were (A) 0.4 mM, (B) 0.8 mM and (C) 1.0 mM. 
Figure 4.17A shows that the major species is the protonated ligand itself at m/z 394 
[DTPA+HJ+, with minor contributions to the protonated DTPA ligand chelating the 
In3+ ion at m/z 506 [DTPA-2H++In3+]+ and the Fe3+ ion at m/z 447 
[DTP A-2H++Fe3+]+. As the concentration of InCl3 was increased the proportion of the 
free protonated ligand [DTPA+HJ+ decreased relative to the [DTPA-2H++In3+]+ 
complex, to a point where in Figure 4.17C, the major species observed was the 
protonated [DTPA-2H++In3+]+ complex at m/z 506 and there was no evidence of the 
[DTPA-2H++Fe3+]+ species. In both Figure 4.19B and 4.19C there was a minor peak
DTPA+METAL ION m/z
[DTPA-(X-l)H++Mx+]+










Table 4 .5  Summary of the masses observed upon coordination of naturally occurring metal ions 
by diethylenetriaminepentaacetic acid (DTPA).
where X = integer value of the charge on the metal ion and,
M = metal ion.
Note that the expected m/z value for the [DTPA-(X-l)H++Mx+]+ was observed in all 
cases except for the [DTPA-H++Fe2+]+ species, in which the observed m/z value (shown 
in brackets) was one less than the expected m/z value (shown in bold).
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due to the ion pair [DTPA-2H++In3++Cl'+H+]+. Such ion pairs have been observed with 
cryptate ligands when chloride salts of the metal ions under investigation have been 
used (281).
This phenomenon was observed with a range of metal ions and the expected and 
observed m/z values for the protonated [DTPA-(X-l)H++Mx+]+ complexes (where X = 
the integer value of the charge on the metal ion and M = the metal ion) are summarised in 
Table 4.5. Note also that for the metal ions that have more than one naturally occurring 
isotope, the conjugation by DTPA of the different isotopes was also observed in the 
ESI spectra. From this table a trend emerged whereby it was presumed that the integer 
value of the charge on the metal ion was the same as the number of carboxylate groups on 
the DTPA that were deprotonated and thus available to conjugate the metal ion. For 
instance, the charge on the indium ion is 3, therefore three of the carboxylate groups of 
the DTPA ligand are deprotonated to coordinate the In3+ ion to produce the 
[DTPA-2H++In3+]+ complex.
The only exception to this apparent rule was the coordination of the Fe2+ ion in which 
case the major ion was at m/z 447 and not at m/z 448 as would be expected for 
[DTPA-H++Fe2+]+. Hence this was investigated in more detail. Firstly, since it is well 
known that the positive test for Fe3+ ions is the 'blood red' colouration that results from 
the formation of the [Fe3++SCN’] complex all solutions of Fe2+ and Fe3+ were tested 
with NaSCN to ensure that there was no Fe3+ present in the Fe2+ solutions and 
vice versa. Secondly, the DTPA/Fe2+ solution was also analysed on the 
VG AutoSpec™ mass spectrometer as shown in Figure 4.18. This confirmed that the 
predominant peak for this reaction mixture was at m/z 447, with minor contributions 
from the isotopic species at m/z 448 and m/z 449. This observation suggests therefore 
that the DTPA coordinates the Fe2+ ion in solution, but during the electrospray process 
the Fe2+ is oxidised to Fe3+. One additional DTPA carboxylate group is deprotonated to 
coordinate the oxidised metal ion, giving rise to the same m/z value as was observed for
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the [DTPA-2H++Fe3+] complex formed from the DTPA/Fe3+ solution. It has been 
shown that neutral metallocenes are ionised by an electrochemical oxidation 
(electron removal) mechanism at or near the electrospray capillary (284), thus it is 
plausible that oxidation of the Fe2+ to Fe3+ could occur in the ESI source.
Figure 4.17 Electrospray mass spectrum of DTPA showing the coordination of Fe3+ ion analysed on 
the VG AutoSpec™ magnetic sector mass spectrometer. Sampling cone 12 V, 
concentration of DTPA, 0.1 mM. Note that the expected m/z for the coordination of 
Fe2+ by DTPA was 448. The loss of a proton is attributed to oxidation of Fe2+ to Fe3+ 
in the ESI source with the concomitant deprotonation of one additional DTPA 
carboxylate group to coordinate the oxidised metal.
From the above data, it can be seen that the coordination of metal ions by DTPA can be 
readily observed by ESI-MS and it is apparent that the metal ion is retained by the ligand 
during the electrospray process. A general trend was observed with the chelation of metal 
ions by DTPA in that the number of carboxylate groups deprotonated to coordinate the 
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Figure 4 .19  Electrospray mass spectra of DTPA showing the selective competition of In3+ ion by 
the DTPA molecule. Skimmer potential 50 V, concentration of DTPA, 1.0 mM. 
Initial ions complexed by DTPA were:
(A) Cu2+
(B) Ga3+
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this was the coordination of the Fe2+ ion and it was presumed that this discrepancy was 
due to the oxidation of Fe2+ to Fe3+ in the ESI source.
4.5.2 D TPA Com petition S tu d ie s ---------------------------------------------------------------
Following on from the above experiments a series of competition studies were performed 
to determine if metal ions coordinated by DTPA could be displaced by other metal ions 
that have higher stability constants with the ligand. The stability constants (log K) of the 
DTPA ligand with a range of metal ions are shown in Table 4.5. These data show that 
the stability constant of the [DTPA-2H++In3+] complex is higher than any of the other 
[DTPA-(X-1)H++Mx+] complexes (except for thallium). Therefore a series of 
experiments were conducted to determine if formation of the [DTPA-2H++In3+] complex 
was favoured over the formation of [DTPA-H++Cu2+] and [DTPA-H++Co2+] complexes.
DTPA+METAL ION Log K
+ Fe2+ 16.55 (285)
+ Fe3+ 28.6 (285)
+ Co2+ 19.00 (285)
+ Cu2+ 21.03 (285)
+ Ga3+ 24.30 (286)
+ In3+ 29.00 (286)
+ T13+ 46.00 (287)
Table 4 .6  Stability constant data (log K) for the coordination of a range of metal ions by 
diethylenetriaminepentaacetic acid (DTPA).
Illustrated in Figure 4.19 is the ESI spectra of the hydrolysed DTPA ligand selectively 
complexing In3+ ions over (A) Cu2+ and (B) Ga3+ ions. The DTPA ligand was initially 
saturated with CuC12 .2H20  or Ga(N03)3 .H20  at concentrations of 1.0 mM and 1.4 mM, 
respectively. Prior to the addition of 1.0 mM InCl3, the [DTPA-(X-1)H++MX+] 
complexes were analysed by ESI-MS to ensure complete complexation of the metals by 
the ligand (data not shown) ie. to ascertain that there was no free DTPA present.
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Figure 4.19A shows that the Cu2+ ion has been completely displaced by the In3+ ion 
therefore implying that the DTPA ligand has selectively bound the In3+ ion. This is 
consistent with the higher stability constant for [DTPA-2H++In3+] complex (Table 4.6). 
In Figure 4 .19B, the major species is again the protonated [DTPA-2H++In3+]+ complex. 
In this exam ple, however, there is a small proportion of the protonated 
[DTPA-2H++Ga3+]+ present at m/z 460 and 462 (for the two isotopes of gallium). This 
implies that the Ga3+ is less readily displaced by In3+ from the DTPA ligand than Cu2+. 
Again this is consistent with solution stability constants for DTPA-metal ion complexes. 
The [D T PA -2H ++ G a 3+] complex has a higher stability constant than the 
[DTPA-H++Cu2+] complex, but is less stable than the [DTPA-2H++In3+] complex 
(Table 4.6).
These competition experiments add to the growing body of evidence that ESI-MS spectra 
reflect differences in relative stabilities of different metal ions coordinated by a specified 
ligand. Ultimately, studies of this type may prove useful for providing information on 
the relative stability of different complexes when log K data is unavailable.
4.5.3 L-Lysine----------------------------------------------------------------------------------------—
The next stage in the analysis of DTPA as a bifunctional chelator, was to study a range of 
peptide and protein-DTTA conjugates. The ESI-MS data obtained for the conjugation of 
DTPA with the amino acid L-lysine, at a ratio of amino acid to cDTPA of 1:1, is given in 
Table 4.7. The protonated unmodified lysine at m/z 147 [lysine+H]+ was the major 
species under the reaction conditions used. In addition, there was a peak at m/z 522, 
which is the protonated lysine-DTTA conjugate [lysine+DTTA+H]+. The peak at 
m/z 504 is most likely due to loss of water from the protonated lysine-DTTA conjugate 
ie. [lysine+DTTA-H20+H]+. This probably arises from the second anhydride moiety of 
cDTPA reacting with the N-terminal amine of L-lysine to produce an intramolecular cross 
link, resulting in the loss of water (see Scheme 4.4). L-lysine has one e-amino group 
plus a free N-terminal amino group, therefore up to two DTPA molecules could be
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conjugated to this amino acid. However, addition of a second DTPA moiety was not 
observed in the spectrum, presumably because addition of one DTPA group may 















Lysine+ DTTA - H2O 504 36.54
Lysine+ DTTA 522 21.22
Summary of the covalent conjugation of diethylenetriaminepentaacetic acid (cDTPA) to 
the amino acid L-lysine to produce the lysine-DTTA (diethylenetriaminetetraacetic acid) 
conjugate. Skimmer potential 50 V, amino acid concentration 200 pmol/pL.
* Relative to the base peak.
4.5.4 cGM P Protein Kinase Substrate P eptide------------------------------------------
The cDTPA reaction was also studied using a small peptide containing more than one 
lysine residue. The cGMP protein kinase substrate peptide (cGMP - RKRSRKE, 
M r 958.58) was reacted with cDTPA at a ratio of peptide to ligand of 1:10 and the data 
obtained for the resulting mixture is given in Table 4.8. There was no evidence of 
unmodified cGMP in the ESI-MS spectrum, implying that the reaction of the peptide with 
cDTPA was complete. cGMP has two lysine residues plus a free N-terminal amino 
group, therefore up to three DTPA groups could potentially be conjugated to the peptide. 
The doubly- and triply-charged species were present for the addition of one and two 
DTPA groups to cGMP, but there was no indication of the addition of a third DTPA 
moiety. The doubly- and triply-charged ions from species arising from the addition of 
one and two DTPA groups minus water were also present. This suggests that one of the 
DTPA moieties conjugated to a lysine residue of cGMP has covalently attached to the 
N-terminus or another of the lysine residues of the peptide, resulting in an intramolecular 
cross link, thereby preventing the addition of a third DTPA molecule. It would be
Figure 4 .20  Electrospray mass spectra of DTTA-myoglobin conjugate showing the coordination of 
Fe2+ ion by the DTTA molecule. Initial protein concentration 2 mg/mL, skimmer 
potential 50 V, protein concentration 20 pmol/pL. Ratio of myoglobin to cDTPA:
(A) 1:10
(B) 1:100 '
(? ) Myoglobin, ( • )  Myoglobin+DTTA+Fe3+.
Chapter 4 Chemically-modified Peptides and Proteins 167
extremely difficult to determine if an intramolecular cross-link had occurred by 
conventional techniques. ESI-MS thus provides an alternative technique for 
characterising peptide-conjugates of this type.




























cGMP 958.6 nd - nd -
cGMP + DTTA-H20 1315.7 659 14.45 440 100
cGMP + OTTA 1333.7 668 12.86 446 96.22
cGMP + 2 OTTA - H20 1690.8 846 5.78 565 20.50
cGMP + 2 OTTA 1708.8 855 5.84 571 30.79
Table 4.8 Summary of the covalent conjugation of diethylenetriaminepentaacetic acid (cDTPA) to 
the cGMP peptide to produce the cGMP-DTTA conjugate. Skimmer potential 50 V, 
peptide concentration 200 pmol/pL.
* Relative to the base peak, nd = not detected.
4.5.5 Horse Heart Myoglobin---------------—---------------------------------------------------
Once the cDTPA reaction for the smaller peptides had been optimised and the modified 
products analysed by ESI-MS these reactions were extended to a larger model protein, 
horse heart myoglobin. This protein has a total of 18 lysine residues and it is known 
from X-ray analysis of sperm whale myoglobin that the lysine residues are located on the 
surface of the protein (269) and therefore amenable to derivatisation.
Illustrated in Figure 4.20A-B are the ESI mass spectra of myoglobin following 
modification with DTPA in protein to cDTPA ratios of 1:10 (Figure 4.20A) and 1:100 
(Figure 4.20B). In both cases, the most abundant ions are due to the 21+ charge state, 
and the observed charge states range from 24+ to 13+. Figure 4.21 A-B shows the spectra 
corresponding to Figure 4.20A-B following transformation from a m/z to a mass scale. 
The addition of one DTPA molecule to a protein, assuming that no metal ion is chelated, 
should increase the overall mass of myoglobin by 375 Da and this would be readily
Figure 4.21  Electrospray mass spectra of DTTA-myoglobin conjugate transformed to a mass scale 
and showing the coordination of Fe2+ ion by the DTTA molecule. Initial protein 
concentration was 2 mg/mL. Skimmer potential 50 V, protein concentration 
20 pmol/|LiL. Molar ratio of myoglobin to cDTPA:
(A) 1:10
(B) 1:100
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detected in the ESI mass spectra. Figure 4.21 A clearly shows a peak due to the native 
myoglobin (16 952±1 Da), which is the major species under these conditions, and the 
peak due to the addition of 1 DTTA group appears at 17 380±1 Da rather than 17 326 Da 
as expected. This mass difference suggests an Fe cation has also been incorporated in the 
conjugate. As was discussed in Sections 4.5.1 and 4.5.2, DTP A has a high affinity for a 
number of metal ions (199), thus we have surmised that during the preparation of the 
myoglobin-DTTA conjugate, the chelator has coordinated iron in solution. This is 
presumed to occur through the three amines and two or three of the four free carboxylate 
groups of the DTTA-protein conjugate, the fifth carboxylate being unavailable for 
coordination since it is covalently linked to myoglobin. ESI spectra showing chelation of 
Fe2+ and Hg2+ by bisMSH-DTPA, a compound consisting of two a-melanocyte 
stimulating hormone (MSH) peptides linked to a single molecule of DTPA have been 
reported by Devreese and co-workers (288). As the ratio of cDTPA to protein was 
increased to 1:100, the most abundant species is still myoglobin (Figure 4.2 IB) but the 
proportion of modified protein increased slightly.
To determine if the iron coordinated by the myoglobin-DTTA complex shown in 
Figures 4.20 and 4.21 was Fe2+ or Fe3+ a series of competition studies were performed. 
Illustrated in Figure 4.22 are the ESI mass spectra of myoglobin following modification 
with DTPA in a protein to cDTPA ratio of 1:100. These spectra show the results of a 
competition experiment in which In3+ has been added the myoglobin-DTTA complex at 
final concentrations of InCl3 (A) 0.5 mM and (B) 5 mM. As was the case in 
Figure 4.20, the most abundant ions are due to the 21+ charge state, and the observed 
charge states range from 24+ to 13+. Figure 4.23A-B shows the spectra corresponding to 
Figure 4.22A-B following transformation from a m/z to a mass scale. Figure 4.23A 
shows a peak due to the native myoglobin (16 951+1 Da), which is the major species 
under these reaction conditions. In addition, there are peaks due to the myoglobin-DTTA 
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Figure 4.22  ESI mass spectra of DTTA-myoglobin conjugate transformed to a mass scale and 
showing the coordination of In3+ and Fe2+ ions by DTTA molecule. Initial protein 
concentration 2 mg/mL, skimmer potential 50 V, protein concentration 20 pmol/|iL. 
Ratio of myoglobin to cDTPA was 1:100 and final concentrations of InCl3 were:
(A) 0.5 mM (B) 5 mM
(T) Myoglobin, (•)  Myoglobin+DTTA+Fe3+, (*) Myoglobin+DTTA+In3+.
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concentration 2 mg/mL, skimmer potential 50 V, protein concentration 20 pmol/pL. 
Molar ratio of myoglobin to cDTPA was 1:100 and final concentrations of InCl3 were:
(A) 0.5 mM
(B) 5 mM
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concentration of L1CI3 was increased to 5 mM (Figure 4.23B) the most abundant species 
is again the native myoglobin, however, the proportion of the myoglobin-DTTA 
conjugate coordinating In3+ has increased and there is no evidence of the conjugate 
coordinating a Fe cation.
From these data it would appear that as the concentration of InCl3 is increased, the 
complexation of the In3+ ion is favoured over complexation of the Fe cation. The 
coordination of a range of metal ions by the myoglobin-DTTA complex was also 
investigated and these data are summarised in Table 4.9. In each case, the Fe cation 
coordinated by the myoglobin-DTTA complex was displaced by the metal ions studied. 
The implication from this is that the Fe cation initially coordinated by the protein-DTTA 
conjugate during the preparation of the complex has a lower stability constant (log K) (see 
Table 4.6) with DTPA than the other metal ions investigated. The stability constant for 
the [DTPA-2H++Fe3+] complex (ie. 28.6) (285) is higher than for the
[DTPA-H++Fe2+] complex (ie. 16.55) (285) and all the other metal ions except for 
In3+ and Tl3+ (Table 4.6). Therefore, based on the log K data, and the evidence 
presented from the ESI-MS analyses of the myoglobin-DTTA-metal ion conjugates, it can 
be presumed that it is Fe2+ that is being complexed during the preparation of the 
myoglobin-DTTA complex rather than the Fe3+ ion. If Fe3+ was initially coordinated, 
then only Tl3+ and In3+ would have displaced Fe3+ from the myoglobin-DTTA conjugate, 
but as the data in Table 4.9 indicates, all the metal ions displaced the iron from the 
conjugate. Note also that in the spectra of the myoglobin-DTTA conjugate coordinating 
the Fe cation (Figures 4.21A-B and Figure 4.23A), that the predicted mass (Table 4.9) 
takes into account the oxidation of Fe2+ to Fe3+ in the ESI source as was observed when 
the DTPA/Fe2+ solution was analysed by ESI-MS (Section 4.5.1).
As has been discussed in the preceding biotinylation and iodination sections, modification 
of proteins by derivatising agents does not appear to affect the protonation of the 
molecule since the same charge states were observed for the unmodified and the modified
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forms. This was also observed in the ESI mass spectra of the myoglobin-DTTA 
conjugates. Thus it would appear that modification of the lysine side chains either does 
not appear to block accessible protonation sites on the protein, or causes the protein to 
unfold making other sites available. Alternatively, the DTTA residue itself may 
accommodate a charge so there is no nett change in the availability of basic sites 
following modification with DTPA. The data obtained for peptides would tend to 






Myoglobin+ DTPA 17 326 Not observed
+ DTPA + Iron-56 17 379* 17 379±1
+ DTPA + Cobalt-59 17 383t 17 382±2
+ DTPA + Copper-65 17 388t 17 387±2
+ DTPA + Gallium-70 17 393* 17 393±2
+ DTPA + Indium-115 17 438* 17 438±1
+ DTPA + Thallium-204 17 527* 17 529±2
Table 4.9  Summary of the coordination of metal ions by diethylenetriaminetetraacetic acid 
(DTTA) conjugated horse heart myoglobin.
Assuming chelation of metals by:
f  three nitrogen donor groups and two carboxylate groups,
* three nitrogen donor groups and three carboxylate groups of the DTPA ligand.
To confirm that the metal ions were conjugated by the DTPA ligand attached to the protein 
and not as a result of attachment of the metal ion directly to the protein itself, native 
myoglobin was incubated with 10 mM InCl3 at room temperature for 60 minutes. The 
sample was desalted and characterised by ESI-MS. The data revealed that there was no 
conjugation of the metal ion by myoglobin, thus confirming that the addition of metal ions 
to myoglobin requires the initial conjugation of a metal chelating ligand.
The side reactions that can occur during the conjugation of DTPA to proteins, such as 
intramolecular and intermolecular cross linking (see Scheme 4.4 and Section 4.5) and the
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hydrolysis of cDTPA with water consume the major part of the anhydride. This causes a 
low conjugation yield particularly when the concentration of the protein is low (232). To 
investigate whether increasing the protein concentration increased the efficiency of 
coupling of cDTPA to myoglobin, the reactions were performed at protein to cDTPA 
ratios of 1 to 100 at concentrations of myoglobin of 2, 5, 10, 15 and 20 mg/mL. The 
present study, however, did not show any significant increase in coupling if protein 
concentration was increased. Low coupling efficiencies have been previously reported 
with MAbs (205), however, these investigators found that increasing the protein 
concentration resulted in a marked improvement in coupling efficiency but the 
immunoreactivity of the MAb was dramatically decreased.
From these experiments it can be seen that the addition of a DTPA moiety to myoglobin 
can be clearly observed in the ESI mass spectrum. In addition, it was shown that this 
technique can also be used to observe the chelation of a number of metal ions by the 
protein-DTTA conjugate, and depending on the strength of the stability constant (log K) 
of the DTPA-metal ion complex, certain metal ions can displace other ions with a lower 
log K from the protein-DTTA complex. Examination of such protein-ligand-metal 
conjugates by ESI-MS would prove to be extremely useful for the analysis of 
radioimmunoconjugates prior to use in vivo in which case it is critical that the stability of 
the protein-radioisotope conjugate is known.
4.5.6 B72.3 Fab F ra g m en t----------------------------------------------------------------------
The cDTPA reaction with the 'papain-resistant' Fab fragment of B72.3 was also 
investigated in detail. The Fab fragment has a total of 28 lysine residues ( 1 1  in the light 
chain plus 17 in the Fd fragment) (190, 235). As was discussed in Section 4.3.5, 
charged residues such as lysine are rarely found in the interior of globular protein 
molecules (91) but rather are located on the exterior of the protein and are therefore 
amenable to derivatisation. The MaxEnt™ deconvoluted mass spectrum of the 
B72.3 Fab subunit modified with cDTPA in a protein to ligand ratio of 1:10 is illustrated
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in Figure 4.24. The average molecular mass calculated from the ESI data for the major 
component ie. the unmodified 'papain-resistant' Fab fragment, was 47 284±16 Da. 
Based on the translated DNA sequence of the B72.3 MAb, the expected mass of the 
Fab fragment is 47 264 Da (Light Chain: D 1 -> C214 plus Fd Fragment: Q1 -> C221) (190, 
235). Thus the mass determined from ESI is in reasonable agreement (0.04%) with the 
theoretical mass. As noted previously, the components of lower mass than the 
unmodified Fab fragment are believed to be due to non-specific cleavages of
papain (220). In addition there is a component of mass 47 705±17 Da which is due to 
the addition of one DTTA molecule to the Fab fragment plus the chelation of Fe2+ by the
ligand (expected mass assuming oxidation of chelated Fe2+ to Fe3+ in the ESI source 
is 47 692 Da).
Figure 4.24 Electrospray mass spectrum of murine 'papain-resistant' B72.3 Fab ffagment-DTTA 
conjugate transformed to a mass scale (MaxEnt™) and showing the coordination of 
Fe2+ ion by the DTTA molecule. Initial protein concentration was 2 mg/mL. Molar 
ratio of murine B72.3 Fab fragment to cDTPA was 1 to 10. Skimmer potential 50 V,
protein concentration 10 pmol/juL.
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The data from these experiments revealed that the addition of a DTPA molecule to the 
B72.3 'papain-resistant' Fab fragment can be observed by ESI-MS, however only one 
addition was evident at a ratio of protein to cDTPA of 1:10. This implies that cDTPA is 
not as reactive towards lysine residues as is NHS-biotin, and this may be due to the 
propensity of cDTPA to hydrolyse rapidly in solution. If this is the case, the ligand is 
then unavailable for conjugation to the protein. Nevertheless, the addition of one ligand 
was observed in the ESI spectrum, as was the coordination of the Fe2+ ion by the 
resultant protein-DTTA complex.
4.5.7 DTPA Summary----------------------------------------------------------------— ----------
The coordination of metal ions by DTPA can be readily observed by ESI-MS and it is 
apparent that the metal ion is retained by the ligand during the electrospray process. 
Selective complexation of ions with higher stability constants with DTPA was also 
shown and thus ESI-MS spectra appears to reflect differences in relative stabilities of 
different metal ions coordinated by a specified ligand. Studies of this type may prove 
useful for providing information on the relative stability of different complexes when 
log K data is unavailable. It can be concluded that the addition of a DTPA moiety to a 
amino acid, peptide, protein or MAb fragment can be detected by ESI-MS as was the case 
with the addition of either biotin or iodine moieties. ESI-MS therefore provides an 
alternative technique for determining if the reaction products (C) and (D) have been 
produced by conjugation of cDTPA to a protein (see Scheme 4.4). An intramolecular 
cross link would be readily detected as the ESI spectrum would reveal a mass 18 Da 
(loss of water) less than the mass of the protein-DTTA conjugate as was observed in the 
spectra of the L-lysine-DTTA and cGMP-DTTA complexes (Tables 4.7 and 4.8). 
Similarly, an intermolecular cross link would result in dimeric species. In the present 
study, intramolecular cross linking was observed with lysine-DTTA and cGMP-DTTA 
conjugates but not with the larger protein-DTTA conjugates. Intermolecular cross linking 
was not observed with any of the peptide or proteins studied. Finally the utility of
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ESI-MS for the analysis of protein-DTTA-metal conjugates as relevant models for 
radioimmunoconjugates was demonstrated.
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4.6 CONJUGATION OF CAGE COMPLEXES VIA EDC COUPLING------
A second method of indirectly attaching a metal ion or radioisotope to a protein involves 
the use of cage complexes in which the metal is firmly held by the ligand and 
subsequently is less likely to be displaced by another metal, or transchelated in vivo by 
serum proteins such as albumin and transferrin. There is increasing interest in using 
stable macrocyclic cage complexes in nuclear medicine, because retention of the 
radioisotope or metal within the cage structure is markedly improved in vivo compared 
with other chelating ligands (199). Attachment of cage complexes to proteins usually 
requires a water soluble carbodiimide which can couple carboxyl groups to primary 
amines leading to the formation of an amide bond with concomitant loss of water during 
the coupling reaction (Scheme 4.5). In the presence of excess cross linker, 
intramolecular and intermolecular polymerisation can occur because proteins contain both 
carboxyl and amine groups, however, these reactions are minimised at acidic pH 
(272, 289).
One of the more commonly used coupling agents is l-(3-dimethylammopropyl)-3- 
ethylcarbodiimide hydrochloride (EDC), which reacts with available carboxyl groups on 
a protein at between pH 4.5 to 5 to form an active (9-acylurea intermediate. This 
intermediate is unstable in aqueous solutions, but in the presence of a primary amine it 
reacts to form an amide derivative. If the reaction with an amine does not occur then the 
activated intermediate hydrolyses to regenerate the carboxyls, accompanied by release of 
A-unsubstituted urea (Scheme 4.5). Hydrolysis of the intermediate can severely limit the 
overall yield of the protein-ligand conjugate (290).
In the present study a readily-available cage compound was used to explore the utility of 
ESI-MS for examining protein conjugates of this type. Attachment of the macrocyclic 
cage complex [Co(diAMsar)]3+ (233) to acidic protein residues (glutamic and 
aspartic acid) or the carboxyl terminus of hen egg-white lysozyme (HEL) was achieved
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via EDC coupling and the protein conjugate was analysed by ESI-MS to determine the 
number of cage complexes that were covalently attached to the protein.
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Schem e 4 .5  Modification of a protein with the macrocyclic cage complex [CtydiAMsar)^] (233) via 
l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) coupling. 
Addition of the cage complex increases the mass of the protein by 355 Da.
4.6.1 Hen Egg-White Lysozym e----------------------------------------------------------------
Shown in Figure 4.25 is the ESI mass spectrum of HEL coupled to the [Co(diAMsar)]3+ 
nucleophile via EDC in the ratio of protein to carbodiimide to ligand of 1:100:1000. This 
shows the addition of one [Co(diAM sar)]3+ moiety to HEL at 14 662±3 Da 
(theoretical mass 14 661 Da). There are also peaks corresponding to the N-acylurea
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protein adduct at 14 467 Da and to tne EDC-modified Co(diAMsar)-HEL conjugate at 
14 818 Da. Despite the use of a 1000-fold molar excess of ligand the spectrum indicates 
that the addition of only one [Co(diAMsar)]3+ moiety to HEL occurred. A similar result 
was obtained by Conrad and co-workers (234) in coupling reactions of [Co(diAMsar)]3+ 
to cytochrome c. These workers also used more detailed mass spectrometric studies to 
demonstrate that there were a number of different attachment sites for this ligand on the 
protein even though in all cases only one [Co(diAMsar)]3+ was attached to the protein. 
The spectrum of the HEL-[Co(diAMsar)] reaction mixture also shows that a number of 
A-acylurea EDC-modified glutamic or aspartic acid residues are present which, have not 
undergone further reaction to covalently bind the [Co(diAMsar)]3+ moiety. This is 
clearly undesirable from the point of view of obtaining maximum incorporation of 
[Co(diAMsar)]3+. This type of structural detail may be useful for the optimisation of the 
chemistry involved in conjugation of such ligands to the protein. ESI-MS can also 
provide an estimate of the degree of purity of the required compound. For example, if
Figure 4 .25  Electrospray mass spectrum of HEL-[Co(diAMsar)] conjugate transformed to a mass 
scale, skimmer potential 70 V, protein concentration, 20 pmol/pL.
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the desired product is the protein plus one ligand without EDC coupling groups and the 
ESI spectrum indicates that this is not the predominant component, the chemistry can be 
modified until this is shown to be the major component by ESI-MS. Alternatively, once 
it has been established by ESI-MS that the required species is present, ESI-MS can be 
used to monitor chromatographic separations to ensure maximum purity of the 
desired product.
HEL has a total of 11 carboxyl groups ie. 2 glutamic acid residues, 8 aspartic acid
residues and a a-carboxyl group. Modification of these groups by the water-soluble
35
carbodiimide-nucleophile procedure has shown that all of the residues except E and
52 7 66D are modified under normal conditions and E and D have also been shown to react
slowly (291). This might be expected as the latter residues are buried within the
three-dimensional structure of the protein. Previous studies on EDC coupling of a
nucleophilic ligand to HEL have indicated that the number of carboxyl groups modified
reached a limiting value and was strongly dependent upon the character of the
nucleophilic ligand (268). *
A major disadvantage of the EDC-coupling procedure is that the reaction is favoured at 
an acidic pH, however, amines are only deprotonated to a large extent at alkaline pH. 
Thus it is apparent that the conjugation reaction of a cage complex such as 
[Co(diAMsar)]3+ is particularly inefficient when EDC is used as a coupling reagent and 
for this reason a huge excess of the nucleophilic ligand is necessary to ensure 
conjugation of the ligand to HEL. Since the majority of the carboxyl groups of HEL are 
known to be amenable to derivatisation (/£. are not buried in the interior of the protein), 
it is possible that only one ligand can be attached to the protein because the bulkiness of 
the cage complex means the addition of more than one ligand is sterically unfavourable. 
Increasing the pH of the reaction results in deprotonation of the amine groups but this 
also leads to a higher proportion of intramolecular cross linking between carboxyl groups 
and the e-amino groups of lysine residues.
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4.6.2 Cage Complex Summary--------------------- — ---------------------------------------
It can be seen that the conjugation of a metal cage complex via EDC coupling is not a 
simple procedure as the coupling efficiency appears to be limited by pH and a large 
excess of the ligand (or nucleophile) is required to observe any conjugation of the cage to 
the protein. Nonetheless it has been demonstrated that ESI-MS can determine the 
number of cage molecules that have been conjugated to the protein and also the number 
of EDC-modified species that have not conjugated a ligand. The conjugation of 
[Co(diAM sar)]3+ via EDC coupling to other proteins eg. MAb fragments was not 
investigated further in the present study, due to the difficulties encountered with the 
conjugation of the cage complex to HEL.
4.7 CONCLUSIONS--------------------------------------------------------------------------------
The work described in this chapter demonstrates that ESI-MS is an extremely useful 
technique for analysing mixtures of modified proteins to determine firstly, if  the 
modification has occurred as observed by the expected increase in mass and secondly, to 
determine the proportions of each type of modified species present in the mixture. 
Conclusions regarding relative proportions based solely on ESI-MS, however, rely on 
the assumption that the relative ionisation efficiency of the native and modified proteins is 
similar. The results from this chapter clearly demonstrate the utility of ESI-MS to detect 
the successive additions of a small ligand on an amino acid, peptide, protein and MAb 
fragment. The resolution of the instrument did not allow the individual additions to be 
observed on the 150 kDa MAb, however, an average estimate of the number of moieties 
incorporated can be determined from the average mass of the modified MAb. 
Alternatively, modified MAbs can be digested and the resultant fragments characterised 
by ESI-MS to determine the loading of a chelator on the MAb. An important feature of 
the analysis of the modified proteins was that all the conjugated proteins examined were 
sufficiently stable to allow subsequent ESI analysis with the exception of Fed+, for which 
only peptide conjugates were observed. In addition, it is apparent that the extent of 
protonation of the derivatised proteins was unaltered by the introduced modification.
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ESI-MS can be used in conjunction with X-ray data (regarding accessibility of various 
residues) in native and modified proteins to confirm sites of modification. Finally it was 
demonstrated that the process of ESI-MS is sufficiently gentle that coordination of 
different metal ions by bifunctional ligands bound to proteins is maintained during the 




TAN D EM  M S OF CH EM ICALLY-M O D IFIED  PEPTID ES
5.1 IN TR O D U C T IO N ------------------------ -------------------------------------------------------
In the course of this study, electrospray ionisation tandem mass spectrometry (MS-MS) 
was to be utilised for the analysis of peptides obtained by enzymatic digestion of 
chemically-modified model proteins, modified MAb fragments and intact MAbs to 
identify sites of chemically-derivatised amino acid residues. It is well known that sites of 
post-translational modification can be determined by MS-MS. As was the case with intact 
proteins, however, there have been fewer MS-MS studies of chemically-modified 
peptides. Hence, this chapter outlines a series of low-energy MS-MS experiments on a 
modified amino acid and modified peptides to determine the influence of a range of 
commonly-used modifying groups on the fragmentation observed in MS-MS spectra. 
Unfortunately, due to time constraints, the examination of peptides derived from tryptic 
digests of modified proteins and MAbs was not undertaken.
5.2 B IO T IN Y L A T IO N -------------------------------------------------------------------------------
The first of the modification reagents to be investigated by MS-MS was NHS-biotin. 
This reagent has been shown to modify lysine side chains and the free N-terminus of 
peptides and proteins (see Chapter 4, Section 4.3). The adducts formed between the 
protein and the biotin moiety are sufficiently stable to be analysed by ESI, even when a 
relatively high potential on the source skimmer lens is used (ie. 150 V for the analysis of 
the biotinylated B72.3 MAb). The amino acid L-lysine and the synthetic A-acetylated 
aB-crystallin C-terminal peptide were modified with NHS-biotin and subjected to 
analysis by MS-MS. Note that the resolution in MSI was set to a minimum, thus the 
ions observed in the product-ion mass spectra are the average rather than the 
monoisotopic masses. The collision gas, argon was used in all cases and all the spectra 
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F igure 5.1 ESI product-ion mass spectra of the [M+H]+ ion of L-lysine modified with NHS-biotin.
The modified amino acid was injected directly into the ESI source and desalted on-line 
by a peptide trap cartridge (Michrom BioResources Incorporated, Auburn, CA). 
Skimmer potential 50 V, collision gas argon.
(A) L-lysine modified with one biotin moiety (Afr 372.18) (£lab 10 eV),
(B) L-lysine modified with two biotin moieties (Afr 598.26) (£ lab 15 eV).
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fragmentation (as judged qualitatively by the numbers and relative intensities of the 
product ions in each case).
5.2.1 L -L y s in e -------------------------------------------------------------------------------------------
ESI-MS spectra following reaction of L-lysine with NHS-biotin showed the addition of 
one and two biotin moieties to yield singly-charged ions at m/z 3 7 3 . 1  and 5 9 9 . 1 , 
respectively (see Chapter 4, Section 4.3.1, Figure 4.2). This is consistent with addition 
of biotin both to the lysine 8 -amino side chain group and to the free N-terminus of the 
amino acid. The ESI product-ion mass spectra of the [lysine+biotin+H]+ (m/z 373.8) 
and [lysine+2 biotin+H]+ (m/z 599.8 ) from biotinylated L-lysine are shown in 
Figure 5.1. The potential on the first source skimmer was 50 V and the laboratory 
collision energies (2%b) were 10 and 15 eV, respectively. The assignments for the major 
fragments are given in Table 5.1.
In the ESI product-ion mass spectrum of the [lysine+biotin+H]+ ion (m/z 373.8) is 
shown in Figure 5.1 A. The ion at m/z 355.7 is due to the loss of water from the 
precursor ie. [lysine+biotin-H2 0 +H]+ and the most predominant product ion (m/z 310.8) 
is presumed to be due to the lysine with biotin attached to the e-amino group of the side 
chain, with concomitant loss of NH2 and COOH. The ion at m/z 283.4 is attributed to 
the conjugation of biotin to the N-terminal of lysine, with the loss of OH and 
(CH2)4 -NH2 from the side chain. The ion at m/z 227.5 is due to the biotin ligand cleaved 
from either the N-terminus or the side chain of lysine, with cleavage presumably 
occurring in the peptide-like bond between the amine group of the lysine and the carboxyl 
group of biotin (see Table 5.1). The ion at m/z 129.4 is due to the loss of water from the 
protonated unmodified lysine ie. [lysine-H2 0 +H]+ and the minor ion at m/z 147.4 is 
attributed to the singly-charged protonated unmodified lysine residue [lysine+H]+. 
Finally, there is an abundant ion at m/z 84.4. Previous studies of MS-MS spectra of the 
amino acid lysine have suggested this ion arises from loss of NH3 via cyclisation of the




























































599.8 X - V 57.28 [lysine+2 biotin+H]+
PRECURSOR ION
582.4 X - V 8.70 [lysine+2 biotin-H20+H]+
373.8 V 55.21 V 21.87 [lysine+biotin+Hl+
PRECURSOR ION
355.7 V 6.86 V 5.21 [lysine+biotin-H20+H]+
310.8 V 100 V 100
h a s\ r T  1
h2c= c (CH2)3 n c (ch2)4->— <  X
N O 
H
283.4 V 4.54 X
h ?  s\  r r  1
0 =  C =  C— N— C — (CH2)4 ---- X X x
N O
H
244.5 X V 9.87
0  S ^ N —  NH
+H3N C (CH2)4-^— X  X -  
N O 
H
227.5 V 73.78 V 16.14
NH
+0 = C  {CH2)4-^ — ( .  X  
N O 
H
147.4 V 7.49 X - [lysine+H]+
129.4 V 43.96 V 6.32 [lysine-H20+H]+
84.4 V 82.58 V 25.60
Table 5.1 Summary of the ions observed in the ESI product-ion mass spectra of L-lysine modified 
with one (m/z 373.8) and two (m/z 599.8) biotin moieties. Assignment of ions are as 
indicated. Skimmer potential 50 V, pH 2.5. The presence or absence of fragment ions 
in the two spectra (Figure 5.1 A and B) are denoted by a (V) or (x).
* Relative to the base peak.
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A similar range of fragment ions were observed in the ESI product-ion mass spectra of 
the [lysine+2 biotin+H]+ ion at mlz 599.8 and the mlz 373.8 ion. The differences 
between the spectra were that the ion at mlz 283.4 was not observed in the spectrum of 
the peptide with two biotins (Figure 5.IB), but there was an ion at miz 244.5 not evident 
in the spectrum of the [lysine+biotin+H]+ precursor (Figure 5.1 A). The ion at mlz 244.5 
is thought to be due to the addition of biotin to the N-terminus of lysine with cleavage 
occurring between the NH group of lysine and the rest of the molecule (see Table 5.1). 
There is also a peak at mlz 582.4 due to the loss of water from the precursor ion 
ie. [lysine+2 biotin-H 20+H ]+. The laboratory collision energy (Eiab) required to 
generate optimum fragmentation for the lysine residue plus two biotin moieties was 
slightly higher than that required for lysine with the addition of only one biotin group. 
Comparison of the centre-of-mass collision energies (Ecm) (292) for the two biotinylated 
species, however, revealed that the maximum energy available for uptake from collision 
for the precursor ions were 0.97 eV and 0.94 eV for the [lysine+biotin]+ and 
[lysine+2 biotin]+ precursor ions, respectively.
5.2.2 N-Acetylated aB-Crystallin C-Terminal Peptide------------------------------
The investigation of the influence of biotin modification on MS-MS spectra was extended 
to a larger peptide containing several lysine residues. This peptide has both a blocked 
N-terminus and a C-terminal lysine residue and is therefore a good model for tryptic 
peptides derived from larger modified proteins (in which case only the N-terminal peptide 
of the protein has a free amino terminal available for reaction with NHS-biotin). Hence, 
in the spectra below any potential reaction pathways arising from reaction of NHS-biotin 
with the N-terminus are excluded. The unmodified and biotinylated N-acetylated 
aB-crystallin C-terminal peptide were subjected to MS-MS analysis to determine if a 
preference for modification of specific lysine residues could be detected. The unmodified 
N-acetylated aB-crystallin C-terminal peptide (Ac-EEKPAVTAAPKK, Mr 1309.72) was 
analysed initially so that a comparison could be made between the product-ion mass 
spectra of the native and modified forms of the peptide. The major component in the
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ESI mass spectrum of the N-acetylated aB-crystallin C-terminal peptide (data not 
shown) was the doubly-charged species at mlz 656.0. The protonated molecular ion was 
not observed and little if any source fragmentation was apparent
The product-ion mass spectrum of the [M+2H]2+ ion at mlz 657.4 obtained a laboratory 
collision energy (£iab) of 10 eV is shown in Figure 5.2. The product ions from the 
[M+2H]2+ at mlz 657.4 of the unmodified A-acetylated aB-crystallin C-terminal peptide 
and the proposed assignments are summarised in Table 5.2. The spectrum showed the 
C-terminal sequence ions Yi", Y3 ", Y4 " and Y9 " as well as several internal fragment ions 
such as PAV 0mlz 269.0), AAP {mlz 240.7), PK or KP (/mlz 226.9) and PA or AP 
{mlz 169.5). The most abundant product ion under the conditions used was the Y i” less 
H2O {mlz 129.6). As mentioned above, Lys gives an abundant ion at mlz 84, as a result
Figure 5.2 ESI product-ion mass spectrum of the [M+2H]2+ ion at mlz 657.4 from the JV-acetylated 
aB-crystallin C-terminal peptide (Ac-EEKPAVTAAPKK, MT 1309.72). The peptide 
was dissolved in water plus 1% formic acid. Skimmer potential 70 V, laboratory 
collision energy (£lab) 10 eV, collision gas argon.
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of cyclisation of its immonium ion side chain with a concomitant loss of ammonia (134). 
Glu also gives an ion at mlz 84, but this is not usually very abundant (134), therefore the 






























169.5 8.25 PA or AP
147.6 6.51 Y f
129.6 100 Yi" less H20
102.8 5.61 Ij and I2
84.6 11.09 *h2n= ^ Sŝ
70.6 14.49 I4 and Iio
Table 5.2 Summary of the product ions observed for the [M+2H]2+ precursor for the Af-acetylaled 
aB-crystallin C-terminal peptide (m/z 657.4). The proposed assignments are based on 
the nomenclature of Roepstorff and Fohlman (137).
* Relative to the base peak (m/z 129.6).
The proline amino acid residue is usually associated with very abundant Yn"-type ions. 
Thus, in a MS-MS spectrum that contains abundant C-terminal fragment ions, the 
Y n" ion that results from cleavage adjacent to Pro is often easily identified because of its 
high intensity (129). This was evident in the product-ion spectrum of the unmodified 
N-acetylated aB-crystallin C-terminal peptide as distinctive Y3" (cleavage between AP)
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and Y9" (cleavage between KP) were evident. The only other Yn"-type fragments 
observed were Yi" and Y4 " ions which were of low intensity. Peptides that contain 
proline, but not at the N- or C-termini often yield abundant internal fragment ions with 
Pro as the first amino acid. Such ions are particularly common in low-energy MS-MS 
spectra (134) and as shown in Figure 5.2 the internal fragment ions PAV (m/z 269.0), 
AAP (m/z 240.7), KP or PK (m/z 226.9) and AP or PA (m/z 169.5) are also clearly 
evident. In addition, the immonium ions of Pro and Glu are present.
5.2.3 B iotinylated N-Acetylated aB-C rystallin  C -Term inal P e p tid e -----------
The derivatised A-acetylated aB-crystallin C-terminal peptide was then analysed by 
MS-MS to determine if preferential targeting of specific lysine residues by NHS-biotin 
could be detected. The A-acetylated aB-crystallin C-terminal peptide was modified with 
NHS-biotin at a peptide to biotin molar ratio of 1:2 and the derivatised peptide 
characterised by ESI-MS to determine the number of biotin moieties that had been 
conjugated (see Chapter 4, Section 4.3.3, Figure 4.4). The ESI spectrum showed that a 
maximum of three biotin moieties were incorporated into the peptide, as there were 
doubly-charged ions due to species formed by the addition of one (m/z 769.1) two 
(m/z 882.2) and three (m/z 995.0) biotin molecules. This is expected for peptides 
containing three lysine residues noting that NHS-biotin can not react with the N-terminus 
of aB-crystallin C-terminal peptide since it is blocked by an acetyl group. There was also 
a minor contribution from the doubly-charged ion for the unmodified peptide (m/z 656.0) 
in the ESI spectrum. The doubly-charged ions of all the biotinylated species were 
individually subjected to MS-MS analysis and the results are summarised in Tables 5.3,
5.4 and 5.5.
Illustrated in Figure 5.3 is the ESI product-ion mass spectrum of the [M+2H]2+ ion at 
m/z 769.6 from the peptide with one attached biotin obtained at an £jab ° f 25 eV. The 
product ions from the [M+2H]2+ precursor ion and the proposed assignments are 
summarised in Table 5.3. The modified lysine residue is as indicated. This spectrum
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showed the sequence ions Y2", Y3", Y4", Y5", Y6", Y7", Yg" and Y9" for the peptide if  
11 12
K  or K  is modified by biotin. The B i ion is also evident at m/z 172.6 which would 
have this mass regardless of which Lys residue was modified. The peak at m/z 372.9
can be attributed to either the Y i"  fragment if  K  is modified or to the Y3" fragment if
3 . .
K  is modified. In addition, there are the Y9" and [Y n "+ H ]2+ fragment ions due to
. . 3 . 3 11
biotinylated K  and Y i"  ion less H2O if  K  or K  is modified. It is interesting to note
11 12
that the addition of biotin to either K or K  results in an almost complete series of
. 3
Y n"-type ions. Modification of K  , however, only produced the Y3" and Y9" ions which 
result from cleavage adjacent to Pro (and has been noted above) are often particularly 
intense ( 129).
aB-crystallin C-terminal peptide modified with one biotin moiety (Mr 1535.80). The 
peptide was injected directly into the ESI source and desalted on-line by a peptide trap 
cartridge (Michrom BioResources Incorporated, Auburn, CA). Skimmer potential 70 V, 
laboratory collision energy (E^b) 25 eV, collision gas argon.
Chapter 5 MS-MS of Modified Peptides 189
The internal fragment ions EK-biotin {m/z 483.8), PA VTA or VTAPP (m/z 440.9) and
KPAV (m/z 397.3) if K3 was modified and EK (m/z 258.6), PAV (m/z 269.0), AAP
11 120m/z 240.7) and AP or PA (m/z 169.5) if K or K was biotinylated were all evident in
the product-ion spectrum. The cyclised Lys immonium ion (m/z 84.4) and the immonium
ions of Pro and Glu were also present. In addition to these peptide ions there are
cleavages present that are specifically due to the incorporated biotin moiety. The fragment
ion at m/z 226.7 is due to the cleavage of the bond between the ligand and the amino side
chain of lysine and the ion at m/z 310.7 is due to cleavage of the bonds as shown in
Scheme 5.1. Formation of these ions is independent of the lysine residue to be modified
and thus these ions could potentially be used to screen for biotinylated lysine residues in
tryptic peptides from larger proteins. Such an approach could involve
LC-MS-MS experiments designed to detect only the precursors of these fragment ions
(128). Thus this spectrum shows that NHS-biotin reacts with any one of the three lysine
3 11 12residues in the peptide (K , K or K ), as three different MS-MS fragmentation 
patterns were observed for all three possible modification sites implying that for the 
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Schem e 5.1 Schematic representation of the proposed cleavage sites to produce the ion at m/z 310.7 
observed in the ESI product-ion mass spectrum of the N-acetylated aB-crystallin 

























1110.4 21.93 V K11 or K12
1014.2 11.77 Yg" K11 orK 12
940.2 4.24 y7" K11 or K12
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741.4 4.72 y5" K11 or K12
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669.4 5.36 Y4" K11 or K12
599.1 26.79 Y3" K11 or K12
501.8 8.37 y2" Kn or K12
483.8 5.52 EK-biotin K3
440.9 5.36 PA VTA or VTAAP K11 or K12
397.3 7.63 KPAV K11 or K12
372.9 15.26 Y3" orY", K3 orK12
310.7 42.66
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268.7 11.13 PAV -
258.6 9.18 EK K11 orK12






172.6 19.40 Bi -
169.5 14.83 PA or AP -
129.5 100 Y," less H20 K3 orK 11




70.6 9.16 I4 and I10
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Figure 5.4 shows the product-ion spectrum of the [M+2H]2+ ion at m !z 882.3 from the 
peptide with two attached biotins obtained at an E]^ of 20 eV and the product ions from 
the [M+2H]2+ precursor ion and the proposed assignments are summarised in Table 5.4. 
The modified lysine residues are as indicated. In this case, NHS-biotin can react with 
any two of the three lysine residues in the peptide (K3, K11 or K12), thus it is again 
plausible that three different MS-MS fragmentation patterns can exist depending on which 
lysine residues have been modified.
The product-ion spectrum in Figure 5.4 shows the sequence ions Yi", [Yn"+H]2+, Y3", 
Y4" and Y9" as well as B7, B9 and B n  for the peptide if K11 and K12 are modified by 
biotin. The ions Yi" less H2O, Y2" less H2O and the sequence ions [YV'+H]2*, Y3", 
Y4\  Y5", Y6m, Y7" less NH3, Y7" and Y9" and B3 less H20  and B3 for the peptide if K3 
and K11 are modified by biotin were all evident The sequence ions Y i”, Y2” less H20 , 
[Y9”+H]2+, Y3", Y4”, Ys", Y6", Y7" less NH3) Y7” and Y9” and [B7+H]2+, B3 less
3 12H2O and B3 for the peptide if K and K are modified by biotin. The addition of biotin 
3 11 3 12to both K and K or K and K results in an almost complete series of Yn"-type ions.
11 12
Modification of K and K , however, only produced Yi", Y3", Y4" and Y9H 10ns.
3 11 3 12 .
This implies that modification of K and K or K and K is favoured over 
modification of K11 and K12. This is feasible as biotinylation of K11 would be sterically 
hindered if K 12 is already modified and vice versa.
Table 5.3 Summary of the product ions (shown opposite) observed for the [M+2H]2+ ion at 
miz 769.6 from the 7V-acetylated ctB-crystallin C-terminal peptide modified with one 
biotin moiety. The principal fragment ions and the proposed assignments based on the 
nomenclature of Roepstorff and Fohlman (137) are given. The modified lysine residues 
are as indicated.
* Relative to the base peak (mlz 129.5).
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The internal fragment ions APK-biotin (m/z 523.5), AAP (m/z 240.7) and AP or PA 
3 11 11 12(im/z 169.5) if K and K or K and K are modified, the cyclised Lys immonium ion 
(m/z 84.3), the Pro and Lys-biotin immonium ions are present. The fragment ions at 
m/z 310.8 and m/z 221A indicative of the biotin moiety are also evident. Unlike the 
unmodified peptide and the peptide plus one biotin, in which the Yi " ion less H2 O is the 
predominant ion, in the spectrum of the peptide plus two biotins the m/z 310.8 is the 
predominant ion.
Figure 5.4 ESI product-ion mass spectrum of the [M+2H]2+ ion at m/z 882.3 for the A-acetylated 
ocB-crystallin C-terminal peptide modified with two biotin moieties (Mr 1761.88). The
peptide was injected directly into the ESI source and desalted on-line by a peptide trap 
cartridge (Michrom BioResources Incorporated, Auburn, CA). Skimmer potential 70 V, 
laboratory collision energy (£jab) 20 eV, collision gas argon.
























485.0 31.79 Y2" less H20 K3 and K11
K3 and K12
373.9 24.85 Y"i K3 and K12
K11 and K12
327.8 5.10 I3 and In -
310.8 100
H O S ^ N — NH "] + 
^ 0 = 0 — —N—ii—(CH2)4  ̂••
H
240.9 4.28 AAP -
221A 8.16 S ^ N — NH
♦ Q=C_(CH2)4-^----( ^ ^ S o
H
169.5 3.25 PA or AP -
129.3 19.04 Y f less H20 K3 and K11
84.3 10.24
70.6 3.36 I4 and Iio -
Table 5 .4  Summary of the product ions observed for the [M+2H]2+ ion at mlz 882.3 for the 
ALacetylated ocB-crystallin C-terminal peptide modified with two biotin moieties and the 
proposed assignments based on the nomenclature of Roepstoiff and Fohlman (137).
* Relative to the base peak (mlz 3.10.8).
Shown in Figure 5.5 is the product-ion spectrum of the [M+2H]2+ ion at m/z 995.5 from 
the /V-acetylated aB-crystallin C-terminal peptide with three attached biotins obtained at
an £iab of 15 eV. The product ions from the [M+2H]2+ precursor ion and the proposed 
assignments are summarised in Table 5.5. Unlike the two instances outlined above, there 
is only one possible MS-MS fragmentation pattern for the conjugation of three biotin 
molecules into the peptide. The product-ion spectrum in Figure 5.5 shows the sequence 
ions Y iM, Y2 ", Y3", Y4 ", Y5 ", Y6m, Y7 " and Y9 " as well as B3 less H2O, [B7+H]2+, B3 ,
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Be and B9 . Fragmentation below mlz 310.9 was not observed implying that the 
incorporation of biotin stabilised the protein and prevented the formation of smaller 
fragmentation products such as the immonium ion series observed for MS-MS studies of 
the plus one and plus two biotin molecules. The fragment ion due to the loss of the biotin 
moiety (mlz 221.4) was also not observed, however the ion due to lysine plus biotin was 
present {mlz 310.9). There were also fragment ions that were attributed to internal 
fragment ions of EK plus biotin {mlz 484.9) and PK plus biotin {mlz 452.5). The most
abundant fragment ion in the spectrum is due to the Y3 M ion which is generated by
9 10
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Figure 5.5  ESI product-ion mass spectrum of the [M+2H]2+ ion at mlz 995.5 from the N-acetylated 
aB-crystallin C-terminal peptide modified with three biotin moieties (Mr 1987.96). 
The peptide was injected directly into the ESI source and desalted on-line by a peptide 
trap cartridge (Michrom BioResources Incorporated, Auburn, CA). Skimmer potential 
70 V, laboratory collision energy (£i*b) 15 eV, collision gas argon.





































373.8 21.90 Y f
310.9 47.72 H 0  S ^ N — NH 1  +
H2C = C — (C H2)3—N—li—(C H2)4-^----C N̂ o
H
Table 5.5  Summary of the product ions observed for the [M+2H]2+ ion at m/z 995.5 from the 
N-acetylated aB-crystallin C-terminal peptide modified with three biotin moieties and 
the proposed assignments based on the nomenclature of Roepstorff and Fohlman (137).
* Relative to the base peak (m/z 825.1).
A number of conclusions can be made from the results of the product-ion experiments of 
biotinylated L-lysine and the /V-acetylated aB-crystallin C-terminal peptide. As expected, 
the biotinylation of the aB-crystallin peptide occurs specifically at lysine residues, as no 
evidence was found of any fragment ions of masses corresponding to biotinylation of 
other residues in the peptide. However, it was observed that there was a minor reaction 
of NHS-biotin with the free N-terminus of the amino acid lysine. Furthermore, there
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were fragment ions evident in the product-ion spectra of the biotinylated peptide species
that were not present in the unmodified peptide and could only be attributed to the
conjugation of biotin. The order of reactivity of the lysine residues towards biotinylation
could not be determined from the results obtained from these experiments, however, it
11 12
would appear that biotinylation of K is sterically hindered if K is modified and vice 
versa. It was interesting to note that the N-acetylated aB-crystallin C-terminal peptide
appeared to be stabilised by the conjugation of one biotin moiety as the laboratory 
collision energy required to generate the most extensive fragmentation of the modified 
peptide was greater than the /%b required to fragment the native peptide (25 eV compared 
to 10 eV). Successive additions of biotin, however, seemed to destabilise the modified 
peptide as the Eiab required for optimum fragmentation of the derivatised peptide 
decreased with increasing number of attached biotin moieties. This is despite the fact that 
the Ecm would also be lower for the higher mass species. It has been shown that a lower 
Elab is required to fragment modified oligonucleotides compared to native DNA (293).
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5.3 1 ODIN A T IO N --------------------------------------------------------------------------------------
The second modification procedure to be investigated by MS-MS was the iodination of 
tyrosine residues. The synthetic human angiotensin I (4-10) peptide was modified with 
iodine-127, in the presence of an oxidising agent, and subjected to MS-MS analysis in an 
attempt to confirm that oxidised iodine (I+) specifically targets tyrosine residues of 
peptides and proteins and to examine the influence of iodination on the observed 
fragmentation.
5.3.1 Human Angiotensin I  (4-10) Peptide------------------------------------------------
The major component in the ESI mass spectrum of the human angiotensin I (4-10) peptide 
(YIHPFHL, Mx 925.48) (data not shown) was the doubly-charged ion 
(m/z 464.0). The triply-charged ion was present as a minor species (m/z 309.6). The 
protonated molecular ion was not observed and little if any source fragmentation was 
apparent. The product-ion mass spectrum of the [M+2H]2+ ion at m/z 464.3 from the 
peptide at a laboratory collision energy (Zqab) of 10 eV is shown in Figure 5.6. The 
product ions from the [M+2H]2+ precursor ion and the proposed assignments are 
summarised in Table 5.6. The spectrum showed the sequence ions Ai (or Ii) and A2 as 
well as Yi", Y2 ", Y4 ", Y5 " less H2O, Y5 ", Yg" and B3 , B6 fragment ions. There is also 
a fragment ion at m/z 326.0 which is attributed to the doubly-charged Y5 " ion 
ie. [Y5 "+H]2+. Several internal fragment ions such as PFH or HPF (m/z 382.7), FH 
(m/z 285.7) and HP (m/z 235.7) are evident.
The presence of Tyr in a peptide sequence can be deduced from the relatively abundant 
immonium ion at m/z 136. In low-energy MS-MS spectra, it is difficult to distinguish lie 
from Leu as the immonium ions produced by both amino acids occur at m/z 8 6 . An 
abundant immonium ion at m/z 110 is usually observed in low- and high-energy MS-MS 
spectra of His-containing peptides (294, 295). Since no other amino acids yield 
fragments of this mass, the presence of such an ion is a good indication that the peptide 






















796.1 2.75 b 6
764.0 1.41 y 6"
650.0 7.09 Y5"




414.4 18.57 b 3








110.1 100 I3 and I6
86.2 33.86 I2 and I7
70.1 6.90 U
Table 5.6  Summary of the product-ion fragment ions observed for the human angiotensin I (4-10) 
peptide and the proposed assignments based on the nomenclature of Roepstorff and 
Fohlman (137).
Relative to the base peak (m/z 110.1).
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with the most abundant product ion under the conditions used being the His 
immonium ion.
Figure 5.6  ESI product-ion mass spectrum of the [M+2H]2+ ion at m/z 464.3 from the human 
angiotensin I (4-10) peptide (YIHPFHL, Mr 925.48). The peptide was dissolved in
water plus 1% formic acid. Skimmer potential 50 V, laboratory collision energy 
(Slab) 10 eV.
5.3.2 lod ina ted  H um an Angiotensin I  (4-10) Peptide--------------------------------
The human angiotensin I (4-10) peptide was modified with iodine-127 and characterised 
by ESI-MS to determine the number of moieties conjugated to the peptide (see Chapter 4, 
Section 4.4.1). The peptide has one tyrosine residue, thus a maximum of two iodine-127 
atoms can potentially be incorporated, however, it was demonstrated by ESI-MS that only 
one iodine-127 atom was conjugated to the peptide under the reaction conditions 
employed. The product-ion mass spectrum of the doubly-charged ion (m/z 527.6) for the 
peptide modified with one iodine-127 atom at a laboratory collision energy (£iab) of 
15 eV is shown in Figure 5.7. The product ions from the [M+2H]2+ precursor ion and 


































110.1 100 I3 and Ig
86.2 51.94 I2 and I7
70.3 8.03 I4
Table 5 .7  Summary of the product ions observed for the [M+2H]2+ ion of the human angiotensin I 
(4-10) peptide modified with one iodine-127 atom and the proposed assignments based 
on the nomenclature of Roepstorff and Fohlman (137).
* Relative to the base peak (m/z 110.4).
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The product-ion mass spectrum again shows the sequence ions Ai and A2 that were 
observed in the unmodified peptide, except in this case these fragment ions indicate that 
one iodine-127 atom has been conjugated to the tyrosine (Y1) residue. The Y2 ", Y3 ", Y4 " 
and B 3 product ions are present and there is again a product ion at m/z 326.0 which is 
attributed to [Y5 "+H]2+. Several internal fragment ions such as PFH or HPF 
(m/z 382.5), FH (m/z 285.4) and HP (m/z 236.0) are also evident. The most abundant 
fragment ion observed under the conditions used is again the His immonium ion. The 
Pro and Leu/Ile immonium ions are evident but the Tyr immonium ion is absent, further 
evidence that the Tyr residue (Y1) has been modified. Unlike the biotinylated species in 
which fragmentation arising from the loss of the biotin moiety (m/z 227) was observed, 
loss of the iodine atom was not apparent. Thus in this example, no product ion was 
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Figure 5.7  ESI product-ion mass spectrum of the [M+2H]2+ ion at m/z 527.6 from the 
angiotensin I (4-10) peptide modified with one iodine-127 atom (Mr 1051.38). The
peptide was injected directly into the ESI source and desalted on-line by a peptide trap 
cartridge (Michrom BioResources Incorporated, Auburn, CA). Skimmer potential 50 V, 
laboratory collision energy (E\ab) 15 eV, collision gas argon.
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It can be concluded from the MS-MS experiments that the iodination of human 
angiotensin I (4-10) peptide occurs specifically at the tyrosine residue (Y1), as no 
evidence was found of any fragment ions of masses corresponding to iodination of other 
residues in the peptide. As with the biotinylated A-acetylated aB-crystallin C-terminal 
peptide, product ions were evident in the MS-MS spectrum of the iodinated angiotensin 
that were not present in the MS-MS spectrum of the unmodified peptide and could only be 
attributed to the conjugation of iodine eg. Ai (m/z 262.4) and A2 (m/z 375.7) fragment 
ions. Similarly, as was observed with the MS-MS analyses of the modified TV-acetylated 
aB-crystallin C-terminal peptide, the conjugation of a moiety which in this case is 
iodine-127 appeared to stabilise the human angiotensin I (4-10) peptide and this was 
reflected in the higher E\ab required to induce fragmentation.
5.4 CONCLUSIONS----------------------------------------------------------------------------------
The results from this chapter clearly demonstrate that MS-MS can be used to locate and 
confirm site(s) of derivatisation in peptides, by the chemical modifying agents of concern 
in this thesis. The order of reactivity of the lysine residues in the A’-acetylated 
aB-crystallin C-terminal peptide towards biotinylation could not be determined from the 
results obtained from these experiments, however, it was concluded that the addition of 
two biotin moieties to the peptide, K is less likely to be modified if K is already 
biotinylated (or vice versa) and this has been attributed to steric hindrance of the second 
lysine residue by attachment of the first biotin group. The MS-MS experiments also 
indicated that derivatisation of an amino acid or a peptide appeared to stabilise the peptide 
and this was reflected in the higher laboratory collision energy required to induce 
fragmentation of the modified species compared to the native peptides. The only 
exception to this was that as the number of biotin moieties conjugated to the /V-acetylated 
aB-crystallin C-terminal peptide increased, the laboratory collision energy required to 
induce fragmentation decreased implying that successive additions of biotin destabilised 
the modified peptide. It was interesting to note, also, that the MS-MS spectrum of the 
peptide plus three biotin moieties did not produce fragments below m/z 300. Product
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ions at m/z 310.7 and m/z 226.7 can potentially be used to screen for biotinylated lysine 
residues in tryptic peptides from larger proteins as these ions are evident in the 
product-ion mass spectra regardless of which lysine residue was modified. No ion 
specifically indicative of iodination of tyrosine residues was evident in the product-ion 
mass spectrum of the modified angiotensin. It is clear from these MS-MS experiments 
that the combination of tandem MS with ESI-MS can provide important structural 
information on modified peptides which otherwise can not often be determined simply 
and efficiently by classical methods. Therefore, the experiments outlined in this chapter 
clearly demonstrate the utility of MS-MS for the structural characterisation of 
chemically-derivatised peptides including location of the specific site(s) of induced 
modification and could in principle be readily extended to the characterisation of peptides 
produced from tryptic digests of modified MAbs and MAb fragments.
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CHAPTER 6
CONCLUSIONS AND GENERAL DISCUSSION
This work has clearly demonstrated the utility of electrospray ionisation mass 
spectrometry (ESI-MS) for the analysis of a range of monoclonal antibodies (MAbs), 
MAb fragments and modified MAb fragments. As a prelude to the analyses of modified 
MAbs, a range of model peptides and proteins were characterised and the information 
gleaned from these data was then extended to the larger MAbs. Analysis of intact MAbs 
and MAb fragments by ESI-MS on the VG Quattro™ triple quadrupole mass 
spectrometer required the optimisation of a range of experimental and instrument 
parameters. Using the B72.3 MAb as a model, the optimum potential on the first source 
skimmer was 150 V and the optimum concentration of the MAb was determined to be 
5 pmol/jiL. In contrast to many smaller proteins, the m/z range for intact MAbs ranged 
from -2000-4000. In addition to optimisation of these parameters, it was imperative that 
the m/z range be carefully calibrated (in this study ammoniated polypropylene glycol 3000 
was chosen as an appropriate calibrant) because small changes in m/z values translate into 
large differences in mass for proteins of this size.
The data processing and software used for the analysis of the ESI data of these proteins 
was particularly important for determining masses accurately. The individual 
glycosylated species could not be resolved, when analysing the intact MAb, on the 
instrumentation used here. Nonetheless by 'oversmoothing the baseline-subtracted ESI 
data an average molecular mass could be determined for the intact MAb. A notable 
characteristic in the ESI spectrum of the MAb was the asymmetry of the peaks at lower 
charge states. This was attributed to isotopic broadening of the peaks, heterogeneity due 
to glycosylation, non-specific salt adduction, which prevents the protonation of certain 
basic sites on the MAb, and poor desolvation of low charge state species (at higher m/z).
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This problem was largely overcome by centroiding the baseline-subtracted and smoothed 
data at 80% of the peak height.
Furthermore, in the calculation of the average molecular mass of the B72.3 MAb only the 
most intense charge states were used. This resulted in an average molecular mass that 
was in close agreement with the mass of the protein calculated from the translated DNA 
sequence and the proposed carbohydrate structure for murine IgG MAbs. Application of 
the experimental, instrumental and software processing to other MAbs, including the 
deglycosylated B72.3, resulted in the successful mass determination for each of the 
individual MAbs. In addition, the components in a mixture of two MAbs and a mixture 
of a MAb and HSA were successfully resolved.
Analysis of the deglycosylated B72.3 revealed that the charge state distribution profile for 
this protein was lower (ie. higher charge states were observed) than that seen with the 
intact and glycosylated MAb. It would appear that removal of the carbohydrate portion of 
the MAb leads to the protonation of otherwise inaccessible-basic protonation sites. In 
addition, removal of the carbohydrate moiety resulted in the peak width-at-half-peak 
height approximately half that observed for the glycosylated protein (ie. 11  m/z units
cf. 25 m/z units).
A selection of the intact MAbs were analysed on the VG AutoSpec™ magnetic sector 
mass spectrometer and the data from these experiments revealed that a higher sampling 
cone (which is the equivalent of the skimmer potential) was required to observe these 
proteins compared to smaller proteins. The optimum protein concentrations were similar 
to those found to be optimum on the triple quadrupole instrument. In addition, the 
spectra of the MAbs on the AutoSpec™ revealed that the charge state profile for these 
proteins extended to m/z 4500, albeit with low intensity, which is beyond the m/z range 
of the triple quadrupole. Calculated average molecular masses of the MAbs from the 
magnetic sector data were slightly higher than those calculated on the triple quadrupole
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instrument, and this was attributed to the non-specific salt adduction to peaks at higher 
m/z and/or poor desolvation of these species. In light of this, only the higher charge 
states (at lower m/z) were used to calculate the average molecular masses of the MAbs on 
this instrument. When this was the case, the masses determined for the same MAb on the 
two instruments were in reasonable agreement with each other.
Further studies on the B72.3 MAb required the protein to be either reduced into the 
constituent chains or digested enzymatically. Reduction of the B72.3 MAb and 
characterisation by ESI-MS confirmed the calculated mass determined from the translated
DNA sequence for the light chain. The mass of the glycosylated heavy chain was also
. . 438consistent with the translated DNA sequence, less the C-terminal K residue, plus a
carbohydrate structure based on other information concerning glycosylation of this MAb.
Deglycosylation and reduction of the B72.3 MAb confirmed the loss of the C-terminal
438K residue from the heavy chain. Removal of the carbohydrate portion from the heavy 
chain enabled molecular masses to be determined accurately for the deglycosylated 
portion of the MAb. -
Characterisation of MAb fragments indicated that the optimum experimental and 
instrument parameters for analysing these proteins by ESI were significantly different to 
those for intact MAbs. The optimum protein concentration for the 50 kDa B72.3 Fab 
fragment was 10-20 pmol/juL and the potential on the first source skimmer was 50 V 
(cf. 150 V for the intact MAb). The charge state distribution profile for this fragment 
ranged from m/z 1000-1900, which is approximately half the distribution range for the 
intact MAb. The analyses of the Fab fragment indicated that digestion of MAbs by papain 
is not a straightforward procedure as there are a number of potential cleavage sites for 
this enzyme in these proteins. In addition, there were two different conformers of the 
B72.3 MAb and this was reflected in the sensitivity towards digestion of the MAb by 
papain and susceptibility to oxidation. The 'papain-resistant' MAb appeared to be 
unaffected by differing concentrations of papain and the same cleavage sites were evident
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as determined from the mass of the resultant Fab fragments. The 'papain-sensitive' 
MAb, however, was overdigested by higher concentrations of papain. This was 
confirmed by Edman sequencing which revealed that there was a loss of QVQ from the 
N-terminus of the F<j region of the 'papain-sensitive' Fab fragment. This apparent 
overdigestion problem was alleviated by decreasing the percentage of papain used to 
digest the 'sensitive' MAb and this led to a similar profile by ESI-MS as was observed 
for the 'papain-resistant' Fab fragment. This confirmed that the differences were in fact 
due to the digestion rather than differences in, for example, the sequence of the 
MAb itself.
Reduction of the 'papain-sensitive' Fab fragment (digested with 0.5% papain) revealed
221the loss of C-terminal C from the Fd fragment. Reduction of the 'papain-sensitive'
overdigested Fab fragment (digested with 5% papain) indicated that in addition to the loss
81 136of the QVQ from the Fd fragment, oxidation of M and M was evident and this was 
presumed to occur in the ESI source. The conclusion from this part of the study was that 
the 'papain-sensitive' MAb had a more relaxed conformation and the 'papain-resistant' 
MAb was more tightly folded and this was reflected in their different sensitivity towards 
digestion with papain and susceptibility to oxidation.
Optimisation of the 100 kDa F(ab'h fragment required a protein concentration of
10 pmol/pE and the skimmer potential was optimised at 100 V ie. the conditions were
intermediate between the intact MAb and the 50 kDa Fab fragment. The m/z range for
this protein was from m/z 1800-2800, which is also higher than for the Fab fragment but
lower than for the intact MAb. Digestion of the 'papain-sensitive' MAb with 5% papain
221 .
(in the absence of cysteine) revealed that cleavage occurred at C of both heavy chains. 
No overdigestion was apparent and although the 'papain-sensitive' MAb was digested, 
the MAb did not appear to be partially unfolded by cysteine. Reduction of the F(ab' )2  
fragment revealed the loss of C during the reduction procedure (same as for the 
reduced 'papain-sensitive' Fab digested with 0.5% papain).
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The fined fragment to be characterised in this study was the Fc fragment. This protein 
required a skimmer potential of 50 V and a concentration of 20 pmol/pL and the observed 
m/z range for the protein was 1000-1700. The carbohydrate heterogeneity of the 
fragment was easily resolved and the observed masses agreed with the translated DNA 
sequence, less C-terminal K , and the proposed carbohydrate structure. Removal of 
the carbohydrate allowed the sites of cleavage by papain to be determined. It was 
revealed that the cleavage sites for the Fd and Fc fragments do not coincide due to the loss 
of the dipeptide I C in the hinge region of the MAb during the digestion 
with papain.
This study clearly shows that a mass analyser with at least a 4000 m/z range can be 
successfully employed to probe the denatured forms of large proteins, such as MAbs. 
This work also shows that the ESI-MS can be used to successfully analyse the purity of a 
MAb by accurately resolving the presence of two components in a mixture. Therefore, 
ESI-MS has the potential to be used for the characterisation of intact MAbs and MAb 
conjugates provided careful attention is paid to the optimisation of protein concentration 
and skimmer potential and a mass analyser with a m/z 4000 or greater is available. 
ESI-MS also offers the capability to indicate where cleavages on a MAb have occurred 
and consequently can provide information on the primary structure of the protein after 
digestion by an enzyme which in turn should prove to be very useful for monitoring the 
production of immunoreactive MAb fragments for use in radioimaging and radiotherapy 
of cancer.
Prior to the investigation of modified peptides, proteins and MAbs, the interaction of 
DTPA ligand with range metal ions was investigated by ESI-MS. It was shown that 
DTPA coordinated a range of metal ions in solution and this was observed by ESI-MS. 
The number of carboxylate groups deprotonated to accommodate the ion was determined 
to be the same as the integer value of the charge on the metal ion. The exception to this 
was Fe2+ in which the mass determined by ESI-MS was one less than expected and this
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was attributed to Fe2+ oxidising to Fe^+ in the ESI source with the concomitant loss of a 
proton from one of the carboxylate groups of DTP A to coordinate the oxidised Fe cation. 
ESI-MS showed that a metal ion (with a lower log K) coordinated by DTPA was 
displaced in solution by ions with a higher affinity for the ligand, thus suggesting that 
such an approach could potentially be extended to determine the relative stabilities of 
ligand-metal interactions if log K data is unavailable. Furthermore, the relative affinities 
of metals to protein-ligand conjugates could be assessed.
A number of conclusions can be made concerning the modification of peptides and 
proteins by a range of readily-available derivatising agents and the subsequent analysis of 
the reaction mixtures by ESI-MS. The dienylcation [(rj5-C6H7) Fe(CO)3]+ (Fed+) was 
conjugated to a range of cysteine- and histidine-containing peptides and the addition of 
the Fed+ adduct was observed in the ESI mass spectra by an increase in mass of peptides 
by 218 Da. The peptide-Fed bond is thermodynamically labile, therefore a low skimmer 
potential (20 V) was required to observe the conjugate. In addition, the peptide-Fed 
bond is acid labile as conjugation of the adduct to the peptide was markedly decreased by 
the addition of acid. Conjugation of Fed+ to hen egg-white lysozyme (HEL) was not 
observed in the ESI-MS apparently because the HEL-Fed conjugate dissociates at 50 V, 
which is the potential required on the first source skimmer to observe HEL (NMR data 
had shown that such a complex was present in solution under the same conditions). 
Thus the analysis of such labile protein-ligand complexes by ESI-MS is limited. It is 
possible, however, that information on the relative stabilities of complexes of this type, 
as determined by ESI-MS, can potentially be correlated with the stability of the
complex in vivo.
A  key factor in the analyses of the reaction mixtures discussed below, is that there is no 
purification step (except for removal of buffer salts and excess conjugation reagents) 
between reaction with the particular derivatising agent and analysis by ESI-MS. Addition 
of biotin to L-lysine, cGMP peptide, aB-crystallin C-terminal peptide, HEL,
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'papain-resistant' and 'papain-sensitive' Fab fragments and the deglycosylated/reduced 
B72.3 MAb were all observed by ESI-MS as shown by the successive additions of 
226 Da on the peptides and proteins. As the molar ratio of protein to modifying agent 
was increased a shift to higher masses was observed in the ESI mass spectra. The 
biotinylation reaction was favoured at alkaline pH and lower initial concentration of 
protein (as shown by the data obtained from biotinylation of HEL) and appeared to be 
complete after ~15 minutes.
Analysis of the biotinylated 'papain-resistant' and 'papain-sensitive' Fab fragment 
revealed that a greater number of biotin moieties were conjugated to the 'papain-sensitive' 
fragment than the 'papain-resistant' fragment. The increasing reactivity of the 'sensitive' 
fragment towards conjugation of biotin cf. the 'resistant' Fab fragment was related to a 
more 'relaxed' conformation of the protein. This allows for greater exposure of the 
lysine side chains to the solvent and subsequent modification. The 'rigid' conformation 
of the 'papain-resistant' fragment apparently hinders access of derivatisation agent to 
lysine residues, therefore fewer additions of biotin to the protein are observed. 
Modification of the intact and glycosylated MAb and digestion to Fab fragment revealed 
that less biotins were conjugated to this Fab fragment than the Fab subunit prepared from 
digestion of the MAb and subsequently modified. This would be expected as the 
Fc fragment is presumably modified as well.
Biotinylation of the deglycosylated B72.3 and subsequent reduction revealed that there 
were more adducts conjugated to the heavy chain than the light chain, implying that the 
light chain is less accessible to modification. Removal of the carbohydrate results in a 
homogeneous protein core and consequently a 'cleaner' spectrum was achieved. This 
method provides an alternative means of assessing labelling efficiency by determining the 
distribution of the label between the light and heavy chains without the interference from 
the carbohydrate heterogeneity. Individual biotin additions to the intact and glycosylated 
B7 2  3  could not be resolved in the ESI mass spectrum, however, an average mass was
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determined and from this the average number of biotin moieties conjugated to the MAb 
was estimated.
Addition of iodine-127 was observed on the human angiotensin I (4-10) peptide, HEL 
and the 'papain-resistant' Fab fragment as observed by the successive increases of 
126 Da. The reaction of iodine with the angiotensin peptide was particularly inefficient 
as only one addition of iodine-127 was observed, with the majority of the peptide 
remaining unmodified. Six iodine-127 atoms could potentially be conjugated to HEL, 
however, only four additions were observed in the ESI mass spectrum even when a large 
excess of Na127I was used. This was consistent with a 'buried' third tyrosine residue as 
shown by X-ray analysis. For the iodinated Fab fragment, the resolution required is 
greater than biotin (approximately twice the mass of iodine-127) but is still well within 
the limits of the quadrupole instrument.
Addition of DTPA to L-lysine and cGMP peptide (no metals chelated by the 
peptide-DTTA conjugate) was observed in the ESI spectra. In addition, intramolecular 
cross linking was observed with these two models, which was evident in the spectra by 
the presence of peaks due to the addition of a DTTA moiety less water. Conjugation of 
DTPA to horse heart myoglobin revealed that the mass determined by ESI was greater 
than expected, and this was attributed to coordination of an Fe cation by the 
myoglobin-DTTA conjugate during the preparation of the complex. A series of 
competition experiments indicated that the Fe cation was Fe2+ as all the metal ions studied 
displaced the Fe cation. Based on the stability constant data (log K), only two of the five 
metal ions investigated would have displaced the Fe cation if it was Fe3+. Masses 
calculated for the myoglobin-DTTA-Fe cation conjugate assumed that Fe2+ is oxidised in 
the ESI source to Fe3+.
To confirm that the metal ions are chelated by myoglobin-DTTA conjugate and not the 
protein itself, native myoglobin was incubated with a metal ion. ESI-MS did not show
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addition of the metal to the protein alone, thus confirming the need for a chelating ligand 
to be covalently attached to the protein prior to the conjugation of the metal ion. Low 
coupling efficiency of DTPA to myoglobin was evident and this was attributed to the 
propensity of cDTPA to hydrolyse prior to conjugation to protein. Increasing the 
concentration of myoglobin did not result in a higher number of DTTA groups attached to 
the protein. The addition of one DTTA group to the 'papain-resistant' Fab fragment 
(chelating a Fe cation) was also demonstrated.
The final modification reagent to be investigated in this study was the conjugation of a 
readily-available cage complex to HEL. Coupling of the macrocyclic [Co(diAMsar)]3+ to 
HEL was achieved by l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDC). The ESI-MS spectrum of the reaction mixture revealed the addition of one 
[Co(diAMsar)]3+ moiety to HEL. There are also peaks corresponding to the A-acylurea 
protein adduct and to the EDC-modified Co(diAMsar)-HEL conjugate. A low yield of 
modified HEL was achieved, despite the 1000-fold excess of the cage complex 
(nucleophile). It is possible that addition of more than one cage complex to HEL is 
sterically unfavourable. The major disadvantage of the EDC-coupling procedure is that 
EDC reaction is favoured at acidic pH, whereas amines are deprotonated at higher pH, 
thus there is a need for a large excess of the nucleophile to achieve any coupling at all.
Modification of the larger proteins (ie. Fab fragment, reduced MAb) with the 
derivatisation reagents described above, resulted in ESI spectra that were difficult to 
interpret. In these instances, the data was converted from a m/z scale to a mass scale by 
deconvolution of the ESI data using the MaxEnt™ algorithm. This software process is 
particularly useful in interpreting data that otherwise is too complex to be transformed to 
a mass scale with conventional algorithms. The skimmer potentials used for the analyses 
of all the protein-ligand conjugates (ie. 50-150 V) did not appear to result in the loss of 
the adduct (except for the peptide-Fed complexes) as evidenced by the absence of these 
moieties in the spectra.
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An interesting observation was made regarding the observed charge states of a modified 
protein compared to the charge states for the native protein. Modification of the lysine 
side chains by biotin or DTPA does not appear to alter the protonation of the molecule as 
the same charge states were observed for the native and modified forms. It is possible 
that the attached ligand accommodates a charge, therefore there is no nett change in the 
availability of basic sites following modification. Alternatively, modification of the 
protein may lead to partial unfolding to expose other basic sites to protonation. For the 
iodinated species, the same charge states were also observed cf. native proteins, 
however, this is not unexpected since tyrosine is not a preferred site for protonation.
A number of pertinent points arose from the analysis of biotinylated and iodinated 
peptides by MS-MS. Biotin addition to lysine residues of aB-crystallin C-terminal 
peptide and the N-terminus of L-lysine was specific as there was no evidence of product 
ions corresponding to the addition of biotin to other residues. In addition, the ions 
present in the product-ion mass spectra of the biotinylated species were not evident in the 
product-ion spectrum of the unmodified peptide. The product-ion mass spectrum of the 
iodinated human angiotensin I (4-10) peptide also showed that iodine addition occurred 
specifically at tyrosine residues. The aB-crystallin C-terminal peptide (which has three 
lysine residues) was chosen as a model for MS-MS studies such as these because it has a 
blocked N-terminus and a C-terminal lysine residue, as might be expected for the peptides 
generated from tryptic digests of modified proteins (except for the N-terminal tryptic 
fragment). For the addition of one or two biotin moieties to the peptide three potential 
fragmentation pathways were observed depending on which of the lysine residues had 
been modified. Conversely, only one fragmentation pathway was possible from the 
peptide modified with three biotin moieties.
The order of reactivity of the lysine residues in aB-crystallin C-terminal peptide could not 
be determined, however, it appeared that biotinylation of K U was sterically hindered if 
K 12 was modified and vice versa. The product-ion mass spectra of all the biotinylated
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species showed two ions specifically attributable to the biotin moiety (m/z 310 and 
m/z 227). Biotin additions to lysine residues in tryptic digests of modified proteins could 
thus be detected by screening for these product ions. In contrast, no product-ion was 
evident in the product-ion mass spectra of the iodinated peptides that could be specifically 
attributed to iodination of tyrosine residues and therefore could be used for screening of 
tryptic digest of iodinated proteins.
Modification of L-lysine, aB-crystallin C-terminal peptide and human angiotensin I 
(4-10) peptide appeared to stabilise the conjugates and this was reflected in the higher 
laboratory collision energy (£jab) required to induce fragmentation. Successive additions 
of biotin to the aB-crystallin C-terminal peptide, however, appeared to destabilise the 
peptide as the optimum E\ab required for the generation of the product-ion mass spectra 
decreased with increasing additions of biotin (and Ecm would also decrease accordingly). 
These experiments clearly indicate that MS-MS could potentially be used for the location 
and confirmation of site(s) of modification in tryptic digests of derivatised proteins, MAb 
fragments and intact MAbs. -
The work described here demonstrates the potential of electrospray mass spectrometry for 
the characterisation of chemically-modified proteins including MAb fragments and intact 
MAbs. ESI-MS offers the capability for both determining the numbers of ligands bound 
to the protein and a measure of the actual distributions of individual species (assuming 
comparable ionisation efficiencies) thus providing a degree of structural information not 
accessible by other methods. We have shown that ESI-MS is not only a versatile 
analytical tool for determining the number of chelating agents that have been conjugated to 
a peptide or protein, but we have also shown the capabilities of ESI-MS for 
demonstrating the coordination of a range of naturally occurring metal ions by a chemical 
chelator. Thus ESI-MS should prove to be a powerful aid in the design and development 































































Alanine Ala A C3H5NO! 71.03712 71.07883
Arginine Arg R c6h12n4o 156.1011 156.1876
Asparagine Asn N c4h6n2o2 114.0429 114.1039
Aspartic Acid Asp D c4h5no3 115.0269 115.0886
Cysteine Cys C C3H5NOS 103.0092 103.1448
Glutamic Acid Glu E c5h7no3 129.0426 129.1155
Glutamine Gin Q c5h8n2o2 128.0586 128.1308
Glycine Gly G QHsNO 57.0215 57.0520
Histidine His H c6h7n30 137.0589 137.1412
Isoleucine lie I C6HhNO 113.0841 113.1595
Leucine Leu L C6HnNO 113.0841 113.1595
Lysine Lys K c6h12n2o 128.-0950 128.1742
Methionine Met M c5h9nos 131.0405 131.1986
Phenylalanine Phe F CçHçNO 147.0684 147.1766
Proline Pro P C5H7N0 97.0528 97.1167
Serine Ser S c3h5no2 87.0320 87.0782
Threonine Thr T c4h7no2 101.0477 101.1051
Tryptophan Tip W c „h 10n2o 186.0793 186.2133
Tyrosine Tyr Y C9H9N0 2 163.0633 163.1760
Valine Val V c5h9no 99.0684 99.1326
Table A1  Molecular weight and composition data of the twenty common amino acid residues.
1 These compositions are for the amino acid residues in the protein or peptide sequence after peptide 
bond formation (ie. a condensation reaction where the amino acid loses H and OH from the N- and
C-termini, respectively). ■
2 The monoisotopic masses are calculated from the masses of the most abundant isotope of the elements
(refer to Table A2).













Table A2 Monoisotopic and average molecular masses of some elements.
TERMINAL CHEMICAL MONOISOTOPIC AVERAGE
GROUPS COMPOSITION MASS MASS
Hydrogen H 1.0078250 1.00794
(N-terminal)
N-formyl HCO 29.00274 29.0183
(N-terminal)
N-acetyl CH3CO 43.01839 43.0452
(N-terminal)
Hydroxyl CH 17.00274 17.0073
(C-terminal)
Amide n h 2 16.01872 16.0226
(C-terminal)




































































































Table B1 Translated DNA sequence of the B72.3 monoclonal antibody heavy chain.
10 20 30 40
DIQMT QSPAS LSVSV GETVT ITCRA SENIY SNLAW YQQKQ
50 60 70 80
GKSPQ LLVYA ATNLA DGVPS RFSGS GSGTQ YSLKI NSLQS
90 100 n o 120
EDFGS YYCQH FWGTP YTFGG GTRLE IKRAD AAPTV SIFPP
130 140 150 160
SSEQL TSGGA SVVCF LNNFY PKDIN VKWK I DGSER QNGVL
170 180 190 200
NSWTD QDSKD STYSM SSTLT LTKDE YERHN SYTCE ATHKT
210
STSPI VKSFN RNEC
Table B2 Translated DNA sequence of the B72.3 monoclonal antibody light chain.
I and IV Heavy chains
II and m  Light chains 
Disulphide bridges:
1:22 - 1:96 1:221 - IV:221 111:214 - ' IV:216
1:141 - 1:196 1:223 - IV:223 IV: 22 - IV:96
1:252 - 1:312 11:23 - 11:88 IV:141 - IV: 196
1:358 - 1:416 11:134 - 11:194 IV:252 - IV:312
1:216 - 11:214 111:23 - 111:88 IV:358 - IV :416
1:218 - IV:218 111:134 - 111:194
Appendix B 215
10 20 30 40
KVFGR CELAA AMKRH GLDNY RGYSL GNWVC AAKFE SNFNT
50 60 70 80
QATNR NTDGS TDYGI LQINS RWWCN DGRTP GSRNL CNIPC
90 100 n o 120
SALLS SDITA SVNCA KKTV S DGDGM NAWVA WRNRC KGTDV
QAWIR GCRL








































Table B4  Translated DNA sequence of horse heart myoglobin.
216
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